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Alzheimer’s disease (AD) affects millions of older adults worldwide, and the prevalence 
and incidence are expected to grow at exponential rates in coming years. Identifying potential 
targets for intervention to delay onset, slow progression, or effectively treat AD is of extreme 
public health importance. Better understanding blood biomarkers of AD is one means of 
identifying such targets. This dissertation investigates potential blood biomarkers of AD, 
including plasma amyloid beta 42 (Aβ42) and Aβ40, and inflammatory markers interleukin 6 
(IL-6), IL-6 soluble receptor (IL-6 sR), and C-reactive protein (CRP). 
Measurement of Aβ42 and Aβ40 in cerebrospinal fluid has been used to identify people 
with AD, and distinguish from other types of dementia. In plasma, the ratio Aβ42/Aβ40 has 
emerged as a potentially useful biomarker of AD. However, correlates of plasma Aβ40 and Aβ42 
are unknown. We investigated the demographic and medical correlates of plasma Aβ40 and 
Aβ42. We found that in community-dwelling, older adults, plasma Aβ40 and Aβ42 were 
significantly associated with age, race, sex, education, Apolipoprotein E (APOE) genotype, and 
serum creatinine. 
Due to the inflammatory state associated with AD pathology, and with risk factors of AD, 
inflammatory markers are potentially useful biomarkers of AD. Previous studies have focused on 
measuring inflammatory markers at one time point; this has major limitations due to the non-
specific nature of inflammatory markers, and the large number of inflammation triggers.  We 
Jane A. Cauley, DrPH 
POTENTIAL BLOOD BIOLOGICAL MARKERS OF ALZHEIMER’S DISEASE 
Andrea L. Metti, PhD 
University of Pittsburgh, 2013
iv 
studied how change in inflammation over time predicts risk of dementia and cognitive decline. In 
a cohort of oldest old women, we found that high IL-6 sR at two time points, or transitioning to 
from low to high reduced the risk of developing dementia. Furthermore, in a cohort of older, 
black and white men and women, we found that extreme variability in CRP over time was 
associated with increased risk for cognitive decline over 10 years. This association was stronger 
among women and among those with no APOE e4 allele. We believe these results not only 
indicate the complexity of the immune system in older adults, but also suggest the role of 
vascular disease in the development of cognitive decline. New evidence suggesting that vascular 
disease is also related to Aβ deposition suggests that the relationships we found may hold for 
vascular dementia and AD. Future research should investigate how all of these markers together 
relate to cognitive function, as well as to AD and vascular dementia pathologies, such as amyloid 
deposition and white matter hyperintensities.  
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1.0  INTRODUCTION 
All cause dementia is classified by the National Institute on Aging and the Alzheimer’s 
Association (NIA-AA) with several criteria (2011).(McKhann et al., 2011) The criteria include 
cognitive or behavioral symptoms that: 1. interfere with normal function at work or home; 2. 
Represent a decline from a previous level of functioning or performing; and 3. Are not explained 
by delirium or another psychiatric disorder.(McKhann et al., 2011)  Furthermore, these criteria 
state that cognitive impairment should be detected or diagnosed through several steps, such as 
history taking from the patient and a knowledgeable informant or caregiver, and objective 
assessment of cognitive function either with a “bedside” mental status examination or 
neuropsychological testing.(McKhann et al., 2011)  For a diagnosis of all-cause dementia, the 
impairment must involve a minimum of two of the following domains: 1. Memory – specifically 
the ability to acquire and recall new information; 2. Reasoning, consisting of the handling of 
complex tasks, poor judgment and poor decision making; 3. Visuospatial ability, such as 
recognition of faces or identifying common objects; 4. Language, including speaking, reading 
and writing; and 5. Personality, also described as behavior or mood, and encompassing things 
such as mood swings, increased agitation, apathy, and socially unacceptable 
behaviors.(McKhann et al., 2011)  It should be noted that these criteria are very similar to the 
newly proposed Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria for a 
major neurocognitive disorder, which include: a substantial decline in cognitive function from a 
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previous level in one or more cognitive domains, cognitive deficits severe enough to interfere 
with independent functioning, and not primarily attributable to delirium or some other 
psychiatric disorder.(American Psychiatric Association, 2012) The NIA-AA also provides 
criteria for the Alzheimer’s disease (AD) type of dementia, and specify distinct criteria for 
probable AD, possible AD, and probable or possible AD with evidence of AD 
pathophysiology.(McKhann et al., 2011)  Specifically, the criteria for probable AD include the 
previously described dementia criteria in addition to: 1. Gradual onset on the order of months to 
years; 2. An obvious history of worsening cognitive function documented either by observation 
or report; and 3. Having cognitive deficits that are either amnestic in nature, including impaired 
learning and memory, or if they are non-amnestic in nature include language deficits such as 
word finding, visuospatial deficits such as impaired object recognition, and/or executive deficits 
such as impaired judgment or reasoning.(McKhann et al., 2011)  These criteria further state that 
probable AD should not be diagnosed if there is evidence of cerebrovascular disease.(McKhann 
et al., 2011) Classification of possible AD is similar, but can include a rapid onset, or be used 
when there is a lack of information of the patient’s history; possible AD can also include a mixed 
presentation of AD-type symptoms with cerebrovascular disease, dementia with Lewy bodies, or 
dementia with other medical comorbidities that may have an effect on cognitive 
function.(McKhann et al., 2011) Finally, for a diagnosis of probable AD with evidence of AD 
pathophysiological changes, the NIA-AA criteria call for measures of low cerebrospinal fluid 
(CSF) amyloid beta (Aβ) 42, or positive positron emission tomography (PET) amyloid imaging, 
or elevated CSF total tau or phosphorylated tau (p-tau).(McKhann et al., 2011) However, it 
should be noted that the NIA-AA does not call for routine diagnoses to include a check of these 
biomarkers at this time.(McKhann et al., 2011)  The proposed DSM-5 has similar diagnostic 
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criteria for a neurocognitive disorder due to Alzheimer’s disease.(American Psychiatric 
Association, 2012)  DSM-5 criteria states a diagnosis should include evidence of a major or 
minor neurocognitive disorder, gradual progression or worsening in one or more cognitive 
domains, an early and prominent feature of impaired memory, and having these symptoms not 
better accounted for by other conditions, such as cerebrovascular disease, Lewy body disease, 
Parkinson’s disease, fronto-temporal lobar degeneration, or another neurologic or systemic 
illness.(American Psychiatric Association, 2012) In the brain, Alzheimer’s disease is classified 
primarily by the formation of amyloid plaques and tau neurofibrillary tangles (NFT).(Maarouf et 
al., 2011) Other pathological changes that occur in the brain include an overall decrease in the 
number of synapses, neuronal death, loss of myelin sheath on neurons, brain atrophy, and 
proliferation of astrocytes in the brain.(Maarouf et al., 2011)  
Clinical diagnoses of AD often differ across settings. For example, in research settings, a 
diagnosis may include assessment of medical and family history, determining changes in 
cognitive function or behavior (from previous visits, or from self or proxy reports), obtaining a 
caregiver or family report on changes in cognitive functioning or functioning in daily tasks, 
neuropsychological testing, and a physical and neurological examination.(Alzheimer's 
Association, 2011)  Additionally, sometimes structural or functional magnetic resonance imaging 
(MRI/fMRI) is used to detect brain atrophy or changes in blood flow, PET scans are conducted 
for amyloid imaging, or single-photon emission computed tomography (SPECT) is used to 
distinguish AD from other types of dementia, specifically, dementia with Lewy bodies.(Barber, 
2010; Hampel et al., 2010; McKeith et al., 2004)  Conversely, in primary care settings, up until 
2011, there were no universally recommended or accepted guidelines for systematic screening of 
dementia, nor a universally recommended tool/assessment for detection or diagnosis.(Fowler et 
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al., 2012) Several organizations, such as the American Geriatrics Society (AGS) or the American 
Academy of Neurology (AAN), provide guidelines or steps that a physician may use; it is up to 
providers, however, to choose to follow such guidelines. Beginning in January 2011, the Centers 
for Medicare and Medicaid Services began covering the costs of annual wellness visits for 
Medicare beneficiaries, at which primary care physicians (in order to receive payment for the 
visit) must focus on preventive care by assessing 9 components or check list items during the 
visit, including screening for cognitive impairment.(Boustani, Peterson, Hanson, Harris, & Lohr, 
2003; Department of Health and Human Services Centers for Medicare and Medicaid Services, 
2010)  In spite of this, there is still no recommended screening tool; rather it is merely stated that 
assessment of cognitive function must be performed by direct observation of the patient, while 
considering information from patient self-report, and concerns raised by family members or 
caregivers, which has limitations.(Department of Health and Human Services Centers for 
Medicare and Medicaid Services, 2010) In a study conducted after these wellness visits were 
mandated, investigators showed that patients and caregivers were both unreliable in accurately 
reporting cognitive function to a physician, and called for objective screening tests for 
dementia.(Clionsky & Clionsky, 2011) Furthermore, some feel this new mandate may not be 
useful until the potential benefits of screening (i.e. an effective treatment) outweigh the potential 
harms (i.e. depression associated with a  diagnosis, loss of driver’s license, etc.).(Brayne, Fox, & 
Boustani, 2007; Fowler et al., 2012) In addition to these concerns, which could very well 
influence a physician, and his/her willingness to diagnose someone with mild cognitive 
impairment (MCI) or dementia, there are other factors may also affect diagnosing in a non-
specialized setting. For example, physicians often face time constraints in general wellness visits, 
and other “check-list” items that take priority over examining cognitive status.  Barriers to 
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diagnosis in a non-specialized setting also occur on the patient end, including stigmatizing or 
fearful beliefs regarding a dementia diagnosis, inability to get to a doctor due to geographic or 
physical conditions, and lack of awareness of cognitive decline. Other limitations to clinical 
diagnoses in both specialized and non-specialized settings include a wide range of clinical 
presentations because of different brain regions affected, difficulty distinguishing between 
different types of dementia, and cognitive problems that could be induced by other neurological 
conditions or medications.(Alzheimer's Association, 2011; Castellani, Rolston, & Smith, 2010)  
Diagnosing dementia may be even further complicated by cognitive reserve which is the term 
often used to describe when older adults have a high degree of AD-type pathology, but in spite of 
the pathology have reasonably in-tact cognitive function.(Scarmeas & Stern, 2004; Stern, 2002, 
2009)  The cognitive reserve hypothesis proposes that some people with a high degree of brain 
pathology may show no apparent cognitive impairment due to an ability to compensate for 
pathology or deficits; the ability to compensate is thought to stem from a combination of 
advantageous lifestyle factors, such as higher education or literacy, and neural factors like 
greater brain volume or greater brain plasticity.(Scarmeas & Stern, 2004; Stern, 2002)  While 
difficult to quantify, studies have previously used education and literacy as surrogate markers of 
cognitive reserve.(Bennett et al., 2003; Kemppainen et al., 2008; Rentz et al., 2010; Yaffe, 
Weston, et al., 2011)  
 In the literature, AD is often distinguished from other types of dementia, such as 
vascular dementia, dementia with Lewy bodies, frontotemporal dementia or dementia from 
multiple causes.  However, in reality these distinctions are often cloudy due to a wide-range of 
methods used for determining cognitive status and dementia diagnosis in research studies; some 
specialized clinics like the Alzheimer’s Disease Research Centers (ADRCs) may have great 
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ability to diagnosis, but some epidemiological studies may rely on self-report of previous 
diagnosis from a physician or on neuropsychological testing. Furthermore,  different types of 
dementia may not have such distinctive boundaries; cerebrovascular disease often contributes to 
many different types of dementia, including AD.(Gorelick et al., 2011)  Finally, while imaging 
and CSF biomarkers are greatly improving the ability to diagnose dementia and AD, especially 
in specialized research settings, the only definitive diagnosis of AD is a post-mortem histologic 
examination of the brain.(Castellani et al., 2010; Knopman et al., 2001)  Thus, in many settings, 
researchers and clinicians are forced to classify people in spite of a clear lack of a biological 
marker that can reliably and validly diagnose dementia patients, and distinguish AD from other 
types of dementia.(Castellani et al., 2010)   
Mild cognitive impairment (MCI) is increasingly recognized as a state of cognitive 
impairment somewhere on the continuum between normal cognitive function and dementia.(R.C. 
Petersen & O'Brien, 2006)  While not all people with MCI progress to dementia, it is estimated 5 
to 15% of people with MCI will progress to dementia every year.(Ganguli, Dodge, Shen, & 
DeKosky, 2004; R.C. Petersen et al., 1999)  MCI has been widely described according to two 
criteria.(R. C. Petersen, 2004; Winblad et al., 2004) The Petersen criteria include: 1. memory 
complaint, ideally reported by subject and informant; 2. Objectively determined impaired 
cognitive function for age, either determined from a previous measure or compared to norms 
(specific to age, education, occupation); 3. Relatively in-tact physical function (activities of daily 
living [ADLs] and instrumental activities of daily living [IADLs]); and 4. Not demented.(R. C. 
Petersen, 2004) In spite of these criteria, recent studies have suggested that people with MCI 
may, in fact, be experiencing some mild loss in function.(Weston, Barton, Lesselyong, & Yaffe, 
2011)  Furthermore, there are several different subtypes, according to the Petersen criteria: 1. 
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Amnestic – impaired cognition with only memory complaints; 2. Multi-domain amnestic – 
impaired cognition with memory complaints, plus complaints in at least one other domain (i.e. 
language, executive function, visual spatial skills); 3. Multi-domain non-amnestic – impaired 
cognition with multiple domains affected, but memory not being one of them; and 4. Single 
domain non-amnestic – impaired cognition with only one, non-memory domain affected (i.e. 
language, executive function, visual spatial skills).(R. C. Petersen, 2004) The Winblad criteria 
for MCI are: 1. The person being neither normal nor demented; 2. Evidence of cognitive 
deterioration based on one of several standards – either objective measures over time and/or 
subjective report of decline by self and/or informant in conjunction with objective cognitive 
deficits; and 3. Activities of daily living are preserved and complex instrumental functions are 
either intact or minimally impaired.(Winblad et al., 2004) Similar to the Petersen criteria, there 
are several different subtypes of MCI, according to Winblad and colleagues: 1. Amnestic; 2. 
Single non-memory; or 3. Multiple cognitive domains.(Winblad et al., 2004) The Winblad 
criteria emphasize there is a lot of heterogeneity in both the etiology and progression.(Winblad et 
al., 2004) 
1.1 EPIDEMIOLOGY 
1.1.1 Prevalence and Incidence  
An estimated 24.3 million older adults worldwide are currently living with dementia, with an  
estimated incidence of 4.6 million cases each year.(C. P. Ferri et al., 2005) Given these 
estimates, the predicted prevalence for the year 2020 is 42.3 million cases, and by the year 2040 
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is 81.1 million cases, unless something is done to slow the progression or delay the onset of 
dementia.(C. P. Ferri et al., 2005) According to estimates published in 2005, the number of 
people living with dementia in North America in 2001 was 3.4 million, with 2.9 million cases 
from the United States; the prevalence is predicted to approach 10 million in North America by 
2040.(C. P. Ferri et al., 2005)  Similarly, the prevalence in Western Europe in 2001 was nearly 5 
million, with projections of 9.9 million by the year 2040.(C. P. Ferri et al., 2005) While studies 
investigating the prevalence of dementia for individual countries in Asia and Africa have been 
limited, it has been estimated that Africa had 1.5 million people with dementia, Latin America 
had  1.8 million, and Asia had 9.9 million in 2001.(C. P. Ferri et al., 2005)  Furthermore, in spite 
of a greater number of dementia studies based in developed countries, it is predicted that it will 
be the developing regions of the world that experience the greatest proportionate growth of 
dementia in the coming years.(C. P. Ferri et al., 2005) For example, between 2001 and 2040, 
developed regions, such as North America and Europe will experience about 100% proportionate 
increase in dementia cases, compared to an estimated 235% to 393% proportionate increase in 
Latin America and Africa, and a 314% to 33% proportionate increase in India, China, southeast 
Asia, and Western-Pacific regions.(C. P. Ferri et al., 2005) These current and expected 
prevalence estimates and incidence rates are alarmingly high due to an exponential increase in 
the aging population caused by a combination of increased life expectancy and the occurring 
demographic transition.(Alzheimer's Association, 2011; Prince & Jackson, 2009) 
1.1.2 Public Health Impact 
In the United States, dementia is the sixth leading cause of death overall, and the fifth leading 
cause of death among adults 65 years of age and older.(Alzheimer's Association, 2011) 
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Worldwide, dementia is thought to cause an average of 7.4 years lived with a disability (YLD) or 
11.9% of the total YLDs caused by any chronic disease.(Prince & Jackson, 2009)  This is the 
second largest YLD attributed to chronic disease (second to blindness), and is greater than that 
caused by stroke, heart disease, diabetes and arthritis.(Prince & Jackson, 2009) Globally, 
dementia also accounts for 4.1% of Disability Adjusted Life Years (DALY).(Prince & Jackson, 
2009) Dementia is thought to cost $315 billion US dollars annually in direct and indirect health 
care costs, and is the leading cause of dependency, or needing care, among older adults in many 
countries.(Prince & Jackson, 2009) In addition to the costs incurred by family members or 
friends who are responsible to the informal care, estimates suggest that 40 to 75% of all dementia 
caregivers seek later care for significant psychological illness and chronic disease, and have an 
increased risk for mortality, which contribute to the burden on health care systems.(Alzheimer's 
Association, 2011; Prince & Jackson, 2009)  With the expected increase in dementia over the 
next 20 years and lack of any effective treatment, we can only expect the public health burden to 
also increase exponentially. 
1.1.3 Risk Factors 
One of the biggest risk factors for AD is increasing age.(Alzheimer's Association, 2011; 
Castellani et al., 2010; Prince & Jackson, 2009)  Prevalence and incidence rates both increase 
rapidly as age increases in adults who are 65 years and older.(Alzheimer's Association, 2011; 
Castellani et al., 2010)  Prevalence is thought to reach as high as 50% in adults who are 85 years 
of age and older.(Zhu & Sano, 2006)  Being Hispanic or African-American are also risk factors 
for dementia.(Alzheimer's Association, 2011; Castellani et al., 2010)  More women than men 
also have AD; in fact, almost two-thirds of all Americans living with AD are 
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women.(Alzheimer's Association, 2011) Approximately16% of women aged 71 years have AD, 
compared with 11% of men.(Alzheimer's Association, 2011) However, this difference is 
primarily due to the greater life expectancy of women.(Alzheimer's Association, 2011) 
Education is another demographic factor that is thought modify the risk of AD; often 
coupled with education are occupational attainment and cognitive activity. High education and 
high occupational achievement are widely known to be associated with reduced risk for 
dementia.(Sattler, Toro, Schonknecht, & Schroder, 2012; Stern et al., 1994)  It is thought that 
higher educational and occupational attainment lead to increased brain size, greater efficiency of 
neuronal networks, and an overall cognitive reserve.(Scarmeas & Stern, 2004; Stern, 2002; Stern 
et al., 1994)  Staying or being mentally active also appears to be associated with reduced risk of 
AD.(Sattler et al., 2012)  However, this may in fact just be representing a delay in the onset, as it 
has been suggested that among people with greater cognitive reserve, onset of dementia is 
delayed, but decline is more rapid once onset occurs.(Hall et al., 2007) Importantly, cognitive 
activity is a modifiable risk factor, and it has been shown that cognitive training in later life can 
improve cognitive function. For example, the Advanced Cognitive Training for Independent and 
Vital Elderly (ACTIVE) study investigated the effects of a 10-week cognitive training in 2,832 
older adults, and found sustained improvements in memory, reasoning and processing speed at 2 
and 5 years follow-up.(Ball et al., 2002; Willis et al., 2006)    
A number of medical conditions are also associated with development of AD. 
Cardiovascular disease (CVD) risk factors such as hypertension(Kivipelto et al., 2001; Skoog et 
al., 1997) and high blood cholesterol(Kivipelto et al., 2002; Yaffe, Barrett-Connor, Lin, & 
Grady, 2002), as well as conditions that affect metabolic regulation such as obesity, diabetes, and 
impaired glucose tolerance(Akomolafe et al., 2006; Hildreth, Van Pelt, & Schwartz, 2012; Yaffe 
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et al., 2004) have all been shown to increase the risk of dementia and cognitive decline in older 
adults.  Having hypertension at midlife has not only been associated with a significantly 
increased risk of developing dementia in prospective studies(Kivipelto et al., 2001) (Kivipelto et 
al., 2001; Prince & Jackson, 2009), but has also been associated with increased formation of 
neurofibrillary tangles (NFT) and plaques found at death.(Petrovitch et al., 2000)  Late-life 
hypertension has also been associated with a greater number of amyloid plaques, and increased 
NFT formation.(Launer, White, Petrovitch, Ross, & Curb, 2001)  Furthermore, a 15-year 
longitudinal study of hypertension in 70 to 85 year olds, showed that high blood pressure within 
the last 5 to 10 years was associated with increased risk of dementia.(Skoog et al., 1997)  
Similarly, high total cholesterol levels at both midlife and late life have been associated with 
increased risk for AD and cognitive decline.(Kivipelto et al., 2002; Solomon, Kivipelto, 
Wolozin, Zhou, & Whitmer, 2009; Yaffe et al., 2002)  Disappointingly, several clinical trials 
investigating anti-hypertensive and cholesterol lowering medications on AD have largely pointed 
towards no significant treatment effect in late-life of statins and other anti-hypertensive drugs in 
reducing the risk of dementia.(Igase, Kohara, & Miki, 2012; McGuinness, Craig, Bullock, & 
Passmore, 2009)  More long-term studies are needed to determine if treatment at midlife reduces 
the risk of dementia. 
Diabetes mellitus and impaired glucose tolerance have also been associated with 
increased risk of MCI and AD.(Luchsinger et al., 2007; Whitmer, Karter, Yaffe, Quesenberry, & 
Selby, 2009; Yaffe et al., 2004) For example, in one longitudinal study, diabetes was associated 
with an increased risk of incident MCI (HR = 1.4, 95% CI: 1.1-1.8).(Luchsinger et al., 2007)  In 
another prospective study of postmenopausal women, there were significant cross-sectional 
associations between impaired fasting glucose (IFG) and diabetes with poorer performance on 
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cognitive tests, even after adjustment for age.(Yaffe et al., 2004)  Similarly, both IFG and 
diabetes were associated with greater cognitive decline over 4 years compared to women with 
normal glucose and with no diabetes, respectively (even after adjustment for age, treatment, race, 
education and depression).(Yaffe et al., 2004) Furthermore, among older adults with diabetes 
mellitus, at least one study has documented a dose-response relationship between the number of 
hypoglycemic episodes and increased risk for dementia.(Whitmer et al., 2009)  There are several 
potential underlying mechanisms between diabetes and AD, including the possibility that insulin 
degrading enzymes play a role in the processing of Aβ in the body.(Farris et al., 2003) Dietary 
fat intake may also alter glucose metabolism, and at the same time increase the risk for 
cardiovascular disease, which through the previously described mechanisms may affect cognitive 
function.(Devore et al., 2009) Another potential mechanism is advanced glycation end products 
(AGE), which are created in a body via reactions between glucose and proteins, and increase in 
diabetes; AGE aggregates with several proteins found in AD pathology, including Aβ, tau 
proteins, and APOE.(Yaffe, Lindquist, et al., 2011)  In spite of observational studies and 
plausible underlying mechanisms linking diabetes and dementia, results from clinical trials have 
not been promising. In recently reported results from the Memory in Diabetes, an ancillary study 
to the Action to Control Cardiovascular Risk in Diabetes study (ACCORD MIND), there was no 
significant effect of intensive glucose lowering on cognitive function over 24 and 40 
months.(Launer et al., 2011)  However, the ACCORD MIND study participants may have been 
too young to see significant effects on cognitive function, as the average age was only 62.5 
years; furthermore 40 months may really be too short to see detectable changes in cognitive 
function.(Launer et al., 2011) Similarly, clinical trials investigating the effects of Rosiglitazone – 
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a treatment for type 2 diabetes - have found no effect on cognitive function.(Gold et al., 2010; 
Harrington et al., 2011)  
Because of its increasing prevalence, obesity has also been a risk factor of great interest 
for dementia. One prospective study found that having a mid-life BMI ≥30 was associated with a 
3-fold increase (HR=3.10; 95% CI: 2.19, 4.38) of AD in late life, and a BMI of ≥25 and <30 was 
associated with a 2-fold increase of AD in late life (HR=2.09; 95% CI: 1.69, 2.6) (even after 
adjustment for age, education, race, sex, hyperlipidemia, hypertension, diabetes, ischemic heart 
disease and stroke).(Whitmer, Gunderson, Quesenberry, Zhou, & Yaffe, 2007)  In another 
longitudinal study, obesity was associated with an increased risk of AD in females (HR=2.23; 
95% CI: 1.09-4.30).(Hayden et al., 2006)  Several underlying mechanisms have been proposed 
for the association between obesity and AD, including increases in inflammation, changes in 
hormones that affect the brain, and increases in other risk factors of AD (i.e. 
hypertension).(Profenno, Porsteinsson, & Faraone, 2010) The metabolic syndrome, a collection 
of cardiovascular and metabolic risk factors, including abdominal obesity, high triglyercides, low 
HDL cholesterol, IFG and hypertension, has also been shown to increase the risk of AD and 
dementia.(Yaffe, Weston, Blackwell, & Krueger, 2009) Importantly, it has been suggested that 
the associated risk of AD resulting from all of these factors together is greater than the additive 
risk of individual factors.(Yaffe et al., 2009)  
Closely related to metabolic and cardiovascular risk factors, physical inactivity has also 
been widely studied as a potential modifiable risk factor for dementia. For example, in one 
prospective study, women who reported regular physical activity at any time in their life had a 
significantly lower risk of cognitive impairment in late life, compared to women who reported no 
regular physical activity.(Middleton, Barnes, Lui, & Yaffe, 2010) In another longitudinal study 
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with an average of 21 years of follow-up, physical inactivity was associated with increased risk 
for AD, and this association was stronger among those with at least one APOE e4 
allele.(Kivipelto et al., 2008)  In fact, one recent study suggested that reduction of physical 
inactivity in the US may have one of the largest effects on reducing AD prevalence (when 
compared to other potential modifiable targets, such as reducing diabetes, mid-life hypertension 
and obesity, depression, smoking and cognitive inactivity).(Barnes & Yaffe, 2011)  
Another behavioral risk factor for AD is cigarette smoking.(Anstey, von Sanden, Salim, 
& O'Kearney, 2007; Cataldo, Prochaska, & Glantz, 2010)  In a meta-analysis of 19 prospective 
studies of older adults, all with one or more years of follow-up, smokers had an increased risk of 
AD (RR 1.79; 95% CI: 1.43, 2.23), and increased risk for cognitive decline over time, as 
measured by the Mini-Mental State Examination (MMSE).(Cataldo et al., 2010)  Furthermore, 
this same study found that when comparing ever smokers versus current smokers, current 
smokers still had an increased risk of incident AD (RR 1.70; 95% CI: 1.25, 2.31).(Cataldo et al., 
2010)  Potential underlying mechanisms between smoking and increased risk of AD include 
increased inflammation in smokers, and increased risk for cardiovascular disease.(Anstey et al., 
2007)  Smoking is an important risk factor to consider because of its modifiable nature, and it 
has been estimated that if we could reduce the number of smokers by 10%, nearly 400,000 cases 
of AD could be prevented worldwide; if the reduction in smokers reached 25%, more than 1 
million cases could be prevented.(Barnes & Yaffe, 2011)  
Psychiatric conditions such as depression and posttraumatic stress disorder (PTSD) are 
other important risk factors for dementia. In older adults, depression and depressive symptoms 
have been associated with an increased risk of cognitive decline, dementia, and mild cognitive 
impairment (MCI).(Barnes, Alexopoulos, Lopez, Williamson, & Yaffe, 2006; Jorm, 2001)  
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While the mechanisms are not fully understood, perhaps it has to do with long term exposure to 
cortisol. For example, it has been shown that among AD patients with a lifetime history of 
depression, there was increased development of amyloid plaques and neurofibrillary tangles – 
two hallmarks of AD – in the hippocampus; it was proposed that a sustained history of cortisol 
exposure may damage the hippocampus, in turn making it more vulnerable to AD 
pathology.(Rapp et al., 2006) Furthermore, in a prospective cohort study of white and black 
community-dwelling older adults, those with low plasma Aβ42/Aβ40 and at least one APOE e4 
allele had an increased risk for depression over 9 years; this relationship was not observed for 
those with low Aβ42/Aβ40 and no e4 allele.(A.L. Metti et al., 2012) PTSD is another important 
risk factor for dementia; it has been estimated that older adults with a history of PTSD are 
approximately 2 times more likely to develop incident dementia compared to those without 
PTSD.(Yaffe et al., 2010)  Finally, although not a psychiatric disorder, traumatic brain injury 
(TBI) is another important risk factor for dementia, and because of its frequent occurrence in 
older adults, should be taken into consideration.(Lye & Shores, 2000; Thompson, McCormick, & 
Kagan, 2006) TBI accounts for nearly 80,000 emergency department visits each year in adults 65 
years and older in the United States, with falls being the major cause of TBI.(Thompson et al., 
2006) Both cross-sectional and prospective studies have found an association between TBI and 
increased risk of AD, with APOE e4 often being an important effect modifier.(Lye & Shores, 
2000)   
There are also several genetic factors that increase the risk of AD. APOE e4 is the most 
widely known genetic risk factor for AD.(Alzheimer's Association, 2011)  While the underlying 
mechanisms are not completely clear, APOE is thought to play a role in the processing and 
clearance of Aβ and in the transport and processing of lipids, both of which could have an effect 
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on AD.(Alzheimer's Association, 2011)  Having one APOE e4 allele is associated with three to 
five times greater risk of developing AD, and with an increased risk of developing the disease at 
an earlier age.(Alzheimer's Association, 2011; Ingelsson et al., 2003) Being homozygous for the 
e4 allele is associated with a 5 to 15-fold increase in the risk of AD.(Ingelsson et al., 2003)  
Having at least one APOE e4 allele may also increase the risk of progression from MCI to 
AD.(Elias-Sonnenschein, Viechtbauer, Ramakers, Verhey, & Visser, 2011)  Furthermore, 
genetic mutations in the amyloid-beta precursor protein (APP), and presenilin 1 and 2 (PESN1 
and PESN2) have been linked with early onset dementia(Cruts et al., 1998; Goate et al., 1991); 
recent studies have also provided evidence that rare APP, PESN1 and PESN2 mutations may 
also increase risk for late onset AD.(Cruchaga et al., 2012)  
1.2 BIOMARKERS 
Ultimately, the previously reported statistics point to a pressing need to improve a clinician’s 
ability to accurately diagnose AD.  Thus, we need to identify reliable biomarkers that can be 
assessed in a large number of older adults, in cost-effective manner, so that large numbers of 
older adults can be screened.  Identifying biomarkers for AD is important for several other 
reasons. For example, with no current treatment for AD, it is important to identify those at risk 
for developing AD, so that the onset of the disease can be delayed and progression slowed.  
Biomarkers may be able to identify those who are at an increased risk for AD based on a specific 
profile of protein levels or a biochemical change in the body.  If we are able to identify those at 
risk for developing AD, preventive strategies such as behavior modification (i.e. increasing 
physical activity, changing diet, increasing cognitive activity, medication management of other 
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diseases) may be effective in delaying the onset of the disease.(Barnes & Yaffe, 2011)  One 
study suggested that if interventions were able to delay both the onset and progression of 
dementia by one year, up to 9.2 million cases could be prevented by the year 2050.(Brookmeyer, 
Johnson, Ziegler-Graham, & Arrighi, 2007)  Furthermore, biomarkers may aid in understanding 
the physiological progression of the disease, or may help us understand which pathways in the 
body play the biggest role in disease progression.(Anoop, Singh, Jacob, & Maji, 2010; 
Teunissen, Verwey, Kester, van Uffelen, & Blankenstein, 2010)  Better understanding the 
critical pathways or physiological changes in the body that lead to AD could shed some light on 
therapeutic strategies for preventing or even curing the disease.  Clearly, identifying biomarkers 
for AD is going to be crucial in coming years.  
An ideal biomarker for AD is described as having several characteristics, according to 
current consensus criteria proposed by the National Institute on Aging (NIA).(Frank et al., 2003; 
The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the 
National Institute on Aging Working Group, 1998)  Specifically, a biomarker for AD would: 
identify fundamental neuropathology of AD, and be validated in confirmed cases; have a 
sensitivity greater than or equal to 85% for detecting AD; be able to distinguish AD from other 
dementias with a specificity of at least 75%; be sensitive to effects of therapy that modified the 
disease progression; be reliable, reproducible, non-invasive, simple to perform, and inexpensive; 
and be confirmed by at least two independent studies with published results in peer-reviewed 
journals.(Frank et al., 2003; The Ronald and Nancy Reagan Research Institute of the Alzheimer's 
Association and the National Institute on Aging Working Group, 1998)  In the current literature, 
potential biomarkers for AD typically come from several different sources: cerebrospinal fluid, 
blood plasma and blood serum; and neuroimaging markers, such as amyloid imaging.(Barber, 
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2010)  The focus of my proposed research will be on blood plasma and serum biomarkers, and 
thus a bulk of this section will focus on these biomarkers. However, I will first briefly highlight 
the current state of CSF and neuroimaging biomarkers for AD. 
1.2.1 Cerebrospinal Fluid 
Studies investigating CSF biomarkers for AD have been conducted for at least 30 years.(Baxter, 
Baldwin, Pomara, & Brinkman, 1984)  Unlink other bodily fluids, such as blood plasma or 
serum, CSF can reflect biochemical changes directly inside the brain because it fills the 
extracellular space within the brain; this direct contact with the brain has made CSF one of the 
most commonly investigated sources for biomarkers of AD.(Anoop et al., 2010) The most 
promising and widely investigated AD biomarkers from CSF have been the amyloid-beta 42 
(Aβ42) protein and the tau protein – both total tau and phosphorylated tau (pTau).(Anoop et al., 
2010; Blennow, Hampel, Weiner, & Zetterberg, 2010; Teunissen et al., 2010)   
It has been shown that concentrations of total tau and pTau in CSF are elevated in 
patients with AD, when compared to healthy controls.(Andreasen et al., 1999; Formichi, Battisti, 
Radi, & Federico, 2006; Kurz et al., 1998)  Recent studies have also shown that if people are 
categorized according to level of CSF tau (both total and pTau), those within the highest tertile 
of total tau and pTau had a faster rate of cognitive decline, less response to cholinesterase 
inhibitor treatment (which is used to treat symptoms of AD), and a higher mortality rate.(Wallin 
et al., 2009)  One limitation to using CSF tau as a biomarker for AD is that it has low specificity 
– that is, it is unable to distinguish AD from other types of dementia (i.e. vascular dementia or
dementia caused by traumatic brain injury).(Anoop et al., 2010) However, pTau has been shown 
to be more successful at distinguishing between AD and other dementias.(Formichi et al., 2006)  
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For example, total tau increases in CSF after ischemic stroke, but pTau does not; pTau also 
remains low in patients with frontotemporal dementia, but increases in patients with AD.(Hesse 
et al., 2001; Sjogren et al., 2000)   
Similarly, a significant decrease in CSF Aβ42 has been documented in patients with AD, 
when compared to normal controls.(Formichi et al., 2006) It has been hypothesized that this 
decrease occurs in the CSF because Aβ42 is accumulating in the brain, and consequently leading 
to the development of the plaques found in AD patients.(Motter et al., 1995)  In fact, in one 
autopsy study, investigators found that lower Aβ42 CSF levels were correlated with the 
neuropathological changes in AD, specifically with the development of plaques.(Strozyk, 
Blennow, White, & Launer, 2003)  Other studies have extended the knowledge of the association 
between Aβ42 and AD by investigating the association in patient populations with less severe 
cognitive impairment.  For example, in patients with MCI, those with the lowest level of CSF 
Aβ42 were more likely to progress to AD than MCI patients with the highest level.(Kester et al., 
2009)   
There are some limitations to using CSF Aβ42 as a biomarker of AD.  Not all studies 
have supported the association between low CSF Aβ42 and AD.  There have been reports of 
increased and unchanged levels of Aβ42 in AD patients.(Csernansky, Miller, McKeel, & Morris, 
2002; Jensen et al., 1999)  These differences could be due to different stages of the disease when 
Aβ42 was measured, different classification systems used to identify AD patients or differing lab 
assays to measure Aβ42.  They could also be caused generally by different population 
characteristics which somehow modify the association between Aβ42 and AD.  Thus, when 
using CSF Aβ42 as an indicator for AD, these intricacies and complications should be 
considered. Several strengths of CSF Aβ42should also be noted: it has been documented as one 
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of the most sensitive biomarkers for detecting prevalent AD(Shaw et al., 2009; Sunderland et al., 
2003); and when  used in combination with CSF tau, the result is a higher accuracy than either 
biomarker alone.(Tapiola et al., 2009) 
There are also several limitations to using CSF biomarkers in general.  For example, CSF 
is obtained through a lumbar puncture which is a highly invasive procedure that must be 
performed by a skilled medical professional.(Anoop et al., 2010)  Another weakness of CSF is 
that the laboratory methods used to quantify biomarkers can be quite expensive.(Anoop et al., 
2010)  Finally, there have been reported limits on the reproducibility of a diagnosis using CSF 
because of varying laboratory techniques, and variations in collection, transportation and storage 
of  CSF samples.(Anoop et al., 2010; Teunissen et al., 2010)  There are also several strengths to 
the use of CSF biomarkers.  As described earlier, CSF comes into direct contact with the brain, 
and thus might be the most reflective biomarker of neurochemical changes that occur directly in 
the brains of AD patients.(Baxter et al., 1984) The relatively high sensitivity and specificity of 
CSF biomarkers, especially when using Aβ42 and tau together, are another major 
benefit.(Tapiola et al., 2009)   
1.2.2 Neuroimaging 
Neuroimaging is useful for identifying pathological features of AD within the brain while the 
patient is still alive (as opposed to post-mortem autopsies of the brains). For example, imaging 
can be used to identify plaques, or to note structural changes of the hippocampus or overall 
neurodegneration.(Barber, 2010)  There are four primary types of imaging that are used to detect 
changes in the brains of AD patients: PET scans, MRI, fMRI, and SPECT.(Barber, 2010; 
Hampel et al., 2010) 
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 PET scans can be conducted using several different radioactive markers that identify 
different characteristics of the brain.  Two such markers are PiB and amyvid, which are used to 
detect amyloid plaques in the brain.(Barber, 2010; Klunk et al., 2004) These markers bind to 
amyloid in the brain, and there is significantly higher retention AD patients, as detected by PET 
scans.(Barber, 2010; Klunk et al., 2004)  Amyloid imaging has been widely validated for 
identifying amyloid build-up in the brain and for distinguishing AD patients from patients with 
other types of dementia.(Barber, 2010)  Another PET marker known as F-2-fluoro-2-deoxy-D-
glucose (FDG) detects changes in glucose metabolism within the brain which is a measure of 
neuronal activity, and thus in AD patients, retention of the FDG marker is greatly 
reduced.(Hampel et al., 2010)   
One primary weakness of PET scans is that the tracing markers injected into patients are 
radioactive.(Barber, 2010; Hampel et al., 2010)  In addition to the patient being exposed to 
radioactive material, these radioactive compounds are relatively unstable and have short half-
lives, so there is a strict timeline required from the time the hospital or clinic acquires the 
compound to the time the patient must get scanned.(Barber, 2010; Hampel et al., 2010)  Another 
potential weakness is PET scans require large scanning equipment, time, money, and a hospital 
or clinical setting where the scanner can be set up with staff to perform the scan and read the 
images, so PET scans have limited usefulness in population based settings.  Identifying reliable 
and valid blood biomarkers is one potential way to alleviate this weakness because they could 
identify those at the highest risk for AD or those in later stages of progression who could then be 
referred for scanning.  A strength of PET scans is that they are detecting a pathophysiological 
change within the brain, and used in combination with other diagnostic tools, such as cognitive 
tests, they can be very useful.(Barber, 2010; Hampel et al., 2010; Stern, 2009) 
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Structural MRIs are used to examine the size and integrity of brain structures; in the 
diagnosis of AD, they are used to assess overall cortical volume loss (atrophy), atrophy of the 
hippocampus, cortical thickness, and volume of the entorhinal cortex.(Barber, 2010; Hampel et 
al., 2010)  A decrease in hippocampal and entorhinal cortex volume and decreased cortical 
thickness are all considered biomarkers for AD.(Barber, 2010; Hampel et al., 2010)  Volumetric 
decreases of the hippocampus are the most widely accepted as an indicator for AD and have been 
well validated.(Barber, 2010; Hampel et al., 2010)  Changes in hippocampal volume have also 
been shown to be reliably predictive of transitioning from MCI to AD.(Barber, 2010)  The fMRI 
detects changes in blood flow in the brain, indicative of neuronal activity, and decreased 
neuronal activity is a marker of AD.(Greicius, Srivastava, Reiss, & Menon, 2004)  Results of 
fMRI studies have shown that AD patients have significantly less neuronal activity than non-AD 
patients – both when they are asked to perform some type of mentally taxing activity and when 
they are just resting; these results have been replicated and well-validated.(Barber, 2010; 
Greicius et al., 2004; Hampel et al., 2010) Similar to fMRI, functional brain imaging using 
SPECT can be used to detect cerebral perfusion, and may be useful in distinguishing AD from 
other types of dementia.(Jagust et al., 2001; McKeith et al., 2004) 
Using MRI imaging as an AD biomarker has several limitations, including requiring a lot 
of time and highly trained staff.(Barber, 2010)  Thus, they are difficult to use for diagnostic 
purposes in a large, population based setting because of limitations on time, staff and money. 
Furthermore, they may not be useful early on in disease progression because of lack of major or 
detectable structural change; for this same reason, they are limited as a biomarker in that they 
may not be able to predict those at high risk. There may also be slight variations in different MRI 
machines based on calibrations and age of the machine, so if multiple measurements are made on 
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one person over time to detect a longitudinal change, the same machine would need to be used to 
increase reliability; this includes differences in magnet strength which is proportional to the 
resolution of the image.(Barber, 2010)  Similar to PET scans, a benefit of MRIs is that they are 
detecting an actual structural change to the brain. A benefit of MRIs over PET scans is that they 
are less invasive to the patient because they use a set of magnets to produce an image of the 
brain, rather than injecting a radioactive substance into the participant.  Finally, while direct cost-
comparisons of MRI and PET scans in a hospital based setting for dementia were not available, a 
comparison for these two modalities for epilepsy has shown that MRIs might be slightly more 
cost-effective than PET scans.(DellaBadia, Bell, Keyes, Matthews, & Glazier, 2002) 
1.2.3 Blood Plasma and Serum (see Appendix A) 
1.2.3.1 Amyloid Beta 
Similar to CSF results, a low level of plasma Aβ42 and a low Aβ42/Aβ40 ratio have been 
associated with increased risk of developing AD.(Graff-Radford et al., 2007; Lewczuk et al., 
2009)  Some studies have reported an association between high plasma Aβ40 and increased risk 
for AD or dementia, although these results have not been consistently found.(Graff-Radford et 
al., 2007; Lambert et al., 2009; van Oijen, Hofman, Soares, Koudstaal, & Breteler, 2006)  In a 
recent prospective cohort study, we found an association between low plasma Aβ42/Aβ40 and 
increased cognitive decline over 9 years, and this association was modified by cognitive reserve, 
such that the association was stronger among those with less education, lower literacy, and with 
≥1 APOE e4 allele.(Yaffe, Weston, et al., 2011)  These results were similar to those from several 
prospective studies which reported an association between the Aβ42/Aβ40 ratio and 
dementia.(Graff-Radford et al., 2007; Lambert et al., 2009; van Oijen et al., 2006)  Notably, two 
 23 
of these studies used the Innogenetics INNO-BIA assay which is one of the newest, and arguably 
one of the most accurate methods of quantifying plasma Aβ.(Innogenetics, 2007; Lambert et al., 
2009; Yaffe, Weston, et al., 2011)  However, not all studies have found an association between 
plasma Aβ40, Aβ42 or Aβ42/Aβ40, and some have even found an association in the opposite 
direction.(Hansson et al., 2010; Lopez et al., 2008; R Mayeux et al., 1999)  For example, in one 
prospective study of 169 individuals who were dementia free at baseline, among those who 
developed AD over a 3.5 year time period, baseline plasma Aβ42 was 60% (p=0.001) higher 
compared to those who did not develop AD; there was no statistically significant association 
with Aβ40.(R Mayeux et al., 1999)  Similarly, the Aβ42/Aβ40 ratio was significantly higher at 
baseline among those who later developed AD (p=0.04).(R Mayeux et al., 1999)  In other cross-
sectional and prospective studies, there have been no reported associations between plasma Aβ42 
and the Aβ42/Aβ40 level and AD.(Hansson et al., 2010; Lopez et al., 2008)  Finally, a small 
number of studies have investigated the longitudinal association between plasma Aβ and 
cognitive decline or dementia, and have found decreasing levels of plasma Aβ42 or Aβ42/Aβ40 
over time are associated with greater declines in cognitive function.(R. Mayeux et al., 2003; 
Okereke, Xia, Selkoe, & Grodstein, 2009; Pomara, Willoughby, Sidtis, & Mehta, 2005; Seppala 
et al., 2010)  
Interpretation of these conflicting results may be due to different laboratory methods, 
heterogeneous study designs, differences in follow-up time, and small sample sizes in 
studies.(Graff-Radford et al., 2007; Hansson et al., 2010; Lewczuk et al., 2009; Lopez et al., 
2008)  Differences may also exist because of different stages of disease progression. Low Aβ42 
or low Aβ42/Aβ40 may represent a decrease of plasma Aβ42 with concurrent formation of 
plaques, but if measured too early in the disease progression, a low level of Aβ42 may not be 
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detected. This is supported by mice studies which have shown CSF and plasma Aβ decline 
concurrently as amyloid deposits form in the brain.(Kawarabayashi et al., 2001) In humans, one 
study reported that plasma Aβ42 decreased as participants age, but Aβ40 remained stable, which 
also supports this theory.(Graff-Radford et al., 2007)  Final supporting evidence comes from 
longitudinal studies which have found an association between decreasing levels of plasma Aβ42 
and greater declines in cognitive function or increased risk in AD.(R. Mayeux et al., 2003; 
Okereke et al., 2009; Pomara et al., 2005; Seppala et al., 2010) 
It is important to note that biological differences in each fragment (Aβ40 and Aβ42) may 
lead to differing associations with dementia and cognitive decline. Both Aβ40 and Aβ42 are 
proteolytic fragments of the 40-42 residues that are a product of APP.(Weggen et al., 2001)  
However, Aβ42 is the longer isoform, is more prone to aggregation, accrues earlier in the plaque 
formation process of AD because it more fibrillogenic(R Mayeux et al., 1999), and is found in 
greater quantities in amyloid plaques than Aβ40.(Gravina et al., 1995)  Thus, Aβ42 is thought to 
contribute more to AD pathology than Aβ40 isoforms.  
As discussed earlier, cognitive reserve may also have an effect on the association 
between plasma Aβ, and should be considered when determining the usefulness of potential 
biomarkers. For example, some individuals with extensive Aβ deposition as measured by 
autopsy or neuroimaging demonstrate little to no clinical symptoms of AD.(Bennett et al., 2006; 
Kemppainen et al., 2008; Rentz et al., 2010) Our recent findings provide support for the 
hypothesis that cognitive reserve modifies the association between plasma Aβ42/Aβ40 and 
dementia, and are also supported by several other studies.(Bennett et al., 2003; Rentz et al., 
2010; Yaffe, Weston, et al., 2011)  
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There are several possible mechanisms underlying the association between plasma Aβ 
and dementia. First, plasma Aβ40 and Aβ42 levels could be directly linked to the development of 
amyloid plaques in the brain, with circulating levels changing as pathological processes of 
dementia begin. While amyloid proteins are made in the brain and CSF, it is also believed that 
peripheral Aβ contributes to plaque formation.(Deane, Bell, Sagare, & Zlokovic, 2009)  Both 
Aβ40 and Aβ42 are thought to cross into the brain primarily via the receptor for advanced 
glycation end products (RAGE), and to be cleared from the brain via low-density lipoprotein 
receptors.(Deane et al., 2009)  Interestingly, a recent Health ABC study found an association 
between high peripheral advanced glycation end products and increased cognitive decline.(Yaffe, 
Lindquist, et al., 2011)  Other brain changes associated with AD have also been linked with 
circulating amyloid levels, and could underlie this association. For example, high plasma 
Aβ40/Aβ42  (consistent with low Aβ42/Aβ40) has been associated with amygdala atrophy, and 
decreased total brain volume.(Sun et al., 2010)  Another potential mechanism through which 
peripheral amyloid may contribute to dementia is through subclinical cardiovascular disease. 
There is evidence suggesting plasma Aβ42, a vasoactive protein, is directly related to 
atherosclerotic risk factors, such as midlife blood pressure, total cholesterol and diabetes.(Blasko 
et al., 2011; Shah et al., 2012) Similarly, plasma Aβ has been shown to accumulate in 
microvessels outside of the brain, and in doing so to play an integral role in increasing 
vasoconstriction, and the development of vascular disease.(Blasko et al., 2011; Shah et al., 2012) 
Interestingly, while these brain changes are associated with increased risk of AD, they are also 
associated with increased risk of depression, which in itself is another possible mechanism 
underlying an association between plasma Aβ and AD.(Sun et al., 2010)  A lifetime history of 
depression has also been associated with formation of amyloid plaques in the 
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hippocampus.(Rapp et al., 2006)  Interestingly, low Aβ42/Aβ40 has also been associated with 
increased risk for depression among older adults in the Health ABC study with ≥1 APOE e4 
allele.(A.L. Metti et al., 2012)  
Plasma Aβ42 and Aβ42/Aβ40 are potentially useful biomarkers for several reasons. First, 
one of the criterion for being a useful AD biomarker is that it should reflect fundamental 
neuropathology of AD.(The Ronald and Nancy Reagan Research Institute of the Alzheimer's 
Association and the National Institute on Aging Working Group, 1998) As explained, amyloid 
plaques are a key pathological component of AD, and there are many underlying mechanisms 
linking plasma Aβ levels and the formation of plaques.  A second key criterion for a useful AD 
biomarker is that it should be sensitive to the effects of therapy; as most current research on 
interventions for AD are focused on altering production and clearance of Aβ, plasma measures of 
these markers are particularly relevant.(Selkoe & Schenk, 2003; The Ronald and Nancy Reagan 
Research Institute of the Alzheimer's Association and the National Institute on Aging Working 
Group, 1998) Furthermore, when compared to imaging or obtaining CSF samples, drawing blood 
to measure plasma Aβ is relatively non-invasive, less expensive, and simpler to perform; all of 
these qualities lend this biomarker to be useful in large, population-based screenings. More 
studies are currently needed to investigate the sensitivity, specificity, and reliability of plasma 
Aβ42 and Aβ42/Aβ40. Furthermore, more longitudinal studies investigating how plasma Aβ40 
and Aβ42 fluctuate at multiple stages of disease progression would be useful. Finally, in order to 
gain a better understanding of how plasma Aβ40 and Aβ42 contribute to the underlying 
pathophysiology of the brain, more studies are needed to determine how these markers change 
with other risk factors for dementia, such as demographic and medical characteristics. While it 
may be difficult to determine the progression of the disease, studies would benefit from having 
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very rigorous screening to ensure participants are dementia-free, and ideally free of 
neuropathology at baseline. Furthermore, consistent laboratory methods for quantifying Aβ 
would strengthen future research.  
There are several weaknesses to the current literature investigating plasma Aβ and AD or 
cognitive decline, including the mixed results. Another weakness is that some studies have 
reported a large overlap between the distributions of Aβ42 in patients with and without cognitive 
impairment, so this biomarker may not be very sensitive.(Pomara et al., 2005)   Finally, many of 
the studies conducted up to this point are of relatively small sample sizes, and are primarily 
cross-sectional in nature; these features make it impossible to interpret causality and generalize 
the results for a large, diverse population.  
The role of Aβ antibodies as a potential biomarker of AD has also been of great interest 
lately with clinical trials investigating the potential use of Aβ immunization to reduce risk of 
AD.(Hock et al., 2002; Hock et al., 2003; Nicoll et al., 2003)  Investigated first in transgenic 
mice, immunization of Aβ anti-body was found to significantly reduce amyloid plaque 
deposition and neuronal death.(Schenk et al., 1999) Following, studies in humans found that in 
AD patients, compared to normal controls, levels of serum and plasma Aβ antibodies are 
significantly lower.(Brettschneider et al., 2005; Moir et al., 2005)  However, these results have 
not been consistent, and some studies have found no difference in Aβ antibody level between 
AD patients and normal controls.(Hyman et al., 2001)   While the first clinical trial investigating 
Aβ immunization to treat patients with AD was terminated early due to inflammation in the 
CNS, some results from Aβ immunization in people have been published.(Hock et al., 2002; 
Hock et al., 2003; Moir et al., 2005; Nicoll et al., 2003)  For example, one study found that 
among mildly to moderately demented patients (MMSE of 16-26) who had an immunoresponse 
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and post-immunization increases in Aβ antibody levels, compared to those who did not respond 
to the immunization, had decreased cognitive decline (p=0.008) and decreased functional decline 
(p=0.03) over 1 year.(Hock et al., 2003)  Furthermore, only 16% of those who exhibited an 
immunoresponse progressed to severe dementia, compared to 67% of those who did not 
(p<0.01).(Hock et al., 2003)  There are several potential underlying mechanisms that may 
explain this association. For example, it has been proposed that Aβ antibodies can cross the 
blood brain barrier (BBB), and higher levels in the periphery of cognitively normal older adults 
reflects the ability of Aβ to be cleared from the brain, reducing the risk of amyloid deposition 
and plaque development.(Moir et al., 2005) Others have hypothesized Aβ antibodies might not 
cross the BBB, but rather bind to Aβ42 and Aβ40 in the periphery, preventing those fragments 
from crossing the BBB and depositing in the brain.(Moir et al., 2005) 
1.2.3.2 Inflammatory Markers 
Several markers of inflammation evaluated in both blood plasma and serum may be potentially 
useful biomarkers, but results are still unclear.  In terms of dementia and AD, the most widely 
investigated inflammatory markers have been C-reactive protein (CRP), interleukin-6 (IL-6), and 
tumor necrosis factor alpha (TNF-α). Individual studies have found that a high level CRP, IL-6, 
or TNF-α, is associated with increased risk of AD and cognitive decline.(Gorelick, 2010; Noble 
et al., 2010; Schneider, Hampel, & Buerger, 2009)  In a prospective study of AD patients looking 
at both CRP and TNF-α with performance on a cognitive test over time, there was a significant 
baseline and longitudinal association between high TNF-α and poorer performance on the 
Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-COG), but no significant 
association with CRP.(Holmes et al., 2009)  However, while this study was prospective in 
 29 
nature, less than a year passed between the time of the first and last cognitive assessment which 
may be too short to detect significant changes in cognitive status.(Holmes et al., 2009) 
Furthermore, these participants already had dementia at the time of measuring inflammatory 
markers, so they may reflect a result of the dementia process rather than a predecessor.(Holmes 
et al., 2009)  In a previous Health, Aging and Body Composition (Health ABC) study, among 
those with the highest serum IL-6 or CRP tertile, 3MS scores were an average of 2 points lower 
at baseline, compared to those who were in the lowest IL-6 or CRP tertile (p<0.001 for 
both).(Yaffe et al., 2003)  Furthermore, those in the highest IL-6 tertile had a 1 point decline over 
2 years, compared to those in the lowest tertile (p=0.01), and the relationship over time was 
similar when comparing those in the high versus the low CRP tertile (p=0.04).(Yaffe et al., 2003)  
However, there were no significant differences at baseline or over time between TNF-α and 
cognitive function.(Yaffe et al., 2003)  A strength of this study is that the older adults were 
highly functioning at baseline with no cognitive impairment, so an association between 
inflammation and cognitive impairment is more likely to indicate a cause of impairment, rather 
than a result; another strength is the fairly diverse population with approximately half men and 
women, and half blacks and whites.(Yaffe et al., 2003) Finally, a large number of potential 
confounders were assessed. However, this study is limited in that it was conducted when 
minimal follow-up visits were completed, so only a 2-year decline in cognitive function was 
assessed. As dementia is a disease that progresses over a long period of time, having more 
follow-up is critical in assessing the development of the disease; we have proposed a follow-up 
study which will be discussed later in this document. In the Rotterdam Study, high IL-6 and α1-
antichymotrypsin (ACT) were significantly associated with an increased risk for dementia (rate 
ratio [RR] = 1.28, 95% confidence interval [CI]: 1.06, 1.55 and RR = 1.49, 95% CI: 1.23, 1.81, 
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respectively), and there was a trend for higher CRP to be associated with increased risk for 
dementia (RR = 1.12, 95% CI: 0.99, 1.25).(Engelhart et al., 2004b) There are several strengths to 
this study, including the complete dementia adjudication, and the large number of potential 
confounders assessed and adjusted for in analyses.(Engelhart et al., 2004b) Furthermore, a large 
number of potential confounders were assessed in both studies.(Engelhart et al., 2004b) 
However, similar to the Health ABC study, the Rotterdam study was limited in having only 2 
years of follow-up visits completed; as dementia is a disease that progresses over a long period 
of time, having more follow-up is critical in assessing the development of the disease.  
Several longitudinal studies have reported slightly longer follow-up when investigating 
the association between inflammation and dementia. In the MacArthur Study of Successful 
Aging, the association between plasma IL-6 and cognitive function was assessed longitudinally 
over follow-up periods of 2.5 and 7 years.(Weaver et al., 2002)  Those in the high, compared to 
those in the low IL-6 tertile, were significantly more likely to experience cognitive decline over 
2.5 years (OR=2.21; 95% CI: 1.44, 3.42 ), and over 7 years (OR=1.90; 95% CI: 1.14-
3.18).(Weaver et al., 2002)  These relationships were only significant when cognitive function 
was dichotomized, and not when a continuous measure of cognitive function was used.(Weaver 
et al., 2002)  Investigators hypothesize that this could be due to the fact that inflammation is not 
related to cognitive performance over the full range of cognitive function (i.e. only associated 
with the worst outcomes, hence the significant dichotomous association).(Weaver et al., 2002) 
This makes sense because these large changes in cognitive function are also more clinically 
meaningful.(Weaver et al., 2002)  A weakness to this study is that investigators measured 
inflammation at only one time point, so change in inflammation over time was not 
assessed.(Weaver et al., 2002) In the Framingham Study, with an average follow-up of 7 years 
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among participants, investigators reported a significant association between the highest tertile of 
TNF-α and an increased risk of developing AD (Hazards Ratio [HR] = 2.59, 95% CI: 1.09, 
6.12), but not among several other inflammatory markers including IL-1, the IL-1 receptor 
antagonist, CRP, or IL-6.(Tan et al., 2007) This study was strengthened by having extensive 
measurement of covariates which were adjusted for in models. However, one weakness is that all 
of the cytokines, with the exception of CRP, were measured relatively close to the time of 
outcome adjudication, so again, there may not have been enough time for the development of 
dementia; while CRP was measured earlier than the other inflammatory markers, investigators 
found no significant association between CRP and increased risk of AD.(Tan et al., 2007)  
In a recent meta-analysis of seven longitudinal studies, pooled hazards ratios were 
calculated to determine the association between peripheral inflammatory markers and risk of all-
cause dementia or AD.(Koyama et al., 2012) With a total of 5,717 pooled participants, 
investigators reported a significant association between high CRP and increased risk for AD and 
all-cause dementia (HR=1.21, 95% CI: 1.03, 1.42 and HR=1.45, 95% CI: 1.10, 1.91, 
respectively).(Koyama et al., 2012) When looking at high IL-6 versus low IL-6, there was a 
significant increased risk for all-cause dementia (HR=1.32, 95% CI: 1.06, 1.64), but not for AD 
alone (HR=1.06, 95% CI: 0.83, 1.35).(Koyama et al., 2012)  This finding highlights the 
possibility that inflammatory markers may be contributing to other types of dementia, such as 
vascular dementia, rather than just AD alone.  Several cautionary notes should be made, 
however, when drawing this conclusion: 1. As stated previously, cerebrovascular disease often 
contributes to many different types of dementia, including AD(Gorelick et al., 2011); 2. AD is 
the most commonly diagnosed form of dementia(Castellani et al., 2010); and 3. It is difficult to 
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interpret from many studies what exact definition of dementia was used, and many causes are 
often grouped together.  
While these results have been promising, some studies have found no association 
between AD and inflammation, or have found associations in the opposite direction. For 
example, in a prospective study of approximately 2,000 men, there was no significant association 
between IL-6 (HR: 0.66; 95% CI: 0.32-1.35) and CRP (HR: 0.79; 95% CI: 0.42-1.44) with risk 
of dementia.(Gallacher et al., 2010)  One weakness to this study is that men were quite young 
(45-59 years) when inflammatory markers were measured, so the markers may not have been 
indicative of cognitive status years later when cognitive function was assessed (65 to 84 years of 
age), and some of these men may have still been too young for the onset of clinically detectable 
dementia symptoms.(Gallacher et al., 2010) Another cross-sectional study found that high IL-6 
and IL-12 were associated with decreased processing speed and executive function, but not with 
other domains of cognitive function, such as memory, language, or spatial ability.(Troller et al., 
2011) Again, this could indicate that inflammation is related to cognitive deficits generally or to 
all-cause dementia, but maybe not specifically to AD. 
The role of inflammation in the oldest old (≥85 years of age) has also been less clear. For 
example, some studies have found that a higher level of CRP, IL-6 or TNF-α is associated with 
an increased risk for cognitive decline, but other studies have found no association between 
inflammation and cognitive decline or dementia.(Kravitz, Corrada, & Kawas, 2009b; Schram et 
al., 2007; van den Biggelaar et al., 2007)  In a prospective study of oldest old adults (all 90 years 
and older) who had CRP measurements assessed at multiple time points over 4.5 years, there was 
no association between elevated CRP and all-cause dementia, even after stratifying by APOE e4 
and gender.(Kravitz et al., 2009b)  Interestingly, at least one study has reported a protective 
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effect of higher CRP on cognitive function in this age group.(Silverman et al., 2009)  Finally, 
several studies have shown a significant interaction between APOE e4, inflammation, and 
cognitive function in this age group.(Kravitz et al., 2009b; Schram et al., 2007)  With such a mix 
of results reported, it is very difficult to make any real conclusions about the role of 
inflammation in the oldest old. This is critical because clinical trials are currently investigating 
the potential role of anti-inflammatory drugs in AD patients.(ADAPT Research Group, 2007; 
Aisen et al., 2003; Relkin, 2008; Tsakanikas & Relkin, 2010)  If there truly is a different 
association between inflammation and dementia in the young old, and the oldest old, 
understanding these differences will be crucial in interpreting results from these trials and in 
targeting therapeutic strategies to the oldest old.   
There have been explanations proposed for why a difference may exist between younger 
old and oldest old adults. For example, genetic polymorphisms in cytokine genes may play a 
crucial role.(Dato et al., 2010)  In a study of 1,651 Danish older adults born in 1905, visited in 
1998 and again in 2008, there were borderline significant associations between single nucleotide 
polymorphisms (SNPs) of the TNFα, IL-10, IL-18 and IL-15 genes and increased risk for poorer 
cognitive performance on the MMSE.(Dato et al., 2010)  This study was limited by being highly 
racially and ethnically homogenous, and by assessing cognitive function with only the 
MMSE.(Dato et al., 2010)  Furthermore, an association between inflammatory cytokine gene 
polymorphisms and cognitive function in the oldest old has not been consistently reported.(Di 
Bona et al., 2009)  Another potential explanation for the difference in the effects of inflammation 
among the young old versus the oldest old is antagonistic pleiotropy.(Silverman et al., 2009) 
This idea proposes that the effects of inflammation may be unfavorable at one time point, but 
favorable at another.  A final potential explanation is selective survival where surviving oldest 
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old adults have some genetic predisposition to be healthier, or more resistant to negative 
influences such as high inflammation or brain pathology.(Silverman et al., 2009)  
As discussed previously, one critical component of a successful biomarker for AD is that 
the biomarker in question should reflect to the etiologic process of AD.(The Ronald and Nancy 
Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging 
Working Group, 1998)  Thus, inflammatory markers are intriguing because they may, in fact, be 
large contributors to the underlying pathology and mechanisms of AD.(Neuroinflammation 
Working Group et al., 2000; Weuve, Ridker, Cook, Buring, & Grodstein, 2006)  It has been 
hypothesized that inflammation is a precursor to the development of neurofibrillary tangles, 
amyloid plaques, and neurodegeneration – all hallmarks of AD.(Neuroinflammation Working 
Group et al., 2000) One weakness to this theory is that in molecular studies, it has been shown 
that fibrillar Aβ and neurofibrillary tangles directly activate the complement pathway, so 
inflammation may be a consequence rather than a cause of AD.(Neuroinflammation Working 
Group et al., 2000)  Additionally, IL-6 is intimately involved in other pathophysiological 
processes of the nervous system, such as demyelination, which could contribute to white matter 
changes, and neurodegeneration.(Brunello et al., 2000; Neuroinflammation Working Group et 
al., 2000)  If IL-6 production is up-regulated or induced by the general aging process or by other 
conditions that occur in aging, it is possible that these changes begin the pathological process of 
dementia. High levels of CRP, IL-6 and TNF-α, have also been associated with decreased total 
brain volume (p<0.001) in a group of approximately 1900 Framingham Offspring.(Jefferson et 
al., 2007)  High serum CRP has also been associated with markers indicative of decreased 
neuronal function and decreased brain metabolism in middle-aged adults, suggesting it may play 
a role in cognitive decline or dementia in later life.(Eagan et al., 2012)  Finally, in middle-aged 
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adults, higher levels of IL-6 have been shown to be related to decreased hippocampal volume – a 
structure critical in the formation of long-term memories, and associated with 
dementia.(Marsland, Gianaros, Abramowitch, Manuck, & Hariri, 2008) 
Another way that inflammation could contribute to the underlying etiologic process of 
AD is through the development of other risk factors of dementia. For example, elevated IL-6 
affects lipid metabolism and triglyceride production, and stimulates the hypothalamic-pituitary-
adrenal axis, which is associated with central obesity, hypertension and insulin resistance; all of 
these factors are associated with increased risk for dementia.(Di Bona et al., 2009; Hildreth et al., 
2012; Kivipelto et al., 2001)  Higher levels of inflammation are also associated with 
cardiovascular disease, which is indeed a risk factor for dementia.(Ridker, Rifai, Rose, Buring, & 
Cook, 2002)  
Another possible mechanism linking inflammation and dementia is depression. 
Depression is a major risk factor for dementia, and a number of studies have shown an 
association between higher peripheral circulating levels of IL-6, CRP and TNF-α with prevalent 
depressive symptoms and major depression in older adults.(Penninx et al., 2003; van den 
Biggelaar et al., 2007)  One potential problem is that depression is often both a precursor and a 
result of dementia, so it is a possibility that results are confounding. In a prospective study of 
oldest old adults who were dementia and depression free at baseline, the association between 
circulating levels of CRP, IL-6, TNF-α and interleukin-1 (IL-1β), and development of depressive 
symptoms and cognitive impairment was investigated with the objective of trying to shed some 
light on the highly intertwined associations.(van den Biggelaar et al., 2007) Results indicated that 
depressive symptoms (Geriatric Depress Scale [GDS] scores) attenuated the relationship between 
MMSE and inflammation to a greater extent than cognitive function attenuated the association 
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between depressive symptoms and inflammation.(van den Biggelaar et al., 2007)  This suggested 
that inflammation plays a larger role in the development of depressive symptoms.(van den 
Biggelaar et al., 2007)  However, this association was limited to oldest old adults, and as we 
have previously discussed, there could be something unique about inflammation in this 
population.  
Genetics may also underlie an association between inflammation and AD.  For example, 
APOE e4 was investigated in a cross-sectional study comparing 206 middle-aged offspring with 
and without parental history of late-onset AD; those with a parental history of AD were 
significantly more likely to have at least one APOE e4 allele (p<0.001), and to have a higher ex-
vivo circulating level of IL-1β (p<0.001), IL-6 (p-value=0.04) and TNF-α (p-value=0.008).(van 
Exel et al., 2009)  However, when compared to those with no parental history of AD, those with 
a history were also significantly more likely to have higher systolic blood pressure and higher 
diastolic blood pressure which could independently affect inflammatory markers.(van Exel et al., 
2009) Circulating levels of serum CRP have also been previously associated with the APOE e4 
allele, where it was reported that 2% to 5% of the variability in circulating CRP may be due to 
APOE e4 allele status.(Chasman, Kozlowski, Zee, Kwiatkowski, & Ridker, 2006) Similarly, in a 
microarray study of immune and inflammation-related genes, investigators showed that there 
was significant up-regulation of immune or inflammatory-related gene expression in the aging 
brain.(Cribbs et al., 2012) Furthermore, in a recent genome-wide association study (GWAS) 
from the Religious Orders Study, investigators identified a variant (rs10808746) associated with 
the rate of cognitive decline, which influences two genes (PDE7A and MTFR1) that affect 
oxidative stress and inflammation; this supports the notion that inflammation is an important 
contributor to the underlying pathways of cognitive decline and dementia.(De Jager et al., 2012) 
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Similarly, in a GWAS study of cognitively normal older adults, another variant (rs17178006), 
influencing the MSRB3 gene, which plays a role in regulating oxidative stress, was associated 
with decreased hippocampal volume.(Bis et al., 2012) 
Finally, infection or systemic inflammation may also underlie an association between 
inflammation and dementia.(Perry, Cunningham, & Holmes, 2007) It has been hypothesized that 
microglia, or the innate immune cells of the central nervous system, are changed in older adults 
after a lifetime of insults due to infection and acute inflammatory response.(Perry et al., 2007) 
This is important because it has been proposed that one way peripheral inflammation affects the 
brain is by inflammatory mediators in the blood communicating with macrophages, which lack a 
BBB, and then go on to communicate with microglia, which triggers an inflammatory response 
in the brain.(Perry et al., 2007) Thus, changes in the microglia associated with aging are quite 
pernicious because rather than triggering a protective or anti-inflammatory response in the brain, 
a heightened inflammatory response is initiated in the brain after infection or systemic 
inflammation occurs, which contributes to more neurodegeneration.(Perry et al., 2007) 
Another criterion of a useful biomarker is sensitivity to the effects of therapy that modify 
the progression of AD.(The Ronald and Nancy Reagan Research Institute of the Alzheimer's 
Association and the National Institute on Aging Working Group, 1998)  However, thus far, 
clinical trials with non-steroidal anti-inflammatory drugs (NSAIDs) have not been 
promising.(Fields, Drye, Vaidya, Lyketsos, & Group; Gorelick, 2010; Weggen et al., 2001)  For 
example, in the AD Anti-inflammatory Prevention Trial (ADAPT, n=2528), there was no 
difference in risk of developing AD in celecoxib or naproxen sodium groups, compared to a 
placebo group after 3 years; similar results were found in the Alzheimer’s Disease Cooperative 
Study (ADCS, n=351) which found no difference in cognitive test scores in naproxen or 
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rofecoxib groups compared to a placebo group.(Fields et al.; Gorelick, 2010)  It should be noted 
that in an extended 2-year follow-up of ADAPT participants, it was concluded that NSAIDs may 
have pleiotropic effects, such that when given to cognitively normal participants, NSAIDs 
reduced the risk of AD after 2 to 3 years of administration, but when given to AD participants, 
NSAIDs had unfavorable effects on disease pathology.(Breitner et al., 2011)   However, in a 
recent comprehensive review of all randomized controlled trials of aspirin, NSAIDs, and steroids 
in the treatment of AD, investigators found no sufficient evidence that any of these treatments is 
effective in the treatment of AD.(Juturapatporn, Isaac, McCleery, & Tabet, 2012)  It is possible 
that more studies are needed to follow up participants for longer time periods, as shown with the 
extended results from the ADAPT trial. It should also be considered that the timing of the anti-
inflammatory administration in these trials was not ideal, and that if we had a clearer idea of 
when inflammation affected AD pathology, new trials administering anti-inflammatory drugs 
during this critical period would prove effective. Furthermore, it could be that special attention 
needs to be paid when classifying trial participants and analyzing data because if there is a 
pleiotropic effect at differing disease stages, this would weaken any reported associations when 
participants are misclassified. Finally, it is possible that more specific treatments targeted 
towards particular inflammatory markers that have been shown to have an effect on cognitive 
function (similar to anti-TNF drugs used in rheumatoid arthritis(Galloway et al., 2011)) would be 
more beneficial. 
One major question that must be addressed is whether peripheral inflammatory markers 
reflect direct changes in the brain. It has been previously reported that cytokines readily cross the 
BBB, suggesting that peripheral measures do reflect direct brain changes.(Banks, Plotkin, & 
Kastin, 1995)  Previous studies of mice have linked inflammatory response in the periphery with 
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inflammation in the brain, especially for IL-6, TNF-α and IL-1β.(Brebner, Hayley, Zacharko, 
Merali, & Anisman, 2000; Dantzer, 2001)  For example, one study of mice investigated the 
effects of circulating system IL-6 and IL-6 sR levels on the CNS and BBB by comparing wild 
type with mice, single transgenic mice overexpressing IL-6 or IL-6 sR in the periphery, and 
double transgenic mice overexpressing both IL-6 and IL-6 sR.(Brunello et al., 2000)  Both 
groups of single transgenic mice were free of neurological impairment, but the double-transgenic 
mice had considerable neurologic damage and a proliferation of astrocytes in the damaged 
areas.(Brunello et al., 2000) This suggests that both IL-6 and IL-6 sR are needed to cross the 
BBB.(Brunello et al., 2000)  Previous studies have also shown TNF-α and IL-6 can be 
transported across the blood brain barrier via saturable systems.(Banks, Kastin, & Broadwell, 
1995; Banks, Plotkin, et al., 1995)  Ability to cross the BBB may differ by type of inflammatory 
marker (i.e. cytokines vs. their soluble receptors). In mice, binding of TNF-α to its soluble 
receptor completely inhibited travel across the BBB, but unbound TNF-α could cross the 
BBB.(Banks, Plotkin, et al., 1995)  Furthermore, the soluble form of the receptor itself could not 
cross the BBB.(Banks, Plotkin, et al., 1995)  Translated to humans, it could mean that having a 
higher level of soluble receptors circulating may ultimately lead to fewer inflammatory cytokines 
crossing the BBB because bound cytokines and unbound soluble receptors could not 
cross.(Banks, Plotkin, et al., 1995)  Peripheral inflammatory markers may also set off a cascade 
of events, for example, up-regulating lipid mediators or communicating with peripheral 
macrophages, that ultimately leads to an inflammatory response in the brain.(Holmes & 
Butchart, 2011; Rosano, Marsland, & Gianaros, 2012) It has also been proposed that pro-
inflammatory markers increase endothelial permeability, which could increase inflammatory 
markers crossing the BBB through post-inflammatory dysfunction of the BBB.(Rosano et al., 
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2012) Thus, there seems to be evidence supporting that peripheral inflammatory markers can 
cross the BBB via multiple pathways, but as most studies thus far have been conducted in 
animals, more work is needed to determine how peripheral inflammatory markers are crossing 
the BBB in humans. 
On the other hand, if inflammatory markers do not cross the BBB, there are other means 
through which a peripheral inflammatory response may affect inflammation in the brain. As 
described previously, altered microglia in older adults, which communicate with macrophages 
after systemic inflammation or injury, may lead to increased inflammatory cytokine production 
in the brain.(Perry et al., 2007) Another proposed pathway of peripheral inflammatory markers to 
influence inflammatory response in the brain is via the vagus nerve.(Rosano et al., 2012) Sensory 
nerve fibers in the vagus nerve, activated in the abdomen and chest by peripheral inflammatory 
markers, relay information very rapidly to the brain, triggering an inflammatory response in the 
brain.(Rosano et al., 2012)  
An important limitation to understanding the association between inflammation and 
dementia is that it is not completely clear if the inflammation precedes the symptoms of AD, or if 
the inflammation is a result.(Neuroinflammation Working Group et al., 2000)  Abnormal 
materials in the periphery are a common cause of inflammation, so it is not strange to consider 
that plaques and tangles in the brain are a cause of inflammation.(Neuroinflammation Working 
Group et al., 2000)  Aβ and tau neurofibrillary tangles as well as neurodegeneration have all 
previously been shown to activate the complement pathway.(Neuroinflammation Working Group 
et al., 2000)  Furthermore, the process of aging is associated with chronic, low-grade 
inflammation which makes it even more difficult to determine if, how and when inflammation 
may be important in the pathway of AD.(Neuroinflammation Working Group et al., 2000) 
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Other limitations to understanding the role of inflammatory markers in predicting 
dementia include relatively new and not well validated or standardized methodology across 
studies, and highly mixed epidemiological and trial results. Furthermore, many studies 
investigating these markers only measure inflammation at one time point,(Kravitz et al., 2009b; 
Schram et al., 2007; Silverman et al., 2009; van den Biggelaar et al., 2007) and it is extremely 
difficult to conclude if the inflammation measured is the result of some acute event, such as 
infection or injury, or is an indicator of a consistently elevated level of inflammation. Thus, more 
studies are needed to assess if change in inflammation over time is associated with dementia. 
Furthermore, the current gold standard of living biomarkers for distinguishing Alzheimer’s 
disease from other types of dementia are cerebrospinal fluid-derived amyloid beta and tau(Anoop 
et al., 2010; Teunissen et al., 2010);  if considered as useful biomarkers for dementia, peripheral 
inflammatory markers should be compared against this gold standard, and achieve a good 
predictive ability, either alone or in combination with other markers. It is unclear if these 
markers would be as useful at distinguishing AD, or perhaps some other subtype of dementia, 
but certainly more work is needed in this area. 
 In spite of these weaknesses, there are important strengths in using peripheral 
inflammatory markers as potential predictors of dementia. For example, the relative ease of 
collecting blood, making it a viable option for large, population-based epidemiological studies. 
Furthermore, methods used to quantify multiple inflammatory markers or inflammation-related 
genes, such as proteomics or microarray studies are emerging and may strengthen the current 
research. For example, one study using proteomics found that a panel of approximately 22 
serum-derived proteins could be used to identify AD patients from normal controls with a 
sensitivity of 0.80 and a specificity of 0.91; interestingly a large number of these proteins were, 
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in fact, inflammatory markers.(O'Bryant et al., 2010) Similar studies have also reported panels of 
plasma-derived proteins that contain a number of inflammatory proteins and with fairly high 
accuracy can distinguish AD patients from normal controls.(Johnstone, Milward, Berretta, 
Moscato, & Alzheimer's Disease Neuroimaging, 2012; Ray et al., 2007) However, one study 
comparing CSF and plasma proteomes found that the CSF proteome was much better at 
distinguishing AD patients from normal controls, and in order for the plasma proteome to 
successfully distinguish these two groups, APOE and age had to be added to the 
models.(Britschgi et al., 2011) 
1.2.4 Summary 
Using serum and plasma inflammatory markers as biomarkers of AD has strengths and 
weaknesses.  Weaknesses include relatively new and not well validated methods, highly mixed 
results in small cross-sectional studies, and the fact that markers taken from the periphery may 
never come into direct contact with the brain.  Furthermore, many studies investigating these 
markers in both the young old and oldest old have been cross-sectional, or if longitudinal, only 
measure inflammation at one time point.(Kravitz et al., 2009b; Schram et al., 2007; Silverman et 
al., 2009; van den Biggelaar et al., 2007)  Thus, more studies are needed to assess if change in 
inflammation over time is associated with dementia. Furthermore, many studies have focused on 
only one inflammatory marker at a time, rather than assessing the role of multiple markers 
together.(Kravitz et al., 2009b; Silverman et al., 2009)  In spite of these weaknesses, there are 
important strengths in using plasma or serum which include the relative ease of collecting blood, 
making it a viable option for large, population-based epidemiological studies. Furthermore, 
methods used to quantify inflammatory markers in blood serum and plasma are less expensive 
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than those used to quantify CSF markers, and costs will likely decrease as technology becomes 
more available. Finally, the peripheral biomarkers discussed today all have biological plausible 
relationships with AD and with other risk factors for AD.  
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2.0  SPECIFIC AIMS 
Plamsa amyloid beta and inflammatory markers need further investigation and validation as 
biomarkers of AD. We aim to overcome limitations of previous studies as outlined above, and to 
advance the knowledge of these proteins as potential biomarkers of AD.  
2.1 PLASMA AMYLOID BETA 
In spite ongoing research investigating the use of plasma Aβ40 and plasma Aβ42 as potential 
biomarkers of AD, dementia and cognitive decline, little is known about the general 
demographic and medical correlates of plasma Aβ40 and Aβ42, and how correlates may impact 
the relationship between plasma Aβ and cognitive decline.  In order to fully understand these 
proteins as biomarkers, we must understand how the proteins relate to other diseases found in 
aging, and with demographic correlates, such as age, race and education. By improving our 
understanding of these relationships, not only will future studies be able to measure and account 
for all potential confounders, but it will also shed some light on the mechanisms underlying an 
association between plasma Aβ and cognitive function.  
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2.1.1 Specific Aim 1 
We aim to identify and describe the demographic and medical correlates of plasma Aβ40 and 
Aβ42 in a population of community-dwelling, non-demented, black and white older adults, age 
70-79 at baseline. 
2.2 INFLAMMATORY MARKERS 
As described previously, numerous studies have investigated the association between 
inflammatory markers and AD, dementia and cognitive decline due to the biological plausibility 
of inflammation contributing to the development of dementia via several potential pathways. 
However, most of these studies have focused on measuring inflammatory markers at only one 
time point which has major limitations, especially given the non-specific nature and fluctuation 
of inflammatory markers. Instead, it is likely that inflammation at one time point is not 
influencing the development of dementia, but rather how steep the slope of change of 
inflammation is, or how much variability a person has in inflammation over time. Furthermore, 
the association between inflammation and dementia appears to weaken with advancing age with 
studies showing inconsistent results in adults who are 85 years of age and older. Better 
understanding trajectories of change of inflammation, as well as how the strength of these 
associations change with age will not only improve our understanding of potential mechanisms 
underlying an association between inflammation and dementia, but also allow us to improve 
intervention and therapeutic strategies involving anti-inflammatory drugs.  
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2.2.1 Specific Aim 2 
We aim to: 1) determine the association between IL-6, IL-6 sR and tumor necrosis factor soluble 
receptor 1 (STNF-R1) measured at an initial and an interim visit and subsequent cognitive status 
among oldest old women from the Study of Osteoporotic Fractures; and 2) to determine the 
association between change in each inflammatory marker and cognitive status.   
2.2.2 Specific Aim 3 
We aim to determine the association between the baseline level, slope of change, and variability 
of CRP and IL-6, measured at a minimum of three time points, and cognitive decline over ten 
years in the Health, Aging and Body Composition Study.  
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3.1 ABSTRACT 
Plasma amyloid beta-42 (Aβ42) and Aβ42/Aβ40 are increasingly recognized as biomarkers for 
dementia, with low levels indicating increased risk. Little is known about the demographic and 
medical correlates of plasma Aβ40 or Aβ42.  In 997 community-dwelling, non-demented older 
adults from the Health, Aging and Body Composition Study, we determined the cross-sectional 
association between a wide range of demographic and medical variables with Aβ40 and Aβ42.  
In multivariate stepwise linear regression models, Aβ40 was significantly associated with race 
(β=-14.70, F=22.01, p<0.0001), age (β=1.34, F=6.39, p=0.01), creatinine (β=52.91, F=151.77, 
p<0.0001), and serum brain-derived neurotrophic factor (BDNF) (β=-0.0004, F=7.34, p=0.007); 
Aβ42 was significantly associated with race (β=-3.72, F=30.83, p<0.0001), sex (β=1.39, F=4.32, 
p=0.04), education (β=1.50, F=4.78,  p=0.03), Apolipoprotein E (APOE) e4 allele status (β=-
2.82, F=16.57,  p<0.0001), and creatinine (β=9.32, F=120.09, p<0.0001).  These correlates 
should be considered as potential confounders in future studies investigating plasma Aβ as a 
biomarker of dementia. Understanding fully how these correlates mediate or modify the 
association between plasma Aβ and dementia will be a fundamental step in determining the 
biological pathways through which plasma Aβ40 and Aβ42 are associated with dementia, and in 
determining their full potential as biomarkers.  
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3.2 INTRODUCTION 
Recent studies have indicated that plasma amyloid beta-40 (Aβ40), Aβ42 and the ratio 
(Aβ42/Aβ40) may be promising biological markers for cognitive impairment or dementia in 
older adults.  For example, decreased plasma Aβ42 was shown to be associated with increased 
risk for developing Alzheimer’s disease (AD) and increased cognitive decline over time.(Graff-
Radford et al., 2007; Lewczuk et al., 2009; Pesaresi et al., 2006; Yaffe, Weston, et al., 2011) 
Similarly, a prospective longitudinal study found that low plasma Aβ40 was associated with 
incident AD in older men.(Sundelof et al., 2008)  Low Aβ42/Aβ40 has also been associated with 
increased cognitive decline over time among non-demented elders, and with increased risk for 
AD.(Graff-Radford et al., 2007; Yaffe, Weston, et al., 2011) These two proteins are of interest 
because they accumulate in the brain, forming the plaques found in AD patients. Furthermore, 
these proteins have been well established as biomarkers for AD when measured from 
cerebrospinal fluid (CSF) samples.  For example, CSF Aβ42 declines in patients with incident 
dementia, and has been documented as one of the most sensitive biomarkers for detecting 
prevalent AD.(Shaw et al., 2009; Sunderland et al., 2003)  Similarly, some studies have shown 
that low CSF Aβ40 is associated with mild cognitive impairment (MCI) or the early stages of 
dementia.(Jensen et al., 1999)  The possibility of identifying Aβ as a useful biomarker from 
plasma is clinically important because a simple blood draw is much less invasive and less 
expensive than the lumbar puncture required to obtain CSF. 
In spite of this ongoing research, little is known about the general demographic and 
medical correlates of plasma Aβ40 and Aβ42, and how correlates may impact the relationship 
between plasma Aβ and cognitive decline.  This information is important so these proteins can be 
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fully understood as biomarkers, and so future studies investigating the potential use of plasma 
Aβ40 and Aβ42 as biomarkers for cognitive decline can measure and account for all potential 
confounders.  Furthermore, understanding what factors are related to plasma Aβ40 and Aβ42 
may shed some light on the mechanisms underlying an association between plasma Aβ and 
cognitive function. Importantly, one previous study has investigated correlates of plasma Aβ, but 
the study population consisted of only 205 cognitively normal controls, while the remaining 
sample was comprised of patients with MCI (n=348) or AD (n=162).(Toledo et al., 2011) As 
previous studies have shown that plasma Aβ levels change at different stages of disease 
progression(Schupf et al., 2008; Seppala et al., 2010), more studies are needed to investigate 
correlates of these markers in community-dwelling, non-demented older adults. Thus, the 
objective of this study is to describe the demographic and medical correlates of plasma Aβ40 and 
Aβ42 in a population of community-dwelling, non-demented, black and white older adults, age 
70-79 at baseline.  
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3.3 METHODS 
3.3.1 Study Population 
Community-dwelling white and black older adults were enrolled in the ongoing Health Aging 
and Body Composition (Health ABC) study.  This prospective cohort study began in 1997, and 
adults ranged in age from 70 to 79 years at enrollment, and lived in Memphis, TN or Pittsburgh, 
PA.  Participants were recruited from a random sample of Medicare eligible adults living within 
the designated zip codes, and were eligible if they reported no difficulties performing activities 
of daily living, walking a quarter mile, or climbing 10 steps without resting.  They also had to be 
free of life-threatening cancers, and plan to remain within the study area for at least three 
years.(Yaffe et al., 2007)  Plasma Aβ42 and Aβ40 were measured in a random sample of 1000 
sex and race stratified participants. Of those, 3 had incomplete plasma amyloid data due to 
insufficient amounts of stored blood or measurement error; thus our analytic cohort was 
comprised of 997 participants. All participants included in this analytic cohort were free of 
cognitive impairment at baseline; consistent with previous literature, cognitive impairment was 
defined as a Modified Mini-Mental Status Exam (3MS) score <80.(Slinin et al., 2010) Compared 
to Health ABC participants who did not have plasma Aβ measured, those in this subgroup were 
more likely to be black, female, and to have lower mean education, but did not differ on other 
characteristics. This study was approved by the institutional review boards of the University of 
Pittsburgh and the University of Tennessee, Memphis, and that of the Coordinating Center, the 
University of California, San Francisco. All participants signed a written informed consent. 
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3.3.2 Beta Amyloid 
Stored plasma obtained at the first Health ABC follow-up visit was used to measure Aβ40 and 
Aβ42.  Plasma was stored at -70° C at Fisher BioServices, Inc. Laboratories and shipped directly 
to the analytical laboratory.  Plasma Aß was measured at the laboratory of Dr. Steven Younkin at 
the Mayo Clinic using Innogenetics INNO-BIA assays.  The detection limit for this assay is 12 
pg/ml for Aß40 and 5 pg/ml for Aß42.  Mean inter-assay coefficient of variation was 9.9% for 
Aß40 and 9.3% for Aß42 and mean intra-assay coefficient of variation was 3.5% for Aß40 and 
2.3% for Aß42. Consistent with previous literature, tertile cutoffs were used to categorize Aβ40 
and Aβ42 into “low” “medium” and “high” groups.   
3.3.3 Potential Correlates 
At baseline, demographic data including self-reported participant age, race, sex and education 
were recorded. Literacy was measured at baseline with the Rapid Estimate of Adult Literacy in 
Medicine (REALM).(Davis et al., 1993)  REALM scores were categorized as ≤8th grade and 
>8th grade, as it has been reported that this cutoff differentiates those who are functionally 
illiterate versus literate in a healthcare setting.(Osborn et al., 2007; Rothman et al., 2004) 
Cognitive function at baseline was measured with the Modified Mini-Mental Status Exam 
(3MS). The 3MS is an assessment of global cognitive function with components for orientation, 
concentration, language, praxis, and immediate and delayed memory.(Teng & Chui, 1987) Social 
support scores were based on the average frequency of visits per week with friends, neighbors, 
and relatives. Scores were dichotomized into two groups: < the median or ≥ the median.  Self-
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reported information on smoking history was recorded and dichotomized into never versus ever 
having smoked.  
Prevalent disease algorithms based on both self-report and physician diagnoses, recorded 
medications and laboratory data were used to create comorbidity variables indicating presence of 
diabetes mellitus, hypertension, stroke or transient ischemic attack (TIA), and myocardial 
infarction (MI). The Center for Epidemiologic Studies Depression Scale (CES-D) was used to 
assess depressive symptoms with a score ≥16 consistent with possible depression.(Radloff, 1977) 
Body mass index (BMI) (kg/m2) was calculated from direct height and weight measurements at 
baseline.  Physical activity level was determined using a standardized questionnaire designed 
specifically for the Health ABC study, which has been previously described.(Brach et al., 2004) 
Total physical activity including household chores, paid work, volunteer work, care giving, stair 
climbing, non-exercise walking, walking for exercise and other moderate and vigorous exercise 
activities, were measured in kilocalories per week (kcal/wk).(Brach et al., 2004)  
Apolipoprotein E (APOE) e4 allele status was determined using standard Single 
Nucleotide Polymorphism (SNP) genotyping techniques and dichotomized into having one or 
more APOE e4 allele versus no allele.(Hixson & Vernier, 1990) Brain-derived neurotrophic 
factor (BDNF) was measured from frozen serum collected at the first follow-up visit. Assays 
were performed by R&D Systems’ Analytical Testing Service, using their own commercial kit 
employing an enzyme-linked immunosorbent assay method.  The detection limit for this assay is 
1250 pg/mL.  The mean inter-assay coefficient of variation is 9.0%, and the mean coefficient of 
variation within assay is 5.0%. 
At baseline, low-density lipoprotein cholesterol (LDL) (mg/dl), high-density lipoprotein 
cholesterol (HDL) (mg/dl), total cholesterol (mg/dl) and triglycerides (mg/dl) were measured 
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from fasting blood serum. Measures of high sensitivity C-reactive protein (CRP), tumor necrosis 
factor-α (TNFα), interleukin-6 (IL-6) and creatinine were obtained from frozen serum or plasma 
collected at baseline after an overnight fast. Samples were frozen at -70°C and were shipped to 
the Core Laboratory at the University of Vermont.(Minev et al., 2010; Yaffe et al., 2003) Serum 
CRP was measured in duplicate by enzyme-linked immunosorbent assay on the basis of purified 
protein and polyclonal anti-CRP antibodies, and assays were standardized according to the 
World Health Organization First International Reference Standard with a sensitivity of 0.08 
µg/ml.(Kalogeropoulos et al., 2010)  Plasma IL-6 and TNFα were measured in duplicate by 
ELISA kits from the R&D Systems (Minneapolis, MN).(Yaffe et al., 2003) The detectable limit 
for IL-6 was 0.10 pg/ml, and for TNFα was 0.18 pg/ml.(Yaffe et al., 2003) Creatinine was 
measured with the colorimetric technique on a Johnson & Johnson VITROS 950 Chemistry 
Analyzer (Johnson & Johnson, New Brunswick, N.J., USA) using the  enzymatic method.(Minev 
et al., 2010)  
3.3.4 Statistical Analyses 
To describe the distribution of plasma Aβ40 and Aβ42, a variety of descriptive statistics were 
calculated including assessment of the mean, median, range and standard deviation. The relationship 
between Aβ40 and Aβ42 was examined using Spearman’s correlation coefficient. Fisher’s exact, 
Pearson’s chi-square, and t-tests were used, as appropriate, to determine the association between 
plasma Aβ40 and Aβ42 tertile and baseline participant characteristics. Finally, stepwise multivariate 
linear regression models were examined for both Aβ40 and Aβ42 to determine which characteristics 
independently predicted plasma level. Variables that were associated in bivariate analyses (p<0.10) 
with Aβ40 or Aβ42, respectively, were considered for these models. We used a forward stepwise 
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selection process with variables significant at the p=0.15 entry and exit criteria to determine the final 
multivariate models. The relative strength of the associations was expressed as an absolute 
difference in units of change chosen to approximate 1 SD in the distribution for each continuous 
variable or null category for dichotomous variables, similar to previous studies investigating 
correlates of markers in older adults.(Cauley et al., 2010; Sheu et al., 2009) The formula used to 
calculate the absolute difference in rate of change in plasma Aβ per unit change (SD) of the 
independent variable was β* = unstandardized β x unit change in independent variable. The 
corresponding 95% confidence intervals (CIs) were calculated using the following formula: β ± 
(1.96 x SE) x unit change. All statistical analyses were performed using SAS version 9.1 (SAS 
Institute Inc., Cary, NC).  
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3.4 RESULTS 
Among the 997 community-dwelling older adults, the means (standard deviation) of Aβ40 and 
Aβ42 were 191.6 pg/ml (50.3) and 33.9 pg/ml (9.6), respectively. The median of Aβ40 was 
192.5 pg/ml, and of Aβ42 was 32.8 pg/ml. The Spearman correlation coefficient was 0.51 
(p<0.0001) for both markers as continuous variables, and 0.42 (p<0.0001) for both markers with 
tertile cutoffs.  
Those with low plasma Aβ40 were significantly younger (73.6±3.0 years for low tertile 
vs. 74.5±2.9 for high tertile, p-value = 0.0001), more likely to have less than a high school 
education (N(%), 223 (67.2%) vs. 197 (59.5%), p-value = 0.03) to be black (201 (60.4%) vs. 147 
(44.1%), p-value <0.0001), to have lower serum creatinine (mg/dl, 1.0±0.2 vs. 1.2±0.5, p-value 
<0.0001), to have higher HDL cholesterol (mg/dl, 56.6±17.7 vs. 52.9±16.5, p-value=0.02), to 
have higher BDNF (pg/ml, 23361.6±10648.3 vs. 20944.4±10022.9, p=0.006), and to have lower 
TNFα (pg/ml, 3.3±2.1 vs. 3.7±1.7, p=0.0007) (Table 3.7.1). There were no differences of Aβ40 
by sex, literacy, baseline 3MS scores, social support, physical activity, history of stroke/TIA, 
diabetes history, myocardial infarction, BMI, depressive symptoms, APOE e4 allele status, C-
reactive protein, IL-6, total cholesterol, LDL cholesterol, triglycerides, or smoking history.   
Those with low plasma Aβ42 were more likely to be female (196 (59.8%) vs. 183 (55.5), 
p-value = 0.05), to have less than a high school education (231 (70.6%) vs. 193 (58.8%), p-value 
= 0.006), to be black (214 (65.2%) vs. 151 (45.8%), p-value <0.0001), to have a history of 
diabetes ( 94 (29.8%) vs. 68 (21.3%), p-value = 0.04) to have at least 1 APOE e4 allele (118 
(38.3%) vs. 73 (23.1%), p-value=0.0002), to have lower creatinine (mg/dl, 1.0±0.2 1.1±0.6, p-
value<0.0001), to have greater social support (179 (54.6%) vs. 154 (46.7%), p-value=0.05), and 
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to have higher HDL cholesterol (mg/dl, 57.3±17.9 vs. 53.5±16.9, p=0.007) (Table 3.7.2). There 
were no differences by Aβ42 and age, literacy, baseline 3MS scores, physical activity, history of 
stroke/TIA, myocardial infarction, BMI, depressive symptoms, C-reactive protein, TNFα, IL-6, 
BDNF, total cholesterol, LDL cholesterol, triglycerides, or smoking history. 
In a stepwise multivariate linear regression model, Aβ40 was significantly associated 
with age (β=1.34, F=6.39, p=0.01), race (β = -14.70, F=22.01, p<0.0001), creatinine (β = 52.91, 
F=151.77, p<0.0001), and BDNF (β=-0.0004, F=7.34, p=0.007) (Table 3.7.3). Similarly, Aβ42 
was significantly associated with race (β=-3.72, F=30.83, p<0.0001), sex (β=1.39, F=4.32, 
p=0.04), education (β=1.50, F=4.78, p=0.03), APOE e4 allele status (β=-2.82, F=16.57,  
p<0.0001), and creatinine (β=9.32, F=120.09, p<0.0001) (Table 3.7.3).   
The strength of the associations are expressed as an absolute difference in units of change 
(1 SD for continuous variables or null category for dichotomous variables) (Table 3.7.4). Age, 
race, creatinine, and BDNF were all significant correlates of Aβ40; race, sex, education, APOE 
e4, and creatinine were all significant correlates of Aβ42, although sex and education were 
borderline (Table 3.7.4). 
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3.5 DISCUSSION 
Our results indicated that plasma Aβ40 and Aβ42 are fairly normally distributed among older 
adults without dementia. Furthermore, our results suggested that in a community-dwelling 
sample of white and black older adults, plasma Aβ40 significantly differed by age, race, 
education, serum creatinine, serum BDNF, HDL cholesterol and the inflammatory marker TNFα. 
Similarly, plasma Aβ42 was significantly associated with race, sex, education, social support, a 
history of diabetes, HDL cholesterol, serum creatinine and APOE e4 allele status.  
Our results are supported by prior indirect associations between demographic and 
medical risk factors and AD. For example, we found black race was associated with significantly 
lower levels of plasma Aβ40 and Aβ42, and being female was significantly associated with a 
lower level of Aβ42. As it has been shown that African Americans and females have an 
increased risk of AD, and other studies have shown low Aβ42 is associated with increased risk of 
dementia, these results seem consistent.(Green et al., 2002; Yaffe, Weston, et al., 2011)  
Our results showing an association between diabetes and plasma Aβ42 are in support of 
earlier studies suggesting that consistently increased insulin levels in the brain may lead to 
increased Aβ42 deposition and plaque formation, and subsequent decreases in peripheral plasma 
Aβ42.(Duckworth, Bennett, & Hamel, 1998; Qiu et al., 1998) Our results differ from another 
longitudinal study that recently found higher total cholesterol and higher LDL cholesterol 
predicted low plasma Aβ42.(Blasko et al., 2011) Furthermore, this previous study found no 
association between HDL cholesterol and Aβ42 at baseline or over time, as we did with plasma 
Aβ40 and Aβ42.(Blasko et al., 2011) Similarly, we found no association between Aβ40 or Aβ42 
with LDL, total cholesterol, triglycerides, or history of myocardial infarction or stroke – both of 
which have high cholesterol as a common risk factor. Finally, the association we found between 
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both plasma Aβ40 and Aβ42 and serum creatinine – a measure of renal function – is supported 
by another study which found that in older patients with chronic renal failure, dialysis 
significantly lowered plasma Aβ42 level; these results indicate a close relationship may exist 
between renal function and plasma Aβ42.(Rubio, Caramelo, Gil, Lopez, & Garcia de Yebenes, 
2006)   
It is widely known that the APOE e4 allele is associated with increased risk for AD, and 
in this study we found older adults with at least one APOE e4 allele were more likely to have 
low Aβ42; APOE has also been shown to modify the association between Aβ42 and Aβ42/Aβ40 
and cognitive decline.(Jarvik, Larson, Goddard, & Wijsman, 1996; Yaffe, Weston, et al., 2011)  
An interesting finding was the association between higher serum BDNF and low plasma Aβ40. 
BDNF is thought to have neuroprotective effects and to promote brain plasticity.(Diniz & 
Teixeira, 2011) BDNF has also been shown to regulate the Amyloid Precursor Protein (APP) 
which is thought to reduce the production of amyloid peptides (i.e. Aβ40).(Diniz & Teixeira, 
2011)  Thus, it is possible that higher levels of serum BDNF may, at least in part, regulate 
plasma Aβ40, resulting in the lower plasma Aβ40 level. There was no relationship found 
between plasma Aβ42 and serum BDNF. The inflammatory marker TNFα has been shown to be 
associated with increased risk of cognitive decline over time.(Gorelick, 2010) While we found an 
association between low TNFα and low plasma Aβ40, which is contrary to what we expected, we 
believe this could be due to the less specific association between Aβ40 and AD or cognitive 
decline (versus the relationship between Aβ42 and cognitive function).(Gorelick, 2010)  
Importantly, our results are also supported in part by the previous study investigating 
correlates and predictors of plasma Aβ in a population of cognitive normal, MCI and AD 
patients.(Toledo et al., 2011)  Both studies reported relatively normal distributions of both 
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plasma Aβ40 and Aβ42, indicating no need to log-transform plasma Aβ40 or Aβ42 when 
analyzing as continuous variables, although it was reported that the ratio needed log-
transformation.(Toledo et al., 2011) Furthermore, both studies found significant associations 
between higher Aβ40 and Aβ42 and poorer kidney function in t-tests, and found that creatinine 
significantly predicted both markers.(Toledo et al., 2011) Other similarities were significant 
associations between age and Aβ42, APOE and Aβ42 and cholesterol and Aβ40.(Toledo et al., 
2011) This study did not support our findings in that it found no association between education 
or race with either plasma marker; in models the most significant predictors of Aβ40 and Aβ42 
were creatinine, total proteins and cholesterol, while our results showed different significant 
predictors of Aβ42 and Aβ40.(Toledo et al., 2011) Interestingly in the other study, age, 
education nor APOE e4 significantly predicted either marker as we found, and these are known 
strong risk factors for AD.(Toledo et al., 2011)  Finally, the prior study found a much stronger 
correlation between plasma Aβ40 and Aβ42 (r=0.83 vs. r=0.51).(Toledo et al., 2011)  We 
believe differences are most likely attributable to different populations, as our study was made 
up of community-dwelling older adults who were all dementia free, compared to a population of 
primarily MCI and AD patients with only a small proportion of cognitively normal 
controls.(Toledo et al., 2011) Given these characteristics, the contrasting results could reflect that 
disease progression largely affects plasma Aβ measurements and correlates. Ultimately, more 
studies are needed to better understand the fluctuations of plasma Aβ40 and Aβ42 in older adults 
who age without cognitive decline, with MCI and with AD to better understand these 
relationships. 
If plasma Aβ40 and Aβ42 are indeed useful biomarkers of cognitive decline and 
dementia, then it is important to fully understand how these biomarkers are influenced by 
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demographic and medical conditions for several reasons. First of all, at a very basic level, it will 
be important so that future studies can measure and adjust for all potential confounders when 
investigating the association of plasma Aβ to ensure the most accurate results are presented. 
Understanding demographic and medical correlates will also be crucial in considering what 
factors may regulate plasma Aβ. This will be critical for gaining a better understanding of the 
mechanisms underlying cognitive decline and dementia. It will also help in identifying possible 
targets for interventions in reducing risk of or preventing dementia.   
This study had several strengths, including the large sample size providing ample 
analytical power for this study. Measurement of numerous potential confounders allowed us to 
investigate a large number of demographic and medical characteristics in one sample.  Finally, 
Innogenetics INNO-BIA assays were used for our measurements of Aβ42 and Aβ40, and this 
method may provide more accurate measurements of Aβ42 and Aβ40 due to its high sensitivity, 
low variability, and high reproducibility.(Innogenetics, 2007)  There are also several weakness 
that should be taken into consideration when interpreting these results. These adults were all 
well-functioning and community-dwelling at baseline, so results may not be generalizable to all 
older adults – for example, nursing home populations. Another potential weakness is that we did 
not have CSF measurements of Aβ and thus, we could not correlate plasma Aβ to measurements 
of CSF Aβ. As CSF Aβ has been such a well-established biomarker for dementia, it would have 
been useful.  
This study identified the demographic and medical correlates of plasma Aβ40 and Aβ42. 
The correlates identified in this paper should be considered in future studies as potential 
confounders of the association between plasma Aβ and cognitive decline or dementia. 
Understanding fully how these correlates mediate or modify the association between plasma Aβ 
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and dementia will be a fundamental step in determining the biological pathways through which 
plasma Aβ contributes to dementia and cognitive decline. Future studies should continue to 
investigate exactly how these demographic and medical correlates may influence the relationship 
between plasma Aβ40 and Aβ42, as it may help us target interventions for preventing and 
reducing the risk of AD and dementia. 
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3.7 TABLES 
 Table 3.7.1 Demographic and Medical Correlates of Plasma Aβ40 among 997 Older Adults 
Baseline Characteristics 
N (%) or Mean (SD) 
Tertile 1 
n=333 
Tertile 2 
n=331 
Tertile 3 
N=333 
p-value 
Age, years  73.6 (3.0) 74.0 (2.8) 74.5 (2.9) 0.0001 
Black Race  201 (60.4) 190 (57.4) 147 (44.1) <0.0001 
Female Sex  184 (55.3) 187 (56.5) 179 (53.8) 0.78 
Education (≤HS) 223 (67.2) 226 (68.5) 197 (59.5) 0.03 
Literacy (REALM, ≤8th grade) 94 (29.9) 85 (27.8) 87 (27.8) 0.79 
3MS 91.0 (5.4) 91.2 (5.5) 91.1 (5.2) 0.90 
Social Support* 171 (51.4) 165 (49.9) 152 (45.7) 0.26 
Body Mass Index  27.7 (5.2) 28.0 (4.8) 27.5 (4.8) 0.35 
Physical Activity (kcal per week) 1055.5 (2373.2) 1133.3 (2455.5) 982.4 (1465.0) 0.66 
Depressive Symptoms (CES-D≥16) 13 (3.9) 22 (6.7) 11 (3.3) 0.09 
Stroke/TIA History 25 (7.5) 33 (10.1) 37 (11.3) 0.25 
Diabetes History  74 (23.2) 83 (25.6) 83 (25.9) 0.69 
Myocardial Infarction History  25 (7.6) 38 (11.6) 42 (12.8) 0.07 
Cholesterol (mg/dl) 202.7 (37.6) 208.4 (41.1) 202.2 (39.3) 0.08 
Triglycerides (mg/dl) 126.8 (80.6) 131.1 (100.5) 138.5 (68.0) 0.19 
HDL (mg/dl) 56.6 (17.7) 55.1 (16.7) 52.9 (16.5) 0.02 
LDL (mg/dl) 121.4 (34.5) 127.2 (35.5) 121.6 (35.4) 0.06 
APOE e4 allele (≥1 e4 allele) 96 (30.9) 101 (32.2) 93 (29.5) 0.77 
BDNF (pg/ml) 23361.6 (10648.3) 21206.2 (11064.9) 20944.4 (10022.9) 0.006 
Creatinine (mg/dl) 1.0 (0.2) 1.0 (0.3) 1.2 (0.5) <0.0001 
C-reactive Protein (µg/mL) 3.0 (3.9) 2.9 (4.0) 3.4 (7.3) 0.42 
Tumor Necrosis Factor (pg/ml) 3.3 (2.1) 3.2 (1.3) 3.7 (1.7) 0.0007 
IL-6 (pg/ml) 2.3 (1.9) 2.2 (1.7) 2.4 (1.8) 0.28 
Smoker (Ever vs. Never) 183 (55.0) 180 (54.4) 180 (54.4) 0.99 
*N (%) below the median; variable defined as a combination of friends, neighbors and relatives
who visit per week. Aβ40 indicates amyloid beta-40; SD standard deviation; HS high school; 
REALM Rapid Estimate of Adult Literacy in Medicine; 3MS Modified Mini-Mental Status 
Exam; CES-D Center for Epidemiologic Studies Depression Scale; TIA transient ischemic 
attack; HDL high-density lipoprotein cholesterol; LDL low-density lipoprotein cholesterol; 
APOE Apolipoprotein E; BDNF brain-derived neurotrophic factor; IL-6 interleukin-6. 
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Table 3.7.2 Demographic and Medical Correlates of Plasma Aβ42 among 997 Older Adults 
Baseline Characteristics 
N (%) or Mean (SD) 
Tertile 1 
n=328 
Tertile 2 
n=339 
Tertile 3 
n=330 
p-value 
Age, years  74.0 (3.0) 73.8 (2.9) 74.2 (2.9) 0.17 
Black Race  214 (65.2) 173 (51.0) 151 (45.8) <0.0001 
Female Sex  196 (59.8) 171 (50.4) 183 (55.5) 0.05 
Education (≤HS) 231 (70.6) 222 (65.7) 193 (58.8) 0.006 
Literacy (REALM, ≤8th grade) 95 (30.8) 97 (30.9) 74 (23.8) 0.08 
3MS Score 90.7 (5.5) 91.1 (5.3) 91.4 (5.3) 0.30 
Social Support* 179 (54.6) 155 (45.7) 154 (46.7) 0.05 
Body Mass Index  27.6 (5.2) 27.5 (4.3) 28.1 (5.3) 0.26 
Physical Activity (kcal per week) 929.8 (1971.7) 1042.1 (1733.5) 1198.4 (2669.9) 0.27 
Depressive Symptoms (CES-D ≥16) 13 (4.0) 12 (3.5) 21 (6.7) 0.17 
Stroke/TIA History 28 (8.6) 31 (9.3) 36 (11.0) 0.56 
Diabetes History  94 (29.8) 78 (23.7) 68 (21.3) 0.04 
Myocardial Infarction History  39 (8.9) 34 (10.2) 42 (12.9) 0.24 
Cholesterol (mg/dl) 203.2 (38.0) 205.4 (39.2) 204.6 (41.2) 0.76 
Triglycerides (mg/dl) 128.5 (80.9) 127.4 (65.6) 140.8 (101.9) 0.08 
HDL (mg/dl) 57.3 (17.9) 53.9 (15.9) 53.5 (16.9) 0.007 
LDL (mg/dl) 120.8 (34.7) 125.8 (35.4) 123.5 (35.4) 0.20 
APOE e4 allele (≥1 e4 allele) 118 (38.3) 99 (31.3) 73 (23.1) 0.0002 
BDNF (pg/ml) 22798.0 
(10910.9) 
21328.8 
(10138.0) 
21408.9 
(10810.7) 
0.14 
Creatinine (mg/dl) 1.0 (0.2) 1.0 (0.2) 1.1 (0.6) <0.0001 
C-reactive Protein (µg/mL) 3.2 (6.4) 2.7 (3.4) 3.4 (5.8) 0.16 
Tumor Necrosis Factor (pg/ml) 3.3 (2.1) 3.3 (1.4) 3.6 (1.7) 0.07 
IL-6 (pg/ml) 2.2 (1.5) 2.4 (2.0) 2.4 (1.9) 0.58 
Smoker (Ever vs. Never) 192 (58.5) 184 (54.3) 167 (50.9) 0.15 
*N (%) below the median; variable defined as a combination of friends, neighbors and relatives 
who visit per week. Aβ42 indicates amyloid beta-42; SD standard deviation; HS high school; 
REALM Rapid Estimate of Adult Literacy in Medicine; 3MS Modified Mini-Mental Status 
Exam; CES-D Center for Epidemiologic Studies Depression Scale; TIA transient ischemic 
attack; HDL high-density lipoprotein cholesterol; LDL low-density lipoprotein cholesterol; 
APOE Apolipoprotein E; BDNF brain-derived neurotrophic factor; IL-6 interleukin-6. 
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Table 3.7.3 Stepwise Multivariate Linear Regression Associations with Plasma Aβ40 and 
Aβ42 
Variable Parameter (β) Standard Error F-value p-value 
Aβ40 
Age 1.34 0.53 6.39 0.01 
Black race -14.70 3.13 22.01 <0.0001 
Creatinine 52.91 4.29 151.77 <0.0001 
Serum BDNF -0.0004 0.0001 7.34 0.007 
Aβ42 
Black race -3.72 0.67 30.83 <0.0001 
Female sex 1.39 0.67 4.32 0.04 
Education 1.50 0.69 4.78 0.03 
APOE e4 -2.82 0.69 16.57 <0.0001 
Creatinine 9.32 0.85 120.09 <0.0001 
Aβ40 indicates amyloid beta-40; Aβ42 amyloid beta-42; BDNF brain-derived neurotrophic 
factor; APOE Apolipoprotein E. 
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Table 3.7.4 Multivariate Correlates of the Rate of Change in Plasma Aβ40 and Aβ42 
Rate of change in plasma Aβ (95% CI) per unit 
Variable Unit Aβ40 Aβ42 
Age 2.91 3.90 (0.88, 6.92) NA 
Race 1 -14.70 (-20.83, -8.57) -3.72 (-5.03, -2.41) 
Sex 1 NA 1.39 (0.08, 2.70) 
Education 1 NA 1.50 (0.15, 2.85) 
Creatinine 0.85 mg/dl 19.58 (16.47, 22.69) -2.82 (-4.17, -1.47) 
APOE e4 1 NA 3.45 (2.83, 4.07) 
BDNF 10631.18 pg/ml -4.25 (-6.33, -2.17) NA 
Aβ40 indicates amyloid beta-40; Aβ42 amyloid beta-42; CI confidence interval; NA not 
applicable; APOE Apolipoprotein E; BDNF brain-derived neurotrophic factor. 
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4.0  PAPER 2: CHANGE IN INFLAMMATORY MARKERS AND COGNITIVE 
STATUS AMONG OLDEST OLD WOMEN FROM THE STUDY OF OSTEOPOROTIC 
FRACTURES 
4.1 ABSTRACT 
Objectives To determine the association between interleukin-6 (IL-6), the IL-6 soluble receptor 
(IL-6 sR) and tumor necrosis factor soluble receptor 1 (STNF-R1) measured at two time points 
and subsequent cognitive status among oldest old women, and to determine the association 
between change in each inflammatory marker and cognitive status. 
Design 20-year longitudinal cohort study. 
Setting Four clinical sites in the United States. 
Participants 905 women from the Study of Osteoporotic Fractures.  
Measurements At Year 20, cognitive status was diagnosed as either normal, mild cognitive 
impairment (MCI), or dementia. Inflammatory markers were measured from stored blood serum 
at Year 10 and Year 16 in a random sample of women using a DuoSet enzyme-linked 
immunosorbent assays (ELISAs). 
Results Baseline mean participant age was 78.3±2.83 years. Over 10 years, 199 (21.99%) 
developed MCI, and 145 (16.02%) dementia. There were no significant associations between IL-
6 or TNF sR1 measured at Year 10 or Year 16 and cognitive status at Year 20. High IL-6 sR at 
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Year 16 was significantly associated with decreased risk for dementia (OR=0.54; 95% CI: 0.30, 
0.97). Women with high IL-6 sR at both time points (OR = 0.39; 95% CI: 0.17, 0.89) or who had 
a low level at Year 10 and transitioned to a high level at Year 16 (OR = 0.35; 95% CI: 0.14, 
0.88) also had reduced risk of dementia.  
Conclusion In this cohort of white, high functioning oldest old women, a consistently high or an 
increasing level of IL-6 sR is associated with reduced risk of dementia. The effect of 
inflammation on dementia may differ in younger old and oldest old. Understanding these 
differences will be crucial in interpreting results from ongoing clinical trials and in targeting 
therapeutic strategies to the oldest old.  
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4.2 INTRODUCTION 
Both age and inflammation are associated with elevated risks of cognitive impairment, cognitive 
decline, and Alzheimer's disease (AD).(Engelhart et al., 2004a; Schmidt et al., 2002; Troller et 
al., 2010; Weaver et al., 2002; Yaffe et al., 2003)  Intriguingly, the relationships between 
inflammatory markers and these disorders appears to weaken with advancing age, with studies 
showing inconsistent results after age 85.(Jenny et al., 2012; Kravitz, Corrada, & Kawas, 2009a; 
Kravitz et al., 2009b; Schram et al., 2007; Silverman et al., 2009)  This is critically important 
with a view both to understanding disease mechanisms and to designing appropriate intervention 
strategies. For example, clinical trials are currently investigating the potential role of anti-
inflammatory drugs in AD patients, (Aisen et al., 2003; Breitner et al., 2011; Fields et al.) and if 
there truly is a different association between inflammation and dementia in the young old, and 
the oldest old, understanding these differences will be crucial in interpreting results from these 
trials and in targeting therapeutic strategies to the oldest old.  Some limitations to the existing 
studies of the oldest old are cross-sectional study design, or measuring inflammatory markers at 
only one time point in longitudinal studies.(Kravitz et al., 2009b; Schram et al., 2007; Silverman 
et al., 2009)  Furthermore, many studies have focused on only one inflammatory marker at a 
time, rather than assessing the role of multiple markers together.(Kravitz et al., 2009b; Silverman 
et al., 2009) Thus, more studies are needed to determine the association between inflammation 
and cognitive status in the oldest old, and to investigate if a change in inflammation over time is 
associated with cognitive function. The objectives of this study were to determine the association 
between interleukin-6 (IL-6), the IL-6 soluble receptor (IL-6 sR) and tumor necrosis factor 
soluble receptor 1 (STNF-R1) measured at an initial and an interim visit and subsequent 
cognitive status among oldest old women. Because we had inflammation measured at more than 
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one time point, a second objective was to determine the association between change in each 
inflammatory marker and cognitive status. 
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4.3 METHODS 
4.3.1 Study Sample 
The Study of Osteoporotic Fractures (SOF) is an ongoing prospective cohort study of 
community-dwelling women, with recruitment of 9,704 mostly Caucasian (99% non-Hispanic 
white) women, aged 65 years or older occurring between 1986 and 1988 from four regions: 
Baltimore County, Maryland; Minneapolis, Minnesota; Portland, Oregan; and the Monongahela 
Valley near Pittsburgh, Pennsylvania. Between 1997 and 1998, a second wave of recruitment 
occurred to increase African American representation in the sample, and 662 African American 
women, aged 65 years or older, also from the same study regions, were enrolled. Originally 
designed to evaluate risk factors for falls and fractures, exclusion criteria included being unable 
to walk without assistance, and bilateral hip replacement. All women provided written consent, 
and SOF was approved by the Institutional Review Board (IRB) and each study site.  
A random sample of 905 women with measured serum IL-6, IL-6 sR and STNF-R1 at an 
initial visit (SOF Year 10 – the baseline for the purposes of this study) and with adjudicated 
cognitive status 10 years later comprised our analytic cohort. These women were also free of 
cognitive impairment at Year 10; cognitive impairment was defined as a modified Mini-Mental 
State Examination (mMMSE) score ≤22 points).(Middleton et al., 2010)  A subset (n=363 for 
IL-6, n=380 for IL-6 sR, n=393 for STNF-R1) also had these markers measured at an interim 
exam (Year 16), and were included in longitudinal analyses.  
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4.3.2 Primary Predictors 
Inflammatory markers were measured from blood serum at Year 10 in a random sample of 
women who came in to the Year 10 clinic visit. Year 16 inflammatory markers, also measured 
from blood serum, were assessed in a random sample of women from the Minnesota and 
Pennsylvania sites who participated in the SOF sleep study (had to be willing to wear an 
actigraphy watch), and had serum collected. IL-6, IL-6 sR and STNF-R1 were measured from 
stored serum using a DuoSet enzyme-linked immunosorbent assays (ELISAs) from R&D 
systems. All assays were performed at the University of Maryland Cytokine Core Laboratory 
(Baltimore, MD). The coefficient of variation for STNF-R1 was 5%, and values ranged from 
1250 to 80,000 pg/ml. For IL-6, the coefficient of variation was 8%, with a range of values from 
2.3 to 150 pg/ml. Finally, the coefficient of variation for IL-6 sR was 4%, and values ranged 
from 1,500 to 100,000 pg/ml.  To account for potentially non-linear relationships, and because 
some studies have shown that inflammation is only associated with cognitive function at the 
extreme ends(Weaver et al., 2002), we decided a priori to create tertile cutoffs for each 
inflammatory marker in order to compare those with the highest levels to those with the lowest. 
4.3.3 Outcomes 
The primary outcome for these analyses was adjudicated cognitive status. Cognitive status was 
adjudicated at SOF Year 20. Study participants who had cognitive test data available from clinic 
or at home visits at the Year 20 visit were eligible for screening and diagnosis of cognitive 
impairment. Participants who had only self-administered questionnaire data on cognitive 
function were excluded. The first step in the adjudication process was identifying those “in need” 
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of cognitive adjudication. Participants who met any of the following criteria at Year 20 were 
determined as being “in need”: Teng Modified Mini-Mental State Exam (3MS) Score of <88; 
California Verbal Learning Test (CVLT) Delayed (10 minute) Recall Score <4; Functional 
Assessment Questionnaire (IQCODE) Score ≥3.6; a self-reported history of dementia diagnosis; 
or living in a nursing home or personal care home.  There were 760 participants who met one or 
more of these criteria, and had complete Year 20 data, as well as past visit data forwarded to the 
adjudication committee for cognitive status determination. All adjudication was performed using 
existing data on age, education, race, previously collected cognitive assessments, functional 
assessments, including assessments activities of daily living and instrumental activities of daily 
living, depressive symptoms, lifestyle (i.e. type of residence, living alone), medical history, and 
medication use.  No further exam was performed on the participant, nor any additional data 
collected. 
A panel of clinical experts, including one neurologist, two neuropsychologists, and one 
geropsychologist, adjudicated cognitive function of the 760 identified as “in need”.  A diagnosis 
of dementia was made based on the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) criteria. Furthermore, likely dementia etiology, including vascular 
dementia, AD, dementia due to multiple etiologies (mixed), or other was determined. MCI was 
diagnosed using a modified Petersen Criteria.(R. C. Petersen, 2004)  Those who did not meet 
criteria for MCI or dementia were classified as being cognitively normal. Similarly, those who 
did not meet any of the original five screening criteria were not adjudicated, and were considered 
cognitively normal. The four different adjudicators were assigned adjudication data packets for 
review at random, with an equal number of packets assigned to each; the majority of participant 
data packets were reviewed by only one adjudicator. To check reliability of adjudications, 20 
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data packets flagged for adjudication were selected at random for review by all four adjudicators 
(120 pairs of rereads, 6 different pairing of adjudicators). The weighted kappa for adjudicated 
outcomes was 0.77 (95% CI: 0.71 - 0.84) which indicates substantial strength of agreement 
between adjudicators.(Landis & Koch, 1977)  Furthermore, 20 participants who did not meet any 
of the criteria for adjudication had their data sent to the adjudication committee, to verify that 
they would be adjudicated as normal (19 of 20 were adjudicated as normal and 1 of 20 was 
adjudicated as MCI). In order to further examine the association between inflammatory markers 
and cognitive function, we also assessed the outcome of change in mMMSE scores from baseline 
to Year 20. 
4.3.4 Other Variables 
Data on age, race and education were collected at the SOF baseline visit; age for these analyses 
was the age at Year 10 because that was the first year inflammation was collected, and serves as 
our study baseline.  Weight and height were measured at study baseline using a balance-beam 
scale and fixed stadiometer in light indoor clothing; BMI (kg/m2) was calculated from direct 
height and weight measurements at our study baseline.  Diabetes was defined as self-reported 
diabetes or taking medication for diabetes. Hypertension was defined as either systolic blood 
pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or taking medications for 
high blood pressure. History of stroke and myocardial infarction were self-reported.  The 15-item 
Geriatric Depression Scale (GDS) was used to assess depressive symptoms; a standard cutoff of 
≥6 symptoms was used to define depression.(Sheikh & Yesavage, 1986)  Apolipoprotein E 
(APOE) phenotype was determined by isoelectric focusing and immunoblotting(Kamboh, 
Ferreli, & Kottke, 1988) on most of the women from the Pittsburgh site (n=220, 24.31% of 
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sample). A categorical variable was created to classify women with ≥1 APOE e4 allele versus no 
e4 allele. Similar to inflammatory markers, Cystatin-C was measured in a random sample of 
women who attended the Year 10 clinic visit, and had enough serum to assay Cystatin-C.  
Concentration of Cystatin-C was determined using a BN100 nephrolometer (Dade Behring Inc., 
Deerfield, IL).  To determine medication use, participants were required to bring in all 
medications taken daily or almost daily in the 30 days prior to the study visit.  Medications were 
classified according to a computerized coding dictionary, according to brand and generic names. 
(Pahor et al., 1994) 
4.3.5 Statistical Analyses 
To examine the association between categorical baseline characteristics of the women, and 
adjudicated cognitive status, Fisher’s exact or Pearson’s chi-square tests were used; to examine 
the association between continuous baseline characteristics and cognitive status, analysis of 
variance tests (ANOVAs) or Wilcoxon rank sum tests were used, as appropriate. For all 
analyses, we first included all types of dementia, and then removed non-AD types to see how 
much results changed. There were no significant changes to the strength or direction of any 
association, so to keep sample size larger (especially for longitudinal analyses), all types of 
dementia were included for all analyses. Multinomial logistic regression was used to determine 
the association between each inflammatory marker at initial and interim visits and subsequent 
cognitive status (normal, MCI and dementia). Multinomial logistic regression was also used to 
determine the association between 6-year change in inflammatory marker and subsequent 
adjudicated cognitive status.  
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To further examine the association between inflammation and cognitive function, we 
conducted post-hoc analyses to examine the change in mMMSE score from SOF Year 1 to SOF 
Year 20. Chi-square tests were used to describe the association between change in mMMSE 
scores (-1 standard deviation [SD] vs. No change/+1 SD) over 20 years and level of 
inflammatory marker at Year 10; similar analyses were performed for predictors of Year 16 
inflammatory marker and change in inflammatory marker from Year 10 to Year 16. Trajectories 
of mean mMMSE scores over time by inflammatory marker change group (high-high, high-low, 
low-high, low-low) were also compared using ANOVAs.  Additionally, we formally examined 
the interaction between baseline mMMSE scores and Year 10 inflammatory marker using a 
likelihood ratio test. Finally, we also examined the association between the ratio of IL-6sR/IL-6 
at Year 10 and adjudicated cognitive status using multinomial logistic regression. All statistical 
analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC).  
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4.4 RESULTS 
The mean baseline age was 78.3±2.83 years and 88.3 years at the time of cognitive status 
determination. After 10 years, 199 (21.99%) developed MCI and 145 (16.02%) dementia. Of the 
145 with dementia, 116 had AD (80.0%), 18 (12.4%) had vascular dementia, 2 were classified as 
“other” (1.4%) and 9 (6.2%) were indeterminate.  At baseline, compared to those who were 
cognitively normal, those with dementia or MCI were significantly older (p<0.0001) and had less 
education (p=0.005) (Table 4.6.1). There was also a borderline significant association suggesting 
those with MCI or dementia were more likely to be depressed (p=0.09) and those with MCI were 
more likely to have poorer kidney function (higher Cystatin-C, p=0.06) (Table 4.6.3). Finally, 
although APOE genotype was only available for a small number of participants, those with 
dementia were significantly more likely to have at least 1 APOE e4 allele (p=0.03) (Table 4.6.1). 
All of these variables except for APOE e4 (due to small sample size) were included as covariates 
in models. Furthermore, although they did not differ by cognitive status, NSAID use and statin 
use were included in models because of their effects on inflammation. 
There were no significant associations between initial or interim level of IL-6 or STNF-
R1 and risk of MCI or dementia in either unadjusted or adjusted models (Table 4.6.2).  While 
there was no significant association between the initial level of IL-6 sR and subsequent cognitive 
status (Table 4.6.2), those with a high level of IL-6 sR at Year 16 were significantly less likely to 
be subsequently diagnosed with dementia in unadjusted (OR=0.54; 95% CI: 0.30, 0.97), and 
adjusted models (Table 4.6.2). When looking at change in inflammatory marker from Year 10 to 
Year 16, and subsequent cognitive status, there were no significant associations between IL-6 or 
STNF-R1 and MCI or dementia. Again, however, a high IL-6 sR level at both time points was 
associated with a reduced risk of a dementia diagnosis in both unadjusted (OR = 0.39; 95% CI: 
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0.17, 0.89) and adjusted models (Table 4.6.3); this was similar among those who did not have a 
high IL-6 sR level at the initial, but transitioned to a high level at the interim visit (unadjusted 
OR = 0.35; 95% CI: 0.14, 0.88) (Table 4.6.3).  
When looking at the association between inflammatory marker and 20 year change in 
mMMSE score, there were once again no significant associations with IL-6 or STNF-R1. 
However, when compared to those with a low level of IL-6 sR at Year 10, those with a high level 
were significantly more likely to have a decline of 1 SD or more in mMMSE scores (28.73% vs. 
71.27%, p=0.03). While not statistically significantly, there was also a  indicating those with a 
high level of IL-6 sR at both time points were more likely to have a decline of 1 SD or more in 
mMMSE score over 20 years (Low, Low: 11.56% vs. High, Low: 21.77% vs. Low, High: 
20.41%, vs. High, High 46.26%, p=0.14), although the cognitive trajectories of all IL-6 sR 
change groups over 20 years are strikingly similar (Figure 4.6.1). To further examine this 
association, we created a scatterplot of baseline mMMSE tertile by 20 year change in mMMSE 
score, stratified by IL-6 sR level at Year 10 (Figure 4.6.2), and formally tested for an interaction 
of baseline cognitive test scores with Year 10 IL-6sR level and adjudicated cognitive status using 
a likelihood ratio test.  The likelihood ratio test indicated a significant interaction between 
baseline mMMSE scores with IL-6sR Year 10 level and adjudicated cognitive status (χ2 degrees of 
freedom =1 = 3.883, p=0.049).  This interaction is further displayed in the scatterplot where those 
with highest baseline scores and a high level of IL-6 sR were more likely to have a decline of 1 
SD or more, but not reach clinically significant cognitive impairment. On the other hand, among 
those with a high IL-6 sR at Year 10 and low baseline mMMSE scores, there was less decline 
over time, but more who reached clinically significant cognitive impairment (Figure 4.6.2). 
Thus, these results do indeed support our original findings.  Finally, while it did not reach 
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statistical significance, there was a borderline significance between the ratio of IL-6sR/IL-6 
(OR=0.69; 95% CI: 0.47, 1.02).  
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4.5 DISCUSSION 
In this study of oldest old women, we found that those with a high level of IL-6 sR were 
significantly less likely to be diagnosed with dementia over 10 years. This was true for women 
with a high level of IL-6 sR at both time points, and for those who started off with a low level, 
but increased to a high level over time. Furthermore, upon examining mMMSE test scores, we 
found that women with a high level of IL-6 sR were more likely to decline 1 SD or more over 20 
years, but were less likely to reach a score that indicated clinically significant cognitive 
impairment (mMMSE ≤22 points). Our results are supported by at least one previous study 
which found that in CSF of AD patients, there were significantly decreased levels of IL-6 sR, 
when compared to cognitively normal controls.(ADAPT Research Group, 2007)  There have 
been other conflicting results reported on the association between IL-6 sR and AD and cognitive 
function.  For example, several early studies reported an association between lower CSF and 
serum IL-6 sR level and increased risk for AD(Angelis, Scharf, Mander, Vajda, & Christophidis, 
1998; Hampel et al., 1997), and others have reported no significant differences.(Marz et al., 
1997) 
A particularly interesting finding from these results was the significant protective 
association between IL-6 sR, and lack of association with IL-6. One explanation for this outcome 
is the way through which IL-6 and IL-6 sR become functionally available in the body; IL-6 sR 
regulates IL-6, such that when bound, the normal effect of IL-6 is actually inhibited.(Bagli et al., 
2003)  Thus, it could be that IL-6 sR is somehow inhibiting negative effects of IL-
6.(Neuroinflammation Working Group et al., 2000)  To examine this hypothesis statistically, we 
performed analyses looking at the ratio of IL-6sR/IL-6 at Year 10 and adjudicated cognitive 
status. If it is indeed true that a high level of IL-6sR is protective because it is inhibiting negative 
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inflammatory effects of IL-6, then a high ratio of IL-6 sR/IL6 should also be protective. While it 
does not reach statistical significance, we did find a borderline significance for this association 
with dementia in the hypothesized direction, indicating that IL-6 sR may be having some small 
effects on IL-6. 
Another interesting finding from these results was that the women with a high level of 
IL-6 sR were less likely to reach a diagnosis of dementia, but still more likely to decline ≥1 SD 
over time.  These results differ from several previous studies which have reported associations 
between a high level of inflammation and increased risk for cognitive decline or 
dementia.(Engelhart et al., 2004a; Eriksson et al., 2011; Holmes et al., 2009; Licastro et al., 
2000; Schmidt et al., 2002; Schram et al., 2007; Sundelof et al., 2009; Weaver et al., 2002; Yaffe 
et al., 2003)  There are several potential explanations for this finding. First, it could be that what 
we are seeing is a healthy participant bias.  A relationship between a high level of inflammation 
and mortality has been previously documented(Alley, Crimmins, Brandeen-Roche, Guarlnik, & 
Ferrucci, 2007), and perhaps women who were the most sick have died. When comparing 
women in SOF who were lost to follow-up or died, to those in our analytic cohort, those lost to 
follow-up were more likely to have a history diabetes (p=0.002) and a previous MI (p<0.0001); 
however there was no difference on having a history of stroke (p=0.33), and the women in the 
cohort were more likely to have hypertension (p=0.0002).  
Another potential explanation is that we are seeing a truly pleiotropic nature of 
inflammation in older adults, and while a high level is harmful at some time points, but in this 
age group, it is beneficial.  It has been proposed that high inflammation is perhaps be an 
indicator of a well-functioning immune system in the oldest old, demonstrating the ability for the 
body to successfully fight off illness, infection, and injury.(Griffin, Michel, Huysman, Logar, & 
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Vallejo, 2012)  Our results may just be highlighting the complexity of immune system 
abnormalities we see in both normal and pathological aging. 
A final explanation could be the idea of cognitive reserve.  Briefly, this theory postulates 
that some people with a high degree of brain pathology may show no apparent cognitive 
impairment due to an ability to compensate for pathology or deficits; the ability to compensate is 
thought to stem from a combination of advantageous lifestyle factors, such as higher education 
or literacy, and neural factors like greater brain volume or greater brain plasticity.(Scarmeas & 
Stern, 2004; Stern, 2002)  Specifically, those with a high IL-6 sR may have a greater cognitive 
reserve due to a high level of IL-6 sR preventing IL-6 from exerting negative effects on the 
brain. This is supported by those with a high IL-6 sR having a higher level of cognitive function 
at baseline (higher mMMSE scores) and a decreased likelihood of being diagnosed dementia.  
There are several strengths and weaknesses that should be considered when interpreting 
the results of this study. One strength is having inflammatory markers measured at multiple 
points in time. Furthermore, cognitive status was clinically adjudicated which provides more 
information than individual cognitive assessments, as used in many previous studies. We had 
data on cognitive test scores over time to strengthen our examination of the association between 
inflammation and adjudicated cognitive status. Finally, we had data on a large number of 
potential confounders and covariates collected, so all analyses can be adjusted for these factors. 
A weakness of this study was having a relatively small sample size, especially in follow-up 
years. We were also unable to see if these results were modified by APOE e4 genotype due to a 
small sample size with APOE assessed.  
In conclusion, findings suggest a consistently high or an increasing level of IL-6 sR is 
associated with a subsequent reduced risk of dementia. Furthermore, the women with high IL-6 
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sR and high baseline mMMSE scores are declining greatly in mMMSE score over 20 years, but 
not reaching clinically significant impairment, and thus seem to be demonstrating cognitive 
reserve. This could be due to a healthy survivor effect.  Our results may also be highlighting the 
pleiotropic nature of inflammation, and the complexity of the immune system in older adults.  
Understanding these differences will be crucial in interpreting results from ongoing clinical trials 
and in targeting therapeutic strategies to oldest old.  
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4.6 TABLES AND FIGURES 
Figure 4.6.1 Cognitive trajectories over 20 years based on mMMSE score, by change in IL-
6 sR group.  
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Figure 4.6.2 Scatterplots of baseline mMMSE tertile, by 20-year change in mMMSE score, 
stratified by year 10 IL-6 sR level. IL-6 sR = 1: High IL-6 sR group; IL-6 sR = 2: Low IL-6 
sR group. Greater numbers in 20-year change in mMMSE scores indicate greater decline 
over 20 years, or a greater loss in cognitive function. Baseline mMMSE tertile was coded 
such that “1” is indicative of the highest baseline scores, or the highest cognitive 
performers, and “3” is indicative of the lowest baseline scores. 
87 
Table 4.6.1 Baseline characteristics of the 905 oldest old women by cognitive status 
Characteristic  
Mean (SD),  
Median, or N (%) 
Cognitively 
Normal (n=561) 
Mild 
Cognitive 
Impairment 
(n=199) 
Dementia 
(n=145) 
p-value 
Age  77.83 (2.55) 78.63 (2.75) 79.41 (3.55) <0.0001 
Black Race 2 (0.36%) 2 (1.01%) 0 (0%) 0.34 
Education, ≤HS 309 (55.08%) 136 (68.34%) 88 (60.69%) 0.005 
Diabetes 19 (3.39%) 5 (2.51%) 7 (4.83%) 0.51 
Hypertension 170 (30.30%) 67 (33.67%) 56 (38.62%) 0.15 
Stroke 17 (3.03%) 4 (2.01%) 1 (0.69%) 0.24 
Myocardial Infarction 8 (1.43%) 1 (0.50%) 1 (0.69%) 0.49 
Depression 22 (3.92%) 11 (5.53%) 12 (8.28%) 0.09 
Body Mass Index 27.17 (4.30) 27.24 (4.58) 26.92 (5.09) 0.79 
APOE e4 allele* 10 (1.78%) 3 (1.51%) 7 (4.83%) 0.03 
Cystatin-C (mg/L)** 0.95 0.98 0.95 0.06 
Interleukin-6 (pg/ml)** 2.48 2.68 2.98 0.19 
Interleukin-6  
Soluble Receptor (pg/ml)** 
45304.16 45630.41 45140.51 0.79 
Tumor Necrosis Factor 
Soluble Receptor 1 (pg/ml)** 
3299.42 3393.24 3280.31 0.32 
NSAID use 156 (27.81%) 55 (27.64%) 31 (21.38%) 0.28 
Statin use 55 (9.80%) 15 (7.54%) 12 (8.28%) 0.59 
*Only on a subset of 220; **Wilcoxon Rank Sum tests used to compare medians rather than
means because of slightly skewed distributions. 
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Table 4.6.2 Adjusted association of inflammation markers at Year 10 or Year 16 and 
subsequent cognitive status 
Inflammation 
Marker 
Odds Ratio (95%CI) 
Mild Cognitive Impairment Dementia 
IL-6 Year 10* (n=905) 
Low Reference Reference 
High 1.19 (0.83, 1.69) 1.32 (0.88, 1.97) 
IL-6 Year 16* (n=360) 
Low Reference Reference 
High 1.26 (0.72, 2.21) 1.08 (0.56, 2.09) 
IL-6 Soluble Receptor Year 10* (n=905) 
Low Reference Reference 
High 1.06 (0.75, 1.52) 0.85 (0.57, 1.26) 
IL-6 Soluble Receptor Year 16* (n=377) 
Low Reference Reference 
High 0.79 (0.46, 1.36) 0.48 (0.25, 0.91) 
TNF Soluble Receptor Year 10* (n=905) 
Low Reference Reference 
High 1.16 (0.78, 1.70) 1.12 (0.73, 1.73) 
TNF Soluble Receptor Year 16* (n=390) 
Low Reference Reference 
High 0.79 (0.46, 1.38) 1.06 (0.54, 2.06) 
*Models are adjusted for age, education, depression, cystatin-C, statin use and NSAID use.
**Low IL-6 ≤1.87 pg/ml and high IL-6 >1.87 pg/ml; low IL-6 sR ≤37401.36 pg/ml and high IL-
6 sR >37401.36; low STNF-R1 <11.98 pg/ml and high STNF-R1 >11.98 pg/ml.  
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Table 4.6.3 Association of change in inflammation markers over time and Year 20 cognitive 
status 
Inflammation 
Marker 
Odds Ratio (95%CI) 
Mild Cognitive Impairment Dementia 
IL-6 Adjusted* 
Low, Low Reference Reference 
High, Low             1.59 (0.61, 4.16) 3.09 (0.89, 10.66) 
Low, High 1.99 (0.80, 4.98) 2.42 (0.69, 8.44) 
High, High 1.50 (0.64, 3.47) 2.15 (0.68, 6.79) 
IL-6 Soluble Receptor Adjusted* 
Low, Low Reference Reference 
High, Low 0.67 (0.28, 1.65) 0.40 (0.15, 1.04) 
Low, High 0.50 (0.21, 1.23) 0.23 (0.09, 0.64) 
High, High 0.70 (0.31, 1.57) 0.30 (0.13, 0.75) 
TNF Soluble Receptor Adjusted* 
Low, Low Reference Reference 
High, Low 1.02 (0.43, 2.44) 1.32 (0.44, 4.00) 
Low, High 0.75 (0.30, 1.89) 1.30 (0.43, 3.93) 
High, High 0.82 (0.39, 1.73) 1.20 (0.46, 3.19) 
*Models are adjusted for age, education, depression, cystatin-C, statin use and NSAID use.
**Low IL-6 ≤1.87 pg/ml and high IL-6 >1.87 pg/ml; low IL-6 sR ≤37401.36 pg/ml and high IL-
6 sR >37401.36; low STNF-R1 <11.98 pg/ml and high STNF-R1 >11.98 pg/ml.  
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5.0  PAPER 3: TRAJECTORIES OF INFLAMMATORY MARKERS AND 
COGNITIVE DECLINE OVER 10 YEARS: FINDINGS FROM THE HEALTH, AGING 
AND BODY COMPOSITION STUDY 
5.1 ABSTRACT 
Background: High inflammation has been associated with elevated risks of cognitive decline, 
and Alzheimer's disease (AD).  However, many studies have only investigated inflammation at 
one or two time points which greatly limits understanding how inflammation affects cognitive 
function over time. The objective of this study was to examine trajectories of inflammatory 
markers over time and cognitive decline over 10 years.  
Methods Cox proportional hazards models were used to examine the association between 
interleukin-6 (IL-6) and C-reactive protein (CRP) trajectory patterns and cognitive decline 
among 1,323 adults,  ≥65 years, enrolled in the Health, Aging and Body Composition Study  
with inflammation measured between three and five time points. Incident cognitive decline was 
defined as a decline of ≥5 points in the Modified Mini-Mental State Examination (3MS). We 
tested for a significant interaction by sex, race and apolipoprotein E e4 (APOE) allele presence.  
Results Three trajectory components were examined: slope, variability, and baseline IL-6 and 
CRP levels. There was no significant association between baseline IL-6, slope, or variability and 
cognitive decline over 10 years. When examined individually, extreme variability in CRP level 
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was associated with greater incident cognitive decline (HR: 1.54, 95% CI: 1.14-2.09), whereas 
slope and baseline levels were not. In models adjusted for age, race, education, sex, baseline 
3MS, body mass index, diabetes, and serum Cystatin-C, including all three components, extreme 
variability of CRP remained a significant predictor of cognitive decline (HR 1.57, 95% CI: 1.08-
2.29). These associations were significantly modified by sex and APOE e4, such that they were 
stronger among women (HR=1.82; 95% CI: 1.09, 3.02) and among those with no APOE e4 allele 
(HR=1.63; 95% CI: 1.06, 2.50) 
Conclusions Significant variability in individual trajectories of CRP level was a stronger 
predictor of cognitive decline than the slope of or an individual level of CRP. This CRP 
variability may reflect poor control of or greater changes in vascular disease over time which 
could in turn be associated with cognitive decline.  
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5.2 INTRODUCTION 
The relationship between inflammation and dementia or Alzheimer’s disease (AD) has been 
widely investigated for several reasons. First, inflammatory markers such as interleukin-6 
(IL-6) and C-reactive protein have been found the amyloid plaques and neurofibrillary tangles 
that develop in AD.(Neuroinflammation Working Group et al., 2000) It has also been proposed 
that inflammatory markers contribute to the etiologic progression of dementia via several 
pathways, including vascular disease and overall neurodegeneration.(Brunello et al., 2000; Eagan 
et al., 2012; Ridker et al., 2002) While many studies have found a significant association 
between elevated CRP and IL-6 measured from one time point, and AD or cognitive decline 
(Kravitz et al., 2009a; Schmidt et al., 2002; Yaffe et al., 2003), several studies have not 
supported such an association.(Gallacher et al., 2010; Sundelof et al., 2009; Tan et al., 2007; van 
Oijen, Witteman, Hofman, Koudstaal, & Breteler, 2005) It has recently been suggested that 
levels of inflammation over time are highly variable (deGoma et al., 2012). Specifically, CRP 
has been shown to have considerable intra-individual variability over time, with a minimum 
of three CRP measurements suggested to accurately determine the association with 
cardiovascular outcomes.(Koenig et al., 2003) Thus these studies are greatly limited by 
having inflammation measured at only one time point. Thus, more studies are needed to 
investigate the association between inflammation measured at multiple time points, and 
cognitive function.  
The objectives of this study were to examine the association between IL-6 and CRP 
trajectory patterns and incident cognitive decline and impairment over 10 years. A second 
objective was to determine if these associations were modified by sex or APOE e4. We 
hypothesized that the slope and variability of IL-6 and CRP trajectories over time would be
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stronger predictors of cognitive function than an individual level of either marker, due to intra-
individual variability over time. As previous studies have found stronger associations among 
non-APOE e4 carriers and women, we expected we may find the same.(Eriksson et al., 2011; 
Kravitz et al., 2009a) 
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5.3 METHODS 
5.3.1 Study Population 
Community-dwelling white and black older adults were enrolled in the ongoing Health Aging 
and Body Composition (Health ABC) study.  This prospective cohort study began in 1997, and 
adults ranged in age from 70 to 79 years at enrollment, and lived in Memphis, TN or Pittsburgh, 
PA.  Participants were recruited from a random sample of Medicare eligible adults living within 
the designated zip codes, and were eligible if they reported no difficulties performing activities 
of daily living, walking a quarter mile, or climbing 10 steps without resting.  They also had to be 
free of life-threatening cancers, and plan to remain within the study area for at least three years.  
Our analytic cohort consisted of 1,323 participants who had CRP and IL-6 measured at a 
minimum of three time points. All participants included in this analytic cohort were also free of 
cognitive impairment at baseline; consistent with previous literature, cognitive impairment was 
defined as a Modified Mini-Mental Status Exam (3MS) score <80.(Slinin et al., 2010) This study 
was approved by the institutional review boards of the University of Pittsburgh and the 
University of Tennessee, Memphis, and that of the Coordinating Center, the University of 
California, San Francisco. All participants signed a written informed consent. 
5.3.2 Cognitive Function 
Cognitive function was assessed with the Modified Mini-Mental Status Exam (3MS) at baseline 
(Year 1), and study Years 3, 5, 8 and 10. The 3MS is an assessment of global cognitive function 
with components for orientation, concentration, language, praxis, and immediate and delayed 
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memory with scores ranging from 0 to 100 (higher scores indicating higher function).(Teng & 
Chui, 1987) Consistent with previous studies, we examined two potential outcomes: 1. Incident 
cognitive decline was defined as the first decline of 5 points or more from baseline, or the 
equivalent 1 SD of baseline 3MS scores, and 2. Incident cognitive impairment was defined as the 
first occurrence of a score ≤80 on the 3MS.(Lin et al., 2013; Stweart et al., 2013)  
5.3.3 Inflammatory Markers 
Measures of high sensitivity CRP and IL-6 were obtained from frozen serum or plasma collected 
five times throughout the study, at baseline (Year 1), and Years 2, 4, 6 and 8, after an overnight 
fast. Samples were frozen at -70°C and were shipped to the Core Laboratory at the University of 
Vermont.(Yaffe et al., 2003) Serum CRP was measured in duplicate by enzyme-linked 
immunosorbent assay on the basis of purified protein and polyclonal anti-CRP antibodies, and 
assays were standardized according to the World Health Organization First International 
Reference Standard with a sensitivity of 0.08 µg/ml.(Kalogeropoulos et al., 2010)  Plasma IL-6 
was measured in duplicate by ELISA kits from the R&D Systems (Minneapolis, MN).(Yaffe et 
al., 2003) The detectable limit for IL-6 was 0.10 pg/ml, and for TNFα was 0.18 pg/ml.(Yaffe et 
al., 2003)  
5.3.4 Covariates 
At baseline, demographic data including self-reported participant age, race, sex and education 
were recorded. Prevalent disease algorithms based on both self-report and physician diagnoses, 
recorded medications and laboratory data were used to create comorbidity variables indicating 
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presence of diabetes mellitus, hypertension, stroke or transient ischemic attack (TIA), and 
myocardial infarction (MI). Body mass index (BMI) (kg/m2) was calculated from direct height 
and weight measurements at baseline.  The Center for Epidemiologic Studies Depression Scale 
(CES-D) was used to assess depressive symptoms with a score ≥16 consistent with possible 
depression.(Radloff, 1977) APOE e4 allele status was determined using standard Single 
Nucleotide Polymorphism (SNP) genotyping techniques and dichotomized into having one or 
more APOE e4 allele versus no allele.(Hixson & Vernier, 1990) Creatinine and cystatin-C was 
obtained from frozen serum collected at baseline after an overnight fast. Samples were frozen at -
70°C and were shipped to the Core Laboratory at the University of Vermont. An inventory of 
prescription and over-the-counter medications was recorded at baseline by examining 
participants’ medication bottle(s). Consistent with a previous study using anti-inflammatory 
medication use as a covariate, we coded medications according to the Iowa Drug Information 
System (IDIS) code.(Pahor et al., 1994; Yaffe et al., 2003) With use of the IDIS, the daily use of 
anti-inflammatory drugs (IDIS code 2808), statins (IDIS code 2406), and oral estrogens (with or 
without progestins) (IDIS code 6816) was compiled.(Pahor et al., 1994; Yaffe et al., 2003)  
5.3.5 Statistical Analysis 
Pearson’s chi-square or analysis of variance (ANOVA) were used to determine the association 
between baseline characteristics and baseline levels of IL-6 and CRP (≤median versus >median). 
Because a minimum of three measurements are required to define variability, all 1,323 
participants in our analytic cohort had CRP and IL-6 available at three to five time points for 
analysis of trajectories. To allow for interpretation on a relative scale, and to account for skewed 
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distributions, CRP and IL-6 levels were log transformed (natural log). We examined the 
distributions of baseline CRP and IL-6 levels, trajectory slope, and variability around the 
trajectory. The slope on the log scale can be interpreted as the annual relative change in the 
original non-transformed scale. The variability around the trajectory was calculated by 
determining the root mean square error (RMSE) in a model with a linear trajectory which is 
equivalent to the coefficient of variation (CV). These analytic techniques were based on a 
previous study examining trajectories of another biological marker with an outcome of 
mortality.(Cappola et al., 2009) 
Cox proportional hazard models were performed to estimate the relative hazard of 
incident cognitive decline and incident cognitive impairment. There were no statistically 
significant results for incident cognitive impairment, so only those for incident cognitive decline 
will be reported. Slope and variability of both IL-6 and CRP were modeled as time-varying 
covariates; at each measurement of either marker, slope and variability were recalculated using 
all measures through that date. By updating the slope and variability at each measurement, the 
hazard ratios (HRs) were estimated with respect to current, not future, exposure status. Relative 
hazards of incident cognitive decline by standard deviation of baseline ln(IL-6) or ln(CRP) level, 
and decile of slope and variability were estimated. All models were then adjusted for 
demographic variables that were selected as covariates a priori, including age, race, education 
and sex, as well as variables that differed by inflammatory marker at baseline, including BMI, 
diabetes, APOE e4 allele, and cystatin-C. We also adjusted all models by anti-inflammatory drug 
use due to the effect this could have on inflammation. Finally, all IL-6 models were adjusted for 
baseline ln(CRP), and all CRP models were adjusted for baseline ln(IL-6). Interactions of 
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baseline IL-6 and CRP level, slope, and variability with sex, race and APOE e4 were assessed 
using likelihood ratio test.  
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5.4 RESULTS 
Participants had a mean age of 73.38 (±2.81) years at baseline, 697 (52.68%) were female, and 
388 (29.33%) were black. At baseline, those above the median CRP level, compared to those at 
or below the median CRP level, were more likely to be black (69.45% vs 49.03%, p<0.001), to 
be female (59.43% vs. 47.10%, p<0.001), and to have diabetes (25.21% vs. 16.85%, p<0.001), 
and were less likely to have an APOE e4 allele (24.04% vs. 29.14%, p=0.02) (Table 5.6.1).  
Those above the median CRP level also had a higher BMI (27.77±4.85 vs. 26.40±4.08, p<0.001), 
had lower baseline ln(IL-6) (0.50±0.60 vs. 0.92±0.68, p<0.001), had higher Cystatin-C (1.02 
mg/L±0.25 vs. 0.99 mg/L±0.21), indicating poorer kidney function (Table 5.6.1). Patterns of 
baseline characteristics by IL-6 levels were similar, and did not change variables for which we 
wanted to adjust models by, so they are not reported here. The correlation coefficient of ln(IL-6) 
and ln(CRP) at baseline was 0.40 (p<0.001), and at Year 8 was 0.36 (p<0.001). The correlation 
coefficient of ln(CRP) at baseline with ln(CRP) at Year 8 was 0.33  (p<0.001); the correlation 
coefficient of ln(IL-6) at baseline with ln(IL-6) at Year 8 was 0.42 (p<0.001).  
In cox proportional hazards models, there were no significant associations between 
baseline ln(IL-6) level, slope or variability and cognitive decline (Table 5.6.2). There were also 
no significant associations between baseline ln(CRP) level or slope and cognitive decline (Table 
5.6.3). However, those with extreme variability of CRP compared to those with minimal 
variability had an increased risk of cognitive decline in 3 models: one with variability only 
(HR=1.54; 95% CI: 1.14, 2.09); one with slope and variability (HR=1.51; 95% CI: 1.06, 2.14); 
and one with baseline ln(CRP), slope, and variability (HR=1.54; 95% CI: 1.07, 2.21) (Table 
5.6.3). These associations remained significant after adjustment for age, race, sex, education, 
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BMI, diabetes, APOE e4, cystatin-C, anti-inflammatory drug use and baseline ln(IL-6) (Table 
5.6.3). 
There was a significant interaction of baseline ln(CRP) level, slope and variability with 
APOE (χ2=372.949, 2 degrees of freedom, p<0.001), and with sex (χ2=52.256, 2 degrees of 
freedom, p<0.001), but not with race. The relationship between the CRP trajectory pattern, 
specifically the variability component of the trajectory pattern, was stronger among women, and 
among those with no APOE e4 allele. In a model with baseline ln(CRP), slope and variability, 
women with extreme variability compared to those with minimal variability had an increased 
risk of cognitive decline (HR=1.82; 95% CI: 1.09, 3.02), but the same was not true for men 
(HR=1.32; 95% CI: 0.82, 2.19) (Table 5.6.4). This remained true after adjustment for age, race, 
education, BMI, diabetes, APOE e4, cystatin-C, anti-inflammatory drug use and baseline ln(IL-
6) (women HR=1.96, 95% CI: 1.17, 3.27 and men HR=1.25; 95% CI: 0.72, 2.17) (Table 5.6.4).
Similarly, in a model with baseline ln(CRP), slope and variability, those with no APOE e4 allele 
and extreme CRP variability had an increased risk of cognitive decline (HR=1.63; 95% CI: 1.06, 
2.50), but the same was not true for those with ≥1 APOE e4 allele (HR=1.37; 95% CI: 0.63, 
2.97) (Table 5.6.5). This remained true after adjustment for age, race, sex, education, BMI, 
diabetes, Cystatin-C, anti-inflammatory drug use and baseline ln(IL-6) (no APOE e4 allele HR= 
1.69; 95% CI: 1.10, 2.60 and ≥1 APOE e4 allele HR=1.39; 95% CI: 0.62, 3.11) (Table 5.6.5). 
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5.5 DISCUSSION 
To our knowledge, this is the first prospective cohort study to look at the association between 
trajectories of inflammation measured from three to five time points and cognitive decline. We 
found no significant associations between trajectory patterns of IL-6 and cognitive decline. 
However, those with extreme variability in CRP over time had an increased risk of cognitive 
decline over 10 years. This association remained significant even after adjustment for multiple 
covariates and confounders, including age, race, education, sex, education, APOE e4, BMI, 
diabetes, cystatin-C, anti-inflammatory drug use, and baseline IL-6. Furthermore, this association 
was stronger among women and among those with no APOE e4 allele. 
Our results complement previous studies reporting a significant association between 
elevated CRP measured from one time point, and AD or cognitive decline.(Kravitz et al., 2009a; 
Schmidt et al., 2002; Yaffe et al., 2003) Similarly, one study which had CRP measured at 2 time 
points found that doubling of CRP was significantly associated with greater decline in the 3MS 
over 9 years.(Jenny et al., 2012) However, it has recently been found that there may be high 
intra-individual variability in CRP levels over time, so our interpretation of the results from these 
previous studies is limited.(deGoma et al., 2012; Koenig et al., 2003) Thus, our study contributed 
uniquely to the literature by not only looking at elevated levels of CRP at baseline, but by 
examining individuals’ slope and variability of CRP trajectories over time. Our finding that 
variability of CRP over time was a significant predictor of cognitive decline points to the need to 
have inflammation and cognitive function measured at multiple time points when assessing such 
an association, and supports previous literature finding similar results with cardiovascular 
outcomes.(deGoma et al., 2012; Koenig et al., 2003)  
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One potential mechanism underlying an association between CRP variability and 
increased cognitive decline over time is greater overall morbidity, especially in terms of vascular 
and metabolic disease. Elevated levels of CRP have been associated with a variety of vascular 
and metabolic disease states, including obesity, cardiovascular disease, atherosclerosis and 
diabetes.(deGoma et al., 2012; C. Ferri et al., 2007; Wang et al., 2013) Other evidence 
supporting such a pathway is  an indication that CRP is more stable, and lacks intra-individual 
variability in the absence of disease.(Kluft & de Maat, 2001)  Thus, what we may be measuring 
with variability in CRP is greater morbidity over time, and perhaps conditions that are more 
poorly controlled by medication and behavior interventions. This could have clinical 
implications because it could mean that measuring CRP over time and detecting greater 
variability could be more useful than obtaining a simple medical history from patients where 
questions are answered with a simple yes/no. The previous associations between CRP and 
increased risk for vascular disease, combined with our findings could also suggest that CRP 
variability over time is associated with cognitive decline may be due to vascular changes in the 
brain, rather than with AD-specific pathology.  
We found the association between CRP variability and increased risk for cognitive 
decline was stronger among those with no APOE e4 allele. This could be due to the etiology of 
the cognitive decline. It is widely known that those with at least one APOE e4 allele are at an 
increased risk for AD(Ingelsson et al., 2003), so perhaps we are measuring cognitive decline 
related to vascular changes rather than AD pathology. Our study also found the association 
between CRP variability and increased cognitive decline was stronger among women. While 
men are known to have a greater burden of vascular disease earlier on in life, this gap decreases 
with age, and once over the age of 80 years, women actually have a greater burden of 
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cardiovascular disease.(Roger et al., 2012) Perhaps, given the age of these participants 
(approximately 73 years at baseline and 83 years when cognitive function was last assessed), this 
is due to and increased vascular disease burden among women.(Roger et al., 2012)    
This study had several strengths, including the measurement of inflammatory markers at 
3 to 5 time points. Furthermore, we had a relatively large sample size providing ample analytical 
power for this study. Measurement of numerous comorbidities and demographic data also 
allowed us to investigate a large number potential covariates and confounders.  There are also 
several weakness that should be taken into consideration when interpreting these results. These 
adults were all well-functioning and community-dwelling at baseline, so results may not be 
generalizable to all older adults – for example, nursing home populations.  We were also limited 
to examining the inflammatory markers CRP and IL-6 due to what was measured, but other 
inflammatory markers have previously been related to cognitive function, and may provide more 
information.  
We found that high CRP variability over time was significantly associated with increased 
risk for cognitive decline over 10 years, and that variability measured from 3 to 5 time points 
was a stronger predictor than individual levels of CRP or the slope of CRP over time. Theses 
associations were stronger among women and those with no APOE e4 allele. We believe CRP 
variability may reflect a greater burden of vascular and metabolic disease, and perhaps signify 
conditions that are more poorly controlled. Future studies should investigate if CRP variability is 
related to AD- and vascular dementia-specific pathologies, such as amyloid deposition in the 
brain and white matter hyperintensities to allow a better understanding of how CRP variability 
may be influencing cognitive function.  
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5.6 TABLES AND FIGURES 
Table 5.6.1 Association between baseline characteristics and baseline CRP level 
Baseline Characteristic 
Mean (SD) or N (%) 
<= Median CRP 
(N=724) 
>Median CRP 
(N=599) 
p-value 
Age 73.47 (2.77) 73.28 (2.86) 0.23 
Black Race 355 (49.03%) 416 (69.45%) <0.0001 
Education (≤High School) 321 (44.34%) 300 (50.08%) 0.11 
Female Sex 341 (47.10%) 356 (59.43%) <0.0001 
Body Mass Index 26.40 (4.08) 27.77 (4.85) <0.0001 
Diabetes 122 (16.85%) 151 (25.21%) 0.0002 
Hypertension 511 (70.58%) 436 (72.79%) 0.38 
Stroke/TIA 58 (8.01%) 44 (7.35%) 0.65 
Myocardial Infarction 70 (9.67%) 53 (8.85%) 0.61 
Baseline 3MS Score 93.89 (3.91) 93.72 (3.74) 0.44 
APOE e4 Allele 211 (29.14%) 144 (24.04%) 0.02 
Serum Creatinine 1.02 (0.24) 1.00 (0.23) 0.21 
Cystatin-C 0.99 (0.21) 1.02 (0.25) 0.01 
Anit-Inflammatory Drug Use 409 (56.49%) 322 (53.76%) 0.34 
CES-D Score 4.47 (5.25) 4.37 (4.66) 0.71 
Baseline IL-6 0.92 (0.68) 0.50 (0.60) <0.001 
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Table 5.6.2 Association between IL-6 and cognitive decline over 10 years 
Unadjusted Model Measure HR (95% CI) 
Baseline only Baseline 1.03 (0.93, 1.14) 
Slope only Slope 1.01 (0.72, 1.42) 
Variability only Minimal Variability Reference 
Moderate Variability 1.11 (0.88, 1.41) 
Extreme Variability 0.84 (0.58, 1.20) 
Slope + Variability Slope 1.04 (0.73, 1.48) 
Minimal Variability Reference 
Moderate Variability 1.11 (0.87, 1.41) 
Extreme Variability 0.83 (0.57, 1.21) 
Baseline + Slope + Variability Baseline 1.05 (0.93, 1.19) 
Slope 0.97 (0.65, 4.44) 
Minimal Variability Reference 
Moderate Variability 1.08 (0.84, 1.39) 
Extreme Variability 0.81 (0.55, 1.18) 
Adjusted Model* Measure HR (95% CI) 
Baseline only Baseline 1.06 (0.93, 1.20) 
Slope only Slope 0.99 (0.69, 1.43) 
Variability only Minimal Variability Reference 
Moderate Variability 1.13 (0.87, 1.46) 
Extreme Variability 0.87 (0.59, 1.29) 
Slope + Variability Slope 1.01 (0.69, 1.47) 
Minimal Variability Reference 
Moderate Variability 1.13 (0.87, 1.47) 
Extreme Variability 0.87 (0.58, 1.30) 
Baseline + Slope + Variability Baseline 1.09 (0.94, 1.26) 
Slope 0.90 (0.59, 1.38) 
Minimal Variability Reference 
Moderate Variability 1.10 (0.84, 1.44) 
Extreme Variability 0.84 (0.55, 1.26) 
*Adjusted for age, race, sex, education, BMI, diabetes, APOE e4, Cystatin-C, anti-inflammatory
drug use and baseline ln(CRP). 
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Table 5.6.3 Association between CRP and cognitive decline over 10 years 
Unadjusted Model Measure HR (95% CI) 
Baseline only Baseline 1.02 (0.92, 1.14) 
Slope only Slope 1.32 (0.97, 1.78) 
Variability only Minimal Variability Reference 
Moderate Variability 1.06 (0.82, 1.37) 
Extreme Variability 1.54 (1.14, 2.09) 
Slope + Variability Slope 1.05 (0.72, 1.53) 
Minimal Variability Reference 
Moderate Variability 1.06 (0.81, 1.37) 
Extreme Variability 1.51 (1.06, 2.14) 
Baseline + Slope + Variability Baseline 1.02 (0.92, 1.14) 
Slope 0.97 (0.65, 1.44) 
Minimal Variability Reference 
Moderate Variability 1.05 (0.80, 1.38) 
Extreme Variability 1.54 (1.07, 2.21) 
Adjusted Model* Measure HR (95% CI) 
Baseline only Baseline 0.99 (0.87, 1.13) 
Slope only Slope 1.20 (0.87, 1.67) 
Variability only Minimal Variability Reference 
Moderate Variability 1.01 (0.77, 1.33) 
Extreme Variability 1.48 (1.07, 2.05) 
Slope + Variability Slope 0.95 (0.63, 1.43) 
Minimal Variability Reference 
Moderate Variability 1.02 (0.77, 1.35) 
Extreme Variability 1.51 (1.04, 2.19) 
Baseline + Slope + Variability Baseline 0.97 (0.85, 1.11) 
Slope 0.85 (0.56, 1.31) 
Minimal Variability Reference 
Moderate Variability 1.01 (0.75, 1.35) 
Extreme Variability 1.57 (1.08, 2.29) 
*Adjusted for age, race, sex, education, BMI, diabetes, APOE e4, Cystatin-C, anti-inflammatory
drug use and baseline ln(IL-6). 
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Table 5.6.4 Association between CRP and cognitive decline over 10 years by sex. 
HR (95% CI) 
Unadjusted Model Measure Male HR Female HR 
Baseline only Baseline 1.05 (0.91, 1.23) 1.01 (0.86, 1.17) 
Slope only Slope 1.52 (0.99, 2.35) 1.18 (0.77, 1.81) 
Variability only Minimal Variability Reference Reference 
Moderate Variability 0.96 (0.67, 1.39) 1.16 (0.82, 1.66) 
Extreme Variability 1.59 (1.05, 2.43) 1.48 (0.95, 2.31) 
Slope + Variability Slope 1.46 (0.87, 2.44) 0.77 (0.44, 1.35) 
Minimal Variability Reference Reference 
Moderate Variability 0.91 (0.63, 1.33) 1.21 (0.84, 1.73) 
Extreme Variability 1.36 (0.84, 2.21) 1.67 (1.01, 2.78) 
Baseline + Slope + Variability Baseline 1.04 (0.89, 1.21) 1.01 (0.87, 1.19) 
Slope 1.48 (0.87, 2.53) 0.65 (0.36, 1.17) 
Minimal Variability Reference Reference 
Moderate Variability 0.91 (0.62, 1.35) 1.19 (0.82, 1.74) 
Extreme Variability 1.32 (0.80, 2.19) 1.82 (1.09, 3.02) 
Adjusted Model* Measure Male Female HR 
Baseline only Baseline 1.03 (0.85, 1.25) 0.93 (0.78, 1.12) 
Slope only Slope 1.36 (0.85, 2.17) 1.08 (0.68, 1.70) 
Variability only Minimal Variability Reference Reference 
Moderate Variability 0.96 (0.65, 1.41) 1.09 (0.74, 1.59) 
Extreme Variability 1.45 (0.90, 2.33) 1.47 (0.93, 2.33) 
Slope + Variability Slope 1.40 (0.81, 2.43) 0.66 (0.36, 1.21) 
Minimal Variability Reference Reference 
Moderate Variability 0.90 (0.61, 1.35) 1.15 (0.78, 1.70) 
Extreme Variability 1.26 (0.73, 2.15) 1.77 (1.06, 2.97) 
Baseline + Slope + Variability Baseline 1.00 (0.82, 1.21) 0.93 (0.78, 1.13) 
Slope 1.40 (0.79, 2.49) 0.53 (0.28, 1.01) 
Minimal Variability Reference Reference 
Moderate Variability 0.88 (0.58, 1.35) 1.15 (0.77, 1.72) 
Extreme Variability 1.25 (0.72, 2.17) 1.96 (1.17, 3.27) 
*Adjusted for age, race, education, BMI, diabetes, APOE e4, Cystatin-C, anti-inflammatory drug
use and baseline ln(IL-6). 
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Table 5.6.5 Association between CRP and cognitive decline over 10 years, by APOE e4 
allele. 
HR (95% CI) 
Unadjusted Model Measure ≥1 APOE e4 allele No APOE e4 
allele 
Baseline only Baseline 1.01 (0.83, 1.23) 1.02 (0.90, 1.17) 
Slope only Slope 1.40 (0.75, 2.60) 1.15 (0.79, 1.67) 
Variability only Minimal Variability Reference Reference 
Moderate Variability 1.02 (0.63, 1.65) 1.02 (0.74, 1.40) 
Extreme Variability 1.35 (0.70, 2.60) 1.51 (1.05, 2.18) 
Slope + Variability Slope 1.21 (0.57, 2.60) 0.87 (0.54, 1.39) 
Minimal Variability Reference Reference 
Moderate Variability 1.00 (0.61, 1.63) 1.04 (0.75, 1.44) 
Extreme Variability 1.22 (0.57, 2.64) 1.61 (1.06, 2.45) 
Baseline + Slope + Variability Baseline 1.03 (0.84, 1.25) 1.01 (0.89, 1.16) 
Slope  1.03 (0.46, 2.30) 0.80 (0.49, 1.32) 
Minimal Variability Reference Reference 
Moderate Variability 1.03 (0.62, 1.70) 1.00 (0.71, 1.41) 
Extreme Variability 1.37 (0.63, 2.97) 1.63 (1.06, 2.50) 
Adjusted Model* Measure ≥1 APOE e4 allele No APOE e4 
allele 
Baseline only Baseline 0.86 (0.67, 1.11) 1.04 (0.89, 1.22) 
Slope only Slope 1.36 (0.71, 2.63) 1.17 (0.80, 1.71) 
Variability only Minimal Variability Reference Reference 
Moderate Variability 1.08 (0.65, 1.77) 1.01 (0.73, 1.40) 
Extreme Variability 1.32 (0.65, 2.77) 1.58 (1.09, 2.30) 
Slope + Variability Slope 1.18 (0.53, 2.63) 0.88 (0.55, 1.41) 
Minimal Variability Reference Reference 
Moderate Variability 1.05 (0.63, 1.75) 1.03 (0.74, 1.44) 
Extreme Variability 1.22 (0.54, 2.73) 1.67 (1.09, 2.54) 
Baseline + Slope + Variability Baseline 0.86 (0.67, 1.11) 1.02 (0.87, 1.19) 
Slope  1.04 (0.45, 2.42) 0.81 (0.49, 1.34) 
Minimal Variability Reference Reference 
Moderate Variability 1.06 (0.63, 1.79) 1.00 (0.70, 1.42) 
Extreme Variability 1.39 (0.62, 3.11) 1.69 (1.10, 2.60) 
*Adjusted for age, race, sex, education, BMI, diabetes, Cystatin-C, anti-inflammatory drug use
and baseline ln(IL-6). 
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6.0  DISCUSSION 
6.1 SUMMARY, CONCLUSIONS AND FUTURE RESEARCH 
The primary aim of these papers was to investigate the potential role of plasma Aβ40, Aβ42 and 
serum- and plasma-derived inflammatory as biological markers of AD. We found plasma Aβ0 
and Aβ42 were significantly associated with age, race, sex, education, APOE e4 genotype, and 
creatinine. We further found that there were borderline significant associations with plasma Aβ 
and myocardial infarction, total cholesterol, and markers of inflammation. Finally, we found that 
changes in inflammatory markers over time had stronger associations with cognitive outcomes 
than measuring these markers at only one time point. Having extreme variability in CRP may 
increase the risk of cognitive decline. Finally, the association between high inflammation and 
dementia may be pleiotropic, appearing to be protective in the oldest old. This could be due to 
survival bias or to the complexity of the immune system in advanced age. While the results do 
not provide sufficient evidence for the use of these proteins as biomarkers of AD, they do 
highlight some potential underlying mechanisms linking these proteins to the development of 
dementia, and provide insight for future directions of this research.  
Taken together, these findings highlight the importance of vascular mechanisms in the 
development of AD and dementia. Our findings that plasma Aβ40 and Aβ42 have borderline 
significant associations with total, HDL and LDL cholesterol, myocardial infarction, and markers 
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of inflammation add to a growing body of literature linking these proteins to vascular disease.(A. 
L. Metti et al., 2012) Recent studies have suggested that Aβ40 and Aβ42 are vasoactive proteins, 
and are directly related to vascular risk factors, such as midlife blood pressure, total cholesterol 
and diabetes.(Blasko et al., 2011; Shah et al., 2012) Importantly, plasma Aβ40 and Aβ42 have 
also been found to accumulate in microvessels outside of the brain, and contribute to 
vasoconstriction of vessels and to the development of vascular disease.(Iadecola, Park, & 
Capone, 2009; Smith & Greenberg, 2009) Plasma Aβ40 has also emerged as a potential 
biomarker of white matter hyperintensities among people with AD and MCI, indicating that it 
may not only be a marker of amyloid development, but also of microvascular damage in older 
adults.(Gurol et al., 2006) Most recently, measures of vascular disease, such as elevated resting 
blood pressure, brachial-ankle pulse wave velocity, and mean arterial pressure were shown to be 
related to amyloid deposition in the brains of non-demented older adults suggesting the 
relationship between vascular disease and amyloid deposition may be bi-directional.(Hughes et 
al.)  
Inflammation is also related to vascular disease. Specifically, inflammation is known as 
both a risk factor and consequence of vascular disease, and vascular disease risk factors such as 
obesity and diabetes.(C. Ferri et al., 2007; Wang et al., 2013) Subclinical measures of vascular 
disease, such as carotid intima-media thickness have also been shown to be risk factors for 
dementia and cognitive decline.(Wendell, Zonderman, Metter, Najjar, & Waldstein, 2009; Zhong 
et al., 2012)  Our finding that high CRP variability is associated with increased risk of cognitive 
decline suggests a potential vascular mechanism. Elevated levels of CRP have been associated 
with a variety of vascular and metabolic disease states, including obesity, cardiovascular disease, 
atherosclerosis and diabetes.(deGoma et al., 2012; C. Ferri et al., 2007; Wang et al., 2013) 
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Furthermore, CRP has been shown to be less variable among adults who are disease-free (Kluft 
& de Maat, 2001), suggesting that with CRP variability, we may be assessing greater morbidity 
over time. Our finding that plasma Aβ40 and Aβ42 had borderline significant associations with 
inflammatory markers also points to the potentially complex interrelationship between 
inflammatory markers and plasma Aβ.(A. L. Metti et al., 2012) Due to limitations in sample size 
with measurements of both inflammation and plasma Aβ, we were unable to investigate the 
association between all of these markers together and cognitive decline, but this is a proposed 
direction of future research. 
Other potential underlying mechanisms, such as diabetes and kidney function were also 
highlighted through our research. Beginning with diabetes, we found that both plasma Aβ40 and 
Aβ42 were significantly associated with a history of diabetes.(A. L. Metti et al., 2012) We also 
found in our inflammatory analyses that a history of diabetes was significantly related to our 
predictors IL-6, IL-6 sR, and CRP. Furthermore, diabetes has also been shown to be a risk factor 
for cognitive decline and mild cognitive impairment.(Luchsinger et al., 2007; Yaffe et al., 2004) 
Interestingly, hyperinsulinemia has also been associated with concurrent increases in CSF 
inflammatory markers and Aβ42, although studies have not investigated similar relationships 
with plasma or serum biomarkers.(Fishel et al., 2005)  We also found that kidney function, 
measured with serum creatinine was significantly associated with plasma Aβ40 and Aβ42.(A. L. 
Metti et al., 2012) In our inflammatory analyses, cystatin-C, another measure of kidney function 
was significantly related to CRP and IL-6 level.  Previous studies have shown that poorer kidney 
function, as measured by cystatin-C, creatinine, or estimated glomerular filtration rate, is related 
to increased risk for cognitive decline and dementia.(Bugnicourt, Godefroy, Chillon, Choukroun, 
& Massy, 2013; Kurella et al., 2005)  When considering the biology of the brain and kidneys, 
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there are several similarities that should not be ignored: 1. They are both passively perfused at a 
high volume throughout the cardiac cycle; 2. Both the brain and kidneys have arterioles that are 
upstream of vasodilation, exposing these arterioles to high pulsatile pressure; and 3. Both organs 
are low-resistance end-organs, exposed to high-volume blood flow under constantly changing 
flow conditions, and are thus both vulnerable to vascular damage.(Barinas-Mitchell, 2013; 
Bugnicourt et al., 2013) Of course, given these similarities relating the brain and kidney back to 
vascular damage, and considering the fact that diabetes is also a risk factor for vascular disease, 
once again, we circle back to the idea that vascular disease may also be a potential underlying 
mechanism.  
Thus, future studies should investigate the role of inflammatory markers and plasma Aβ, 
and determine if vascular disease, diabetes, kidney disease or a combination of all three are a 
potential mechanism underlying an association between inflammation, amyloid and cognitive 
decline.  More work is also needed to determine the reproducibility, validity and reliability of 
these markers in predicting cognitive decline or dementia, but before that can be done, 
standardization of laboratory methods across studies will need to be a primary goal. Due the 
heterogeneity and complexity of dementia, and the vascular implications discussed above, 
studies should investigate how these biomarkers are related to specific types of dementia 
pathology – for example white matter hyperintensities and amyloid plaques. Additionally, future 
research should investigate how these markers fluctuate over time with the development of these 
pathologies, and in terms of these comorbid conditions. Finally, in the future, it would be ideal if 
studies could use multiple-array techniques or proteomics to allow for the investigation of 
multiple biological markers at one time, rather than just measuring these markers individually, as 
they are likely highly interrelated.   
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6.2 PUBLIC HEALTH IMPLICATIONS 
An estimated 24.3 million older adults worldwide are currently living with dementia, with an  
estimated incidence of 4.6 million cases each year.(C. P. Ferri et al., 2005) In the United States, 
dementia is already the sixth leading cause of death overall, and the fifth leading cause of death 
among adults 65 years of age and older.(Alzheimer's Association, 2011) Furthermore, the 
predicted prevalence for the year 2020 is 42.3 million cases, and by the year 2040 is 81.1 million 
cases, unless something is done to slow the progression or delay the onset of dementia.(C. P. 
Ferri et al., 2005) With the expected increase in dementia over the next 20 years and lack of any 
effective treatment, we can only expect the public health burden to also increase exponentially, 
and as such, there is a pressing need to improve the ability to accurately diagnose AD. 
Identifying reliable markers that can be assessed in a large number of older adults, in a cost-
effective manner, so that large numbers of older adults can be screened, such as the blood-
derived biomarkers discussed in these papers, is one potential way of improving diagnosis. 
Gaining a better understanding of these biomarkers is also important because it will continue to 
shed light on those who are at an increased risk for the disease, and potential targets for treatment 
or behavioral interventions. As discussed previously, vascular disease, kidney disease and 
diabetes all seem to be underlying mechanisms highlighted in our work that may potentially be a 
link between these markers and cognitive function. Thus, perhaps primary or secondary 
prevention of these conditions may be potentially useful in either delaying the onset of dementia 
or preventing the occurrence altogether. In fact, one study showed that in the United States, if we 
could reduce diabetes prevalence by 10%, we could prevent nearly 17,000 cases of AD; a similar 
reduction in midlife hypertension, midlife obesity, physical inactivity or smoking – all risk 
factors for vascular disease – could prevent nearly 40000, 36000,  90000 and 50000 cases of AD, 
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respectively.(Barnes & Yaffe, 2011) If all efforts were combined, this could lead to more than 
200,000 cases of AD prevented in the United States alone. Finally, it is important to remember 
that we have no current treatment for AD. Thus, by further examining these complex 
interrelationships between biomarkers, comorbidities and dementia, we can hopefully shed some 
light on therapeutic strategies for preventing or curing this disease. For example, drugs that 
effectively prevent or treat inflammation, vascular disease, kidney disease or diabetes may be 
potentially useful. 
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APPENDIX A 
A.1 SUPPLEMENTARY TABLE 
Table A.1.1 A summary of current, promising plasma and serum biomarkers of Alzheimer’s disease. 
Biomarker/Reference Source  Outcome Association Potential Mechanism Sample 
Characteristics 
Adjusted 
Covariates 
Aβ42 Amyloid 
pathway/deposition 
Fukumoto, et al., 2003. 
Arch Neurol. 
Plasma AD, MCI, 
cognitively 
normal 
No association between 
continuous level of plasma 
Aβ42 and diagnosis of AD or 
MCI, compared to normal 
controls (52.4 ±17.5 pmol/L 
and 47.8±15.0 pmol/L vs. 
48.9±17.2, respectively) 
N=371; Memory 
clinic setting; 
overall μage not 
reported; μage =76.0 
for AD and 69.4 for 
normal controls 
Age, sex, APOE; 
family history, 
medication use 
Graff-Radford, et al., 
2007. Arch Neurol. 
Plasma Risk of 
developing 
MCI or AD 
over time (3 to 
7 years) 
No association between q-
uartile of Aβ42 and risk of 
developing MCI or AD 
Q1:Q4 RR=1.18 (0.50, 2.75) 
N=563; μage =78.0 
years; all white 
Age, APOE 
Lopez, et al., 2008. 
Neurology. 
Plasma Incident 
dementia 
No association between 
continuous Aβ42 and 
development of incident 
dementia 4 to 5 years later; 
OR: 1.46 (0.96, 2.22) 
N= 274; 
Cardiovascular 
Health Study 
Cognition Study; 
μage=74.0 years at 
Age, 3MS scores, 
APOE, cystatin-C, 
MRI identified 
infarcts 
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Incident MCI 
Cross-sectional 
with AD 
diagnosis 
No association; OR=1.34 
(0.90, 1.99)  
No association; OR=1.30 
(0.87, 1.94) 
baseline 
Mayeux, et al., 2003. 
Neurology. 
Plasma Incident AD Those in the highest quartile, 
compared to the low had 
increased risk of developing 
AD; RR: 2.5 (1.3, 4.8) 
N=530; 
community-
dwelling; μage for 
those who 
developed 
dementia=79.3 
years at baseline vs. 
75.5 years for those 
who didn’t; white, 
Hispanic, and 
African-American 
(overall percentages 
not reported) 
Age, education, 
APOE, BMI 
Mehta, et al., 2000. Arch 
Neurology. 
Plasma Cognitive 
status 
No significant association 
between continuous level and 
cognitive status (no specific 
measure of association or p-
value reported).  
N=78 with AD and 
75 controls; 2 
university medical 
centers (New York 
and Finland); 53% 
women 
Not reported 
Pomara, et al., 2005. Am 
J Geriatr Psychiatry. 
Plasma Cognitive 
decline 
(MMSE) over 
~4.2 years 
Higher initial Aβ42 
(continuous measure) 
(Spearman’s r=-0.35, p=0.05) 
and greater reductions were 
associated with greater 
declines on the MMSE 
(Spearman’s r=0.41, p=0.02) 
N=34; μage=65.4 
years at baseline; 
56% women 
None 
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Table A.1.1 Continued
Schupf, et al., 2008. 
Proc Natl Acad Sci. 
Plasma Incident AD 
over ~4.6 years 
Change in 
plasma Aβ with 
risk of AD 
Those in the highest quartile 
were significantly more likely 
to develop AD, compared to 
lowest quartile; HR=3.4 (1.6, 
7.6) 
Compared to those with 
increasing levels, those with 
decreasing levels had a higher 
risk of AD; OR=2.8 (1.6, 5.1) 
N=1,125; 
Washington 
Heights-Inwood 
Columbia Aging 
Project; >50% 
women (overall 
percentage not 
reported); white, 
Hispanic and 
African American 
(specific 
percentages not 
reported) 
Age, sex, 
ethnicity, 
education, BMI, 
APOE 
Van Oijen, et al., 2006. 
Lancet Neurol. 
Plasma Incident AD 
over a mean of 
8.6 years 
No association between high 
quartile compared to low; 
HR: 1.32 (0.90, 1.96) 
N=1756; Rotterdam 
Study; μage=68.6 
years at baseline; 
61% women 
Age, sex, APOE, 
creatinine, total 
cholesterol, HDL 
cholesterol, BMI 
Yaffe, et al., 2011. 
JAMA. 
Plasma 9-year change 
in 3MS 
Low tertile: -6.96 (-5.53, -
8.03) vs. High tertile: -4.30 (-
3.03, -5.47); p=0.007 
N=977; Health 
ABC; μage=74.0 
years at baseline; 
54% black; 55% 
female 
Age, race, 
education, 
diabetes, smoking, 
APOE, baseline 
3MS scores 
Aβ42/Aβ40 Amyloid 
pathway/deposition 
Graff-Radford, et al., 
2007. Arch Neurol. 
Plasma Risk of 
developing 
MCI or AD 
over time (3 to 
7 years) 
Q1:Q4 RR=3.08 (1.12, 8.30) N=563; μage =78.0 
years; all white 
Age, APOE 
Lopez, et al., 2008. 
Neurol. 
Plasma Incident 
dementia 
No association between 
continuous Aβ42/Aβ40 and 
development of incident 
dementia 4 to 5 years later 
OR: 1.37 (0.91, 2.06) 
N= 274; 
Cardiovascular 
Health Study 
Cognition Study; 
μage=74.0 years at 
Age, 3MS scores, 
APOE, cystatin-C, 
MRI identified 
infarcts 
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Incident MCI 
Cross-sectional 
with AD 
diagnosis 
No association; OR=1.06 
(0.74, 1.54) 
No association; OR=1.19 
(0.81, 1.75) 
baseline 
Schupf, et al., 2008. 
Proc Natl Acad Sci. 
Plasma Incident AD 
over ~4.6 years 
Change in 
plasma Aβ with 
incident AD 
No association; Q4:Q1 
HR=0.9 (0.5, 1.7) 
Compared to those with 
increasing levels, those with 
decreasing levels had a higher 
risk of AD; OR=3.6 (1.1, 
12.1) 
N=1,125; 
Washington 
Heights-Inwood 
Columbia Aging 
Project; >50% 
women (overall 
percentage not 
reported); white, 
Hispanic and 
African American 
(specific 
percentages not 
reported) 
Age, sex, 
ethnicity, 
education, BMI, 
APOE 
Van Oijen, et al., 2006. 
Lancet Neurol. 
Plasma Incident AD 
over a mean of 
8.6 years 
Those in the high quartile, 
compared to those in the low 
quartile have a reduced risk 
of AD; HR: 0.53 (0.35, 0.76) 
N=1756; Rotterdam 
Study; μage=68.6 
years at baseline; 
61% women 
Age, sex, APOE, 
creatinine, total 
cholesterol, HDL 
cholesterol, BMI 
Yaffe, et al., 2011. 
JAMA. 
Plasma 9-year change 
in 3MS 
Low tertile: -6.38 (-5.15, -
7.61) vs. High tertile: -3.44 (-
2.21, -4.67); p=0.02 
*Modified by low cognitive
reserve (education and 
literacy) and by APOE e4 
allele status 
N=977; Health 
ABC; μage=74.0 
years at baseline; 
54% black and 55% 
female 
Age, race, edu, 
diabetes, smoking, 
APOE e4, baseline 
3MS scores 
Aβ Antibodies Amyloid 
pathway/deposition 
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Brettschneider, et al., 
2005. Biol Psychiatry. 
Serum AD vs. normal 
control 
Aβ42 autoantibodies were 
significantly reduced in AD 
patients, compared to normal 
controls (3.1±3.28  vs. 
5.88±4.54, p=0.001), even 
after age-matching (p=0.01) 
N=; University 
clinic, Germany;  
μage=70 years at 
baseline for AD and 
55 at baseline for 
controls; 61% 
female 
Age, APOE, 
MMSE score 
Hock, et al., 2003. 
Neuron. 
Serum Cognitive and 
functional 
decline after 
active Aβ42 
immunization  
Patients who generated 
antibodies (as measured in 
serum) after immunization 
had significantly lower rates 
of cognitive decline 
(p=0.008) and functional 
decline (activities of daily 
living; p=0.03) compared to 
those who didn’t.  
After 1 year, 67% of those 
who didn’t develop 
antibodies progressed to 
severe dementia (MMSE 
<14) vs. only 16% of patients 
who developed antibodies 
(p<0.01) 
N=28 (19 with 
antibodies and 9 
controls); mildly to 
moderately 
demented (MMSE 
16-26) at baseline 
Age, sex, 
medication 
(including acetyl-
cholinesterase 
inhibitors), head 
trauma, and APOE 
Hyman, et al., 2001. Ann 
Neurol. 
Plasma Risk of 
developing AD 
over 7 years 
There were low detectable 
levels of Aβ antibodies in 
only half of the samples.  
Aβ antibodies were not 
significantly correlated with 
risk of developing AD 
(p=0.85) 
N=365 (82 with 
AD, 271 healthy 
controls); sub-
cohort from 
prospective study of 
Medicare-eligible 
in Manhattan, NY; 
μage=76 years; 
>60% women; 
African American, 
Sex, age, 
ethnicity, APOE 
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Hispanic and white 
(exact percentages 
not given) 
Moir, et al., 2002. J Biol 
Chem. 
Plasma Cross-sectional 
comparison of 
Aβ antibody 
levels in AD 
patients vs. 
normal controls 
Plasma immunoreactivity to 
Aβ was significantly 
decreased in AD patients 
compared to normal controls 
(p=0.02) 
N=118 (59 AD and 
59 normal control); 
memory clinic 
setting (Boston);  
None reported 
IL-6 Inflammation 
Engelhart, et al., 2004. 
Arch Neurol. 
Plasma Risk of AD 
over 1 year 
High IL-6 was significantly 
associated with increased risk 
for AD (Rate ratio per 
standard deviation increase in 
IL-6 =1.28 (1.06-1.55) 
N=727; μage=71.7 
years at baseline; 
53% female; 
Rotterdam Study 
subgroup 
Age, sex, 
education, 
smoking, BMI, 
diabetes, anti-
inflammatory 
medication use, 
atherosclerosis 
Eriksson, et al., 2011 Serum Prevalent and 
incident all-
cause dementia 
and AD 
When compared to controls, 
those with all-cause dementia 
and AD had significantly 
elevated levels of IL-6. There 
was no significant association 
between serum IL-6 and 
incident all-cause dementia or 
AD. 
N=3,937; μage=77.7 
years for controls; 
75.3 years for 
dementia cases 
APOE e4, BMI, 
smoking, blood 
pressure, 
education, 
diabetes, coronary 
heart disease, 
stroke 
Gallacher, et al., 2010. 
Arterioscler Thromb 
Vasc Biol. 
Plasma Risk of 
dementia over 
20 years 
There was no significant 
association between 
continuous baseline IL-6 and 
risk of dementia (HR: 0.66; 
95% CI: 0.32-1.35)  
N=865; all men; 
65-84 years of age 
at cognitive status 
determination, but 
45 to 59 when 
inflammatory 
markers measured) 
Age, social class, 
systolic blood 
pressure, BMI, 
smoking, total 
cholesterol, 
alcohol use 
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Licastro, et al., 2000. J 
Neuroimm. 
Plasma Cross-sectional 
comparison of 
level in AD 
patients and 
normal controls 
Levels of IL-6 were increased 
in patients with AD compared 
to normal controls (p<0.001) 
N=196 (145 AD, 51 
controls); hospital 
setting, neurology 
department, Italy; 
μage=78 years for 
AD and 75 years 
for controls; 62% 
female 
None stated 
Ravaglia, et al., 2007. 
Neurobiol Aging. 
Serum Incident all-
cause 
dementia, AD, 
and vascular 
dementia 
There were no significant 
associations between IL-6 
and incident all-cause 
dementia, AD, or vascular 
dementia. However, when 
considered in combination 
with CRP, high levels of both 
were significantly associated 
with an increased risk of 
vascular dementia (HR=2.56, 
95% CI: 1.21, 5.50). 
N=804; μage=73.6 
years at baseline 
Age, sex, 
education, APOE 
e4, stroke, 
cardiovascular 
disease, physical 
activity, BMI, 
homocysteine, 
creatinine, folate, 
Vitamin B12 
Schram, et al., 2007. J 
Am Geriatr Soc. 
Plasma Cognitive 
function (test 
scores) and 
decline (over 
4.5 years in the 
Rotterdam 
Study and 5 
years in the 
Leiden 85+ 
Study) 
Rotterdam Study: Higher IL-
6 (per SD) was associated 
cross-sectionally with lower 
MMSE scores, poorer global 
cognitive function and poorer 
executive function (p=0.03, 
p=0.009, and p=0.008). There 
was no significant association 
between IL-6 and decline 
over time. 
Leiden 85+ Study: 
There was no cross-sectional 
association between 
continuous IL-6 and cognitive 
N=3,874 from the 
Rotterdam Study; 
μage=72 years 
N=491 from the 
Leiden 85+ Study; 
Age, sex, 
education, BMI, 
diabetes, 
cardiovascular 
disease 
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function (p>0.2 for all). 
Those with higher IL-6 had 
greater decline over time on 
delayed recall tasks (p=0.03). 
Associations were modified 
by APOE e4 allele, such that 
they were stronger among 
those with ≥1 allele. 
Sundelof, et al., 2009. J 
Alzheimers Dis. 
Serum Risk of all-
cause 
dementia, AD, 
and non-AD 
dementia over 
11.3 years 
Age 70 Cohort: Those with a 
high level of serum IL-6 had 
a significantly greater risk of 
all-cause dementia (HR=1.45, 
95% CI: 1.06, 2.07) and non-
AD dementia (HR=2.21, 95% 
CI: 1.23, 3.95), but there was 
no association with AD.  
Age 77 Cohort: There were 
no significant associations 
between IL-6 and all cause 
dementia, AD, or non-AD 
dementia.  
Age 70 cohort 
N=1,062; μage=71.0 
years 
Age 77 cohort; 
N=749; μage=77.5 
years 
Age, APOE e4, 
diabetes, NSAID 
treatment, aspirin 
treatment, 
smoking status, 
BMI, 
hypertension, 
serum cholesterol, 
stroke, education 
Tan, et al., 2007. 
Neurology. 
Serum Risk of 
developing AD 
There was no significant 
association between serum 
IL-6 and risk of developing 
AD.  
N=691; μage=79 
years; Cohort from 
the Framingham 
Study 
Age, sex, APOE 
e4, stroke, 
education, 
homocysteine 
levels, smoking 
history, BMI, anti-
inflammatory drug 
use 
Weaver, et al., 2002. 
Neurology. 
Plasma Baseline 
cognitive 
function and 
There was trend-level 
significance for those in the 
highest tertile, compared to 
N=779; MacArthur 
Study of Successful 
Aging; about half 
Age, race, sex, 
education, alcohol 
use, activity level, 
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cognitive 
decline over 
2.5 and 7 years 
*Measured
with 5 tasks 
assessing 
verbal memory, 
naming, recall, 
language, and 
spatial ability, 
with a 
combined score 
those in the lowest tertile, to 
have significantly worse 
cognitive function at baseline 
(OR=1.46; 95% CI: 0.97, 
2.20) 
After 2.5 years, those in the 
highest tertile were 
significantly more likely to 
experience cognitive decline 
than those in the low tertile 
(OR=2.03; 95%CI: 1.30, 
3.19) 
After 7 years, those in the 
highest tertile were 
significantly more likely to 
experience cognitive decline 
than those in the low tertile 
(OR=1.90; 95% CI: 1.14, 
3.18) 
men; majority white 
(exact percentages 
for full sample not 
given) 
BMI, history of 
cancer, diabetes, 
fasting blood 
glucose levels 
Yaffe, et al., 2003. 
Neurology. 
Plasma Cognitive 
function 
(3MS), change 
in 3MS over 
time, and 
clinically 
significant 
cognitive 
decline (>5 
point decline 
over 2 years) 
Those in the highest IL-6 
tertile had significantly worse 
scores on the 3MS, compared 
to those in the lowest tertile 
(88.9 points vs. 90.6 points, 
p<0.001) 
Those in the highest IL-6 
tertile experience 
significantly greater cognitive 
decline over 2 years (-2.0 
points vs. -1.2 points, p=0.01) 
IL-6 was not significantly 
N=3,031; Health 
ABC participants; 
μage=74 years at 
baseline; 41% 
African American 
Age, education, 
race, sex, 
smoking, alcohol 
use, BMI, self-
reported health, 
depression, MI, 
diabetes, 
hypertension, 
stroke, NSAID 
use, and estrogen 
use (for women) 
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associated with clinically 
significant cognitive decline 
after adjustment (OR=1.23, 
95% CI: 0.96, 1.59) 
CRP Inflammation 
Engelhart, et al., 2004. 
Arch Neurol. 
Plasma Risk of AD 
over 1 year 
High CRP was not associated 
with increased risk for AD 
(Rate ratio per standard 
deviation increase in CRP 
=1.12 (0.99,1.25) 
N=727; μage=71.7 
years at baseline; 
53% female; 
Rotterdam Study 
subgroup 
Age, sex, 
education, 
smoking, BMI, 
diabetes, anti-
inflammatory 
medication use, 
atherosclerosis 
Eriksson, et al., 2011 Serum Prevalent and 
incident all-
cause dementia 
and AD 
There was no significant 
association between serum 
CRP and prevalent or incident 
all-cause dementia or AD. 
N=3,937; μage=77.7 
years for controls; 
μage=75.3 years for 
dementia cases 
Apolipoprotein E 
(APOE) e4, BMI, 
smoking, blood 
pressure, 
education, 
diabetes, coronary 
heart disease, and 
stroke 
Gallacher, et al., 2010. 
Arterioscler Thromb 
Vasc Biol. 
Plasma Risk of 
dementia over 
20 years 
There was no significant 
association between 
continuous baseline CRP and 
risk of dementia (HR: 0.79; 
95% CI: 0.42-1.44) 
N=865; all men; 
65-84 years of age 
at cognitive status 
determination, but 
45 to 59 when 
inflammatory 
markers measured) 
Age, social class, 
systolic blood 
pressure, BMI, 
smoking, total 
cholesterol, 
alcohol use 
Holmes, et al., 2009. 
Neurology. 
Serum Cognitive 
performance on 
the ADAS-
COG, and 
change in 
ADAS-COG 
At baseline, there was no 
significant difference in 
ADAS-COG scores between 
those in the lowest CRP 
quartile compared to those in 
the highest quartile (p=0.1) 
N=300; 
community-
dwelling from 
United Kingdom; 
all had mild to 
severe AD  
Not stated 
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over 1 year 
There was no significant 
association between 
worsening in ADAS-COG 
scores and CRP quartile 
(p=0.03) 
Kravitz, et al., 2009. 
Alzheimers Dement.  
Serum Prevalent all 
cause-dementia 
Compared to undetectable 
CRP levels (reference group), 
those with detectable CRP 
levels and elevated CRP 
levels were significantly more 
likely to have all cause 
dementia (OR=3.0, 95% CI: 
1.2, 7.3; OR=5.0, 95% CI: 
1.9, 12.9, respectively) 
N=305; μage=94.3 
years; Leiden 90+ 
Study; Netherlands; 
62% women 
Age, sex 
Kravitz, et al., 2009. J 
Am Geriatr Soc. 
Serum Risk of 
developing 
dementia over 
time (> 1 year) 
There was no significant 
association between CRP 
tertile and risk of developing 
dementia (HR=1.2, 95% CI: 
0.6-2.1), even among those 
with ≥1 APOE e4 allele 
(HR=4.5; 95% CI: 0.9, 23.3) 
N=227; μage=93.9 
years; Leiden 90+ 
Study; Netherlands; 
62% women  
Age, sex, 
education, APOE, 
hypertension, 
coronary artery 
disease, 
congestive heart 
failure and 
transient ischemic 
attack 
Ravaglia, et al., 2007. 
Neurobiol Aging. 
Serum Incident all-
cause 
dementia, AD, 
and vascular 
dementia 
There were no significant 
associations between CRP 
and all-cause dementia, AD, 
or vascular dementia. 
However, when considered in 
combination with IL-6, high 
levels of both were 
significantly associated with 
an increased risk of vascular 
N=804; μage=73.6 
years at baseline 
Age, sex, 
education, APOE 
e4, stroke, 
cardiovascular 
disease, physical 
activity, BMI, 
plasma total 
homocysteine, 
serum 
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dementia (HR=2.56, 95% CI: 
1.21, 5.50). 
creatinine, 
serum folate, and 
serum Vitamin 
B12 
Schmidt, et al., 2002. 
Ann Neurol. 
Serum All-cause 
dementia, AD, 
AD with 
cardiovascular 
disease (CVD), 
and vascular 
dementia 
Those with a high level of 
CRP were significantly more 
likely to have all-cause 
dementia (HR=2.8, 95% CI: 
1.6,5.1), AD with CVD 
(HR=4.7, 95% CI: 1.2, 17.9), 
and vascular dementia: 
(HR=5.1, 95% CI: 1.8, 14.8). 
However, there was no 
significant association 
between CRP and AD 
(HR=2.2, 95% CI: 0.9, 5.1). 
*All reported hazard ratios
are comparing the highest 
quartile of CRP with the 
lowest quartile reference 
group. 
N=1,050; μage not 
reported for entire 
cohort; Cohort from 
the Honolulu-Asia 
Aging Study 
Education, midlife 
smoking status, 
midlife average 
cholesterol, 
midlife blood 
pressure, age, 
years of follow-
up, APOE e4, 
BMI 
Schram, et al., 2007. J 
Am Geriatr Soc. 
Plasma Cognitive 
function (test 
scores) and 
decline (over 
4.5 years in the 
Rotterdam 
Study and 5 
years in the 
Leiden 85+ 
Study) 
Rotterdam Study: Higher 
CRP (per SD) was associated 
cross-sectionally with poorer 
global cognitive function and 
executive function (p<0.001 
for both). There was no 
significant association 
between CRP and decline 
over time. 
Leiden 85+ Study: There was 
N=3,874 from the 
Rotterdam Study; 
μage=72 years 
N=491 from the 
Leiden 85+ Study; 
Age, sex, 
education, BMI, 
diabetes, 
cardiovascular 
disease 
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no cross-sectional association 
between continuous CRP and 
cognitive function (p>0.2 for 
all). There was no significant 
association between CRP and 
decline over time. 
Silverman, et al., 2009. 
Res Letters. 
Plasma Performance 
(scores) on a 
neuropsych test 
battery 
Those in the lowest CRP 
tertile had significantly worse 
memory scores than those in 
the other 2 tertiles (p<0.0001) 
N=176; Bronx VA 
Medical Center; 
μage=85 years; 36% 
women 
Age, sex, 
education, APOE 
Sundelof, et al., 2009. J 
Alzheimers Dis. 
Serum Risk of all-
cause 
dementia, AD, 
and non-AD 
dementia over 
11.3 years 
There were no significant 
associations between CRP 
and all-cause dementia, AD 
or non-AD dementia for 
either cohort. 
Age 70 Cohort: 
N=1,062;μage =71.0 
years at baseline 
Age 77 Cohort: 
N=749; μage =77.5 
years at baseline 
Age, APOE e4, 
diabetes, non-
steroidal anti-
inflammatory drug 
(NSAID) use, 
aspirin treatment, 
smoking status, 
BMI, 
hypertension, 
serum cholesterol, 
stroke, education 
Tan, et al., 2007. 
Neurology. 
Serum Risk of 
developing AD 
There was no significant 
association between serum 
CRP and risk of developing 
AD.  
N=691; μage =79 
years; Cohort from 
the Framingham 
Study 
Age, sex, APOE 
e4, stroke, 
education, 
homocysteine 
levels, smoking 
history, BMI, anti-
inflammatory drug 
use 
Yaffe, et al., 2003. 
Neurology. 
Serum Cognitive 
function (3MS) 
and clinically 
Those in the highest CRP 
tertile had significantly worse 
scores on the 3MS, compared 
N=3,031; Health 
ABC participants; 
μage=74 years at 
Age, education, 
race, sex, 
smoking, alcohol 
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significant 
cognitive 
decline (>5 
point decline 
over 2 years) 
to those in the lowest tertile 
(88.7 points vs. 90.4 points, 
p<0.001) 
Those in the highest CRP 
tertile experience 
significantly greater cognitive 
decline over 2 years (-1.7 
points vs. -1.1 points, p=0.05) 
CRP was not significantly 
associated with clinically 
significant cognitive decline 
after adjustment (OR=1.24, 
95% CI: 0.96, 1.63) 
baseline; 41% 
African American 
use, BMI, self-
reported health, 
depression, MI, 
diabetes, 
hypertension, 
stroke, NSAID 
use, and estrogen 
use (for women) 
TNF-α Inflammation 
Holmes, et al., 2009. 
Neurology. 
Serum Cognitive 
performance on 
the ADAS-
COG, and 
change in 
ADAS-COG 
over 1 year 
At baseline, those in the 
lowest TNF-α quartile had 
significantly better ADAS-
COG scores, compared to 
those in the highest quartile 
(p=0.02) 
Worsening in ADAS-COG 
scores was significantly 
greater among those in the 
highest serum TNF-α 
quartile, compared to those in 
the low quartile (p=0.02) 
N=300; 
community-
dwelling from 
United Kingdom; 
all had mild to 
severe AD  
Not stated 
Yaffe, et al., 2003. 
Neurology. 
Plasma Cognitive 
function (3MS) 
and clinically 
significant 
cognitive 
decline (>5 
There was no significant 
association between baseline 
TNF-α tertile and 3MS scores 
(high 89.5 points vs. low 89.4 
points, p=0.66) 
N=3,031; Health 
ABC participants; 
μage=74 years at 
baseline; 41% 
African American 
Age, education, 
race, sex, 
smoking, alcohol 
use, BMI, self-
reported health, 
depression, MI, 
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point decline 
over 2 years) 
There was no significant 
association between TNF 
tertile and cognitive decline 
over 2 years (high -1.4 points 
vs. low -1.3 points, p=0.75) 
IL-6 was not significantly 
associated with clinically 
significant cognitive decline 
(OR=1.23, 95% CI: 0.95, 
1.63) 
diabetes, 
hypertension, 
stroke, NSAID 
use, and estrogen 
use (for women) 
α1-antichymotrypsin 
(ACT) 
Inflammation 
DeKosky, et al., 2003. 
Ann Neurol. 
Plasma Cross-sectional 
comparison of 
level in AD 
patients and 
normal controls 
Plasma ACT was 
significantly higher in AD 
patients vs. normal controls 
(541.34±8.13 mg/L vs. 
500.58±13.78 mg/L, p=0.01) 
Plasma ACT level was 
significantly related to 
dementia severity (several 
cognitive test scores) 
There was no association 
between plasma ACT and 
other types of dementia 
N=561 (359 AD, 44 
other dementia, 113 
normal controls); 
all white; 
University of 
Pittsburgh 
Alzheimer’s 
Disease Research 
Center (ADRC) 
Sex, education, 
APOE, ACT 
genotype 
Engelhart, et al., 2004. 
Arch Neurol. 
Plasma Risk of AD 
over 1 year 
High ACT was significantly 
associated with increased risk 
for AD (Rate ratio per 
standard deviation increase in 
ACT =1.49 (1.23-1.81) 
N=727; μage=71.7 
years at baseline; 
53% female; 
Rotterdam Study 
subgroup 
Age, sex, 
education, 
smoking, BMI, 
diabetes, anti-
inflammatory 
medication use, 
atherosclerosis 
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Licastro, et al., 2000. J 
Neuroimm. 
Plasma Cross-sectional 
comparison of 
level in AD 
patients and 
normal controls 
Levels of ACT were 
increased in patients with AD 
compared to normal controls 
(p<0.001) 
N=196 (145 AD, 51 
controls); hospital 
setting, neurology 
department, Italy; 
μage=78 years for 
AD and 75 years 
for controls; 62% 
female 
None stated 
*All biomarkers selected to be summarized here were published in manuscripts during or after the year 2000, included humans (not animal models)
and were selected based on two comprehensive reviews of the most promising blood and serum biomarkers (Schneider, Frank). 
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APPENDIX B 
B.1 SUPPLEMENTARY FIGURE 
Figure B.1.1 Proposed association between established risk factors of AD and potential 
blood biological markers. 
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B.1.1 Figure legend. 
In Figure B.1.1. a purple arrow indicates risk factors that have a proposed effect on both plasma 
Aβ and inflammatory markers; a blue arrow indicates  risk factors that have a proposed effect on 
inflammatory markers only. Following is a proposed description of the association between these 
risk factors and biomarkers.  
Plasma Aβ42 increases with risk factors for AD (i.e. increased age, low education, black 
race, female sex, APOE e4 genotype).(Graff-Radford et al., 2007; A. L. Metti et al., 2012). It has 
been proposed that levels of plasma Aβ42 increase to a certain point before beginning to 
selectively aggregate in the form of Aβ plaques 10 to 15 years before the clinically detectable 
onset of dementia.(Graff-Radford et al., 2007) Because Aβ42 is more fibrillogenic, and is more 
likely to form amyloid plaques, following the increase, Aβ42 may begin to decrease to a greater 
extent among those who are at an increased risk for AD, as it begins to aggregate and form 
amyloid plaques.(Gravina et al., 1995; R Mayeux et al., 1999) Furthermore, cardiometabolic risk 
factors are related to plasma Aβ42: 1) Those with low Aβ42 are more likely to have a history of 
diabetes;(A. L. Metti et al., 2012) 2) Aβ42 enhances vasoconstriction, and is thus associated with 
increased blood pressure (BP), increased vascular pathology, and microvessel dysfunction;(Shah 
et al., 2012) 3) There is an interaction between midlife BP and plasma Aβ42 such that those with 
low Aβ42 are at an even greater risk for developing AD as BP increases;(Shah et al., 2012) 4) 
Low plasma Aβ42 measured in life has been associated with greater cerebral amyloid angiopathy 
at autopsy;(Shah et al., 2012) 5) Higher levels of total cholesterol and LDL cholesterol are 
associated with lower plasma Aβ42;(Blasko et al., 2010) and 6) Higher BMI is associated with 
lower Aβ42.(Blasko et al., 2010) Depression has also been associated with low plasma Aβ42, 
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and low Aβ42/Aβ40.(A.L. Metti et al., 2012) TBI has been associated with, at least short term, 
increases in CSF Aβ42 – which has been shown to be highly correlated with plasma Aβ42.(Lye 
& Shores, 2000)  
Plasma Aβ40 also increases with increased risk factors for AD/MCI (i.e. increased age, 
lower education, greater number of family members with a history of dementia, APOE e4 allele 
status).(Graff-Radford et al., 2007) However, Aβ40 is less likely to accumulate in the form of 
amyloid plaques, and therefore will likely not decrease as much with the development of 
MCI/dementia.(Gravina et al., 1995; R Mayeux et al., 1999) Aβ40 has been shown to have some 
associations, albeit weaker than those found with Aβ42, with cardiometabolic factors.(Blasko et 
al., 2011; A. L. Metti et al., 2012; Shaw et al., 2009)  
Inflammatory markers increase with age and with increased cardiometabolic disorders, 
and cigarette smoking.(Chung, Kim, Kim, & Yu, 2001; Pearson et al., 2003; Yasue et al., 2006) 
High levels of inflammation also lead to increased permeability of the BBB, and a greater 
inflammatory response within the brain (via several different pathways), which all leads to an 
increased risk of AD and dementia.(Rosano et al., 2012) Soluble receptors may be higher among 
those with normal cognitive function, and decreased in those with MCI/dementia. While the 
mechanisms of this decrease still remain unclear, it be due to injury, infection, cardiometabolic 
disorders, genetic disorders, or naturally with age.(Banks, Kastin, et al., 1995; Banks, Plotkin, et 
al., 1995; Griffin et al., 2012; Holmes & Butchart, 2011)   
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